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Abstract 
 
DEVELOPMENT AND PRELIMINARY EVALUATION OF THE ASSESSMENT OF 
OPIOID TAKING BEHAVIORS AND ADHERENCE (AOTBA) SCALE IN 
PATIENTS WITH SICKLE CELL DISEASE 
 
By Abdulkhaliq Jassem Alsalman, M.S. 
A Dissertation submitted in partial fulfillment of the requirements for the degree 
of Doctor of Philosophy in of Pharmaceutical Sciences at Virginia 
Commonwealth University. 
 
Virginia Commonwealth University, 2013 
 
Major Director: Wally R. Smith, MD 
Professor of Pharmacy and Medicine  
 
The rapid growth in opioid therapy for non-cancer pain has occurred without an adequate 
appreciation of the consequences of this growth.  Few studies provide patient-centered 
evidence that can be used to inform the current proposed standards for efficacious (safe 
and effective) opioid prescribing in non-cancer pain. Furthermore, different terms may be 
used interchangeably in the literature to refer to opioid-taking behaviors, resulting in 
imprecise or vague interpretation of existing evidence. We therefore sought to explore 
patterns of opioid-taking behavior and their biopsychosocial-spiritual determinants in 
African-American adults with sickle cell disease (SCD). Many questions surround opioid 
use for non-cancer pain, but little has been published about behavioral patterns of taking 
opioids in these conditions. The main objective of this study was to develop a disease-
 
 
 
 
xxiii 
specific scale for describing prescribed opioid taking in patients with sickle cell disease 
(SCD). As part of a multiphase, mixed-methods study, we used an adaptation of several 
published methods to construct 9 sequential, chronological steps for developing a new 
scale. We report here wide-ranging quantitative and semi-structured, qualitative 
interviews of 13 male and 11 female African-American adults with SCD, average age 36 
years, from various socioeconomic and educational levels. We used grounded theory, 
priori and posteriori procedures to analyze the qualitative data, and to conduct an 
appraisal of translational validity. Scale development results have led to inclusion in the 
draft scale of new concepts namely momentary medication-taking behavior. The scale 
also captures concrete patterns of adherence for as-needed and scheduled medication and 
allows for several discovered conceptual domains that explain observed opioid-taking 
behaviors. These concepts challenge the current theories and models of medication-
taking behavior and adherence. In summary, we found that contextual factors may 
drastically affect opioid-taking behaviors. Together, These uncovered phenomena raise 
new hypotheses that may challenge current theories and models of medication-taking 
behaviors and methods of assessing adherence. These hypotheses call for a new round of 
research on opioid-taking behavior, and need to be rigorously tested in future research
 
 
1 
 
CHAPTER 1 INTRODUCTION 
 
I. Background and Significance 
 
Opioid use in sickle cell disease (SCD) is controversial.  It has been discovered that 
patients may have acute, chronic, or perhaps acute-on-chronic pain, unlike what was 
previously hypothesized.  Thus, the principle of treating patients mainly with acute short-
acting opioids, and mainly during pain “crises”, has now been updated to the principle of 
using long-acting opioids chronically as needed for chronic pain, along with short-acting 
opioids for break-through and acute pain.  In either case, physicians may underprescribe 
opioids for SCD, may not trust patients to use opioids responsibly, and may 
inappropriately single out SCD patients to screen for abuse. Patients may not trust 
physicians to prescribe opioids liberally or appropriately, and may exhibit 
pseudoaddiction behaviors, including hoarding and taking medicines from different 
physicians to get pain relief.   
 
Like any patients using prescribed opioids, SCD patients may become addicted, or may 
divert and/or manifest criminal behavior in their use of opioids, although this has been 
estimated to be rare.  While a few studies of long-term opioid use for SCD have been 
published, no one has performed in-depth analysis of just how and exactly why sickle cell 
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patients use prescribed opioids in general. Specifically, no one has performed studies of 
time-specific and context-specific use which give the ability to identify and evaluate the 
temporal pattern of medication use and enable a closer assessment of the contexts 
(environmental, emotional, situational) underlying opioid use that are present in most 
biopsychosocial-spiritual phenomena (definitions of these categories of adherence are 
introduced in the method section under definitions). Current models of adherence do not 
capture time-specific or context-specific patterns of adherence, often important when 
patients are using as-needed opioids for pain. Because sickle cell pain is unpredictable, 
and may be managed with both as-needed and scheduled opioids, it represents an ideal 
disease in which to study such patterns of opioid usage or adherence. Previous work has 
found patterns of adherence for drugs in general, which may apply to opioids.  But we 
found no studies that have tested whether these patterns apply to opioid use, particularly   
in SCD.   
 
The current study uses a multiphase mixed-methods design to address the following 
objectives: a) Explore adherence and opioid taking behaviors, both over time and at 
particular times; b) Identify and explore attitudes, beliefs, and contextual factors related 
to adherence and these opioid taking behaviors; c) Capture, describe, and interpret key 
themes from these opioid taking behaviors and contextual factors that may generate new 
concepts of adherence; d) Generate key themes, concepts, and results from the qualitative 
interviews and the literature to construct and begin testing a quantitative survey of opioid 
taking behavior, and contextual factors related to these behaviors, in adults with SCD; e) 
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use results from the above to construct a taxonomy of opioid use in adults with SCD.  
The immediate goal of this dissertation is exploratory qualitative and quantitative 
multiphase, mixed-methods research to develop a disease-specific research instrument 
designed to describe prescribed opioid adherence and opioid taking behavior in patients 
with SCD. The results of this mixed-methods study will be used to design future 
quantitative studies intended to test hypotheses generated here. 
 
A. Epidemiology of Sickle Cell Disease 
 
SCD is an inherited blood disorder of hemoglobin structure. It is a progressive disabling 
illness that leads to chronic hemolytic anemia, with severe clinical consequences. It 
occurs primarily in people of African ancestry. (1, 2) SCD affects approximately 100,000 
Americans. In the United States, approximately one in 300 African-Americans have SCD 
(>70,000 people) and 8% have sickle cell trait. (3) 
 
B. Pain in SCD 
 
Symptoms of sickle cell anemia vary, but its main symptom is sudden pain throughout 
the body. Pains crises constitute the most characteristic clinical feature of sickle cell 
disease and are considered the most common reason for emergency department visits and 
hospitalizations of the affected patients. (4) The pain from sickle cell anemia can be acute 
episodic, chronic, or a combination of both, but acute episodic pain is more common. 
 
 
 
 
4 
This acute episodic pain is caused by vasoocclusion of the microcirculation -to the organ 
supplied- that is obstructed by sickled RBCs. There is high significant variableness in the 
rate of recurrence and severity of pain SCD patient’s experience. (5-7) Acute or chronic 
pain can be hard to tolerate and mentally exhausting and may limit the quality of life of 
patients daily activities. There is relationship between the frequency of painful crisis and 
early death. (8) Pain has a major impact on health resource utilization and quality of life. (9-
11) It is significantly associated with depression,(12,13) anxiety, cognitive impairment,(14- 17) 
decreased appetite, weight loss, as well as disturbance to sleep, gait, dysfunction general 
activity, mood and distorted communication, possible unnecessary loss of employment 
and productivity (15) by patients and caregivers, and mistrust even from family members 
and friends of patients relationships with other people. In  the PiSCES study, results 
showed that daily pain in SCD patients who completed daily pain diaries for up to 6 
months is far more prevalent and severe than previously described, with more significant 
effects on all aspects of life. PiSCES investigators found that >50% of adults with SCD 
experienced pain, crises, or healthcare utilization on >50% of the days. Almost 33% 
experienced pain nearly every day, with the mean intensity in the middle range. Only 
approximately 15% rarely experienced pain. Crises and healthcare utilization were far 
less common than reported pain days; pain days that were not associated with a crisis 
occurred 10 times more often as pain days associated with healthcare utilization. (18-25) 
Many studies have documented that depression and anxiety disorders are common in 
SCD and may be correlated with SCD. (17) New research reconfirms that individuals with 
SCD have poor baseline health-related quality of life, and painful episodes have a further 
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negative impact. Worse health-related quality of life in SCD patients is associated with 
disease severity and pain intensity. (26) Anecdotal reports from patients and new research 
suggests that there are sleep disturbances related primarily to SCD pain, and vice versa, 
in SCD patients. (27) In fact, the frequency of painful crises in Sickle cell disease is a 
measure of clinical severity and correlates well with early death.  Because of the 
recurrent and chronic nature of crises, and due to severe form of pain on daily basis pain, 
and its complex nature and complex interaction between physical, social, and 
psychological factors and because pain relieve is priority for patient in sickle cell anemia, 
prescribing of aggressive analgesics pain-relieving medication is needed and it is an most 
important of multidisciplinary treatment of these patients.  
 
C. Pain Management in SCD 
 
Opioid analgesics are the most often used and accepted in the management of sickle cell 
pain. Several studies, theories and anecdotes showed that many patients with sickle cell 
anemia can achieve clinically significant relief from stable doses of opioid medication. In 
the light of research that demonstrates better patient outcomes, reduced length of stay, 
and reduced resource use as a result of effective pain management and mobility. (28) 
 
Many patients need to take opioid analgesics at home in an attempt to relieve the pain. In 
prescribing analgesics for home use, some patients’ pain is managed with” as needed” 
(PRN) analgesic prescription only. Since the pain in some patients will persist for a long 
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duration, writing analgesic orders on an “as needed” basis (PRN) results in a recurrence 
of pain, increase anxiety, discomfort, and ultimately, a need to prescribe a larger dose of 
narcotic in order to achieve the same effect which may create concerns about abuse and 
addiction with short acting opioid. Subsequently, a long-acting (administered “around the 
clock” at a frequency consistent with their duration of action) rather than a short- acting 
narcotic is much more effective and could provide more consistent pain relief, generate 
less euphoria with administration, result in slower development of tolerance, and offer a 
more favorable side-effect profile than immediate-release preparations. (29) However, 
when these methods do not control the pain, PRN analgesia should be used promptly 
rather than letting the intensity of the pain increase until it can be managed only by 
hospital admission.  
 
As physicians have generally increased their use of opioids to treat chronic non-
malignant pain, (30) patients with severe and/or chronic SCD pain have increasingly been 
treated with opioids, including long-acting opioids. Numerous writers have advocate that 
prescription of opioids for pain in SCD is both complex and challenging. (31-35)Despite 
this, only a little data has been published about the short-term or long-term use of short-
acting and long-acting opioids in SCD pain.   
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Opioid use in sickle cell disease (SCD) is controversial. As controversial points of view 
and evidence about the unnecessary treatment and inadequate treatment of pain has 
increased (36, 37), there have been vast increases in the prescription of opioid medications 
in the US. (38) Epidemiologic studies indicate that use of opioids for chronic noncancer 
pain has increased substantially over the last two decades. (39) Use of more potent opioids 
(such as morphine, hydromorphone, oxycodone, and fentanyl) has also increased. Over 
the same two decades, the proportion of office visits in which prescriptions for potent 
opioids were given increased from 2% to 9%. A recent study found that 2% of a random 
sample of adults in the United States reported regular use of opioid pain medications in 
the last year. (40) Although the rate of prescribing and use is increasing, there is still 
significant data of inadequate pain management (37, 41).  
 
Simultaneously, there has been a large increase in prescription opioid related problems, 
such as misuse, abuse, overdose, and litigation against physicians.  (42, 43) Research on 
enhancing patients' proper use of prescribed pain medications has focused on identifying 
risk factors for criminal over-using opioids. Consequently, many screening instruments 
for identifying patients at risk for criminal over-using opioids have been developed 
(evaluated and assessed in one study (44), but with conflicting success in another one (45).  
 
Although evidence shows that overuse and underuse is widespread with high rate of 
associated problems, less attention has been paid to non-criminal overuse or under-use of 
prescribed opioids. (46) Opioid nonadherence (as under use or overuse) is a challenging 
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problem because to date few have studied contextual factors involved. Underuse or 
overuse could spring from biological factors such as lack of efficacy, or from, emotional, 
social or other contextual factors. Understanding why and when patients over-use or 
under-use their prescribed opioid is crucial for establishing approaches to enhance the 
effectiveness and efficiency of pain management.  
 
Previous studies attempted to provide insight into why and when patients’ under-use or 
over-use medications. (47) General risk factors for medication under-use include low 
socioeconomic status, patient- provider relationship, severity of illness, comorbidity, 
complexity of medical regimen, duration of treatment, side effects, knowledge and 
beliefs, motivation to manage their illness, and lifestyle. (48) However, the 
biopsychosocial reasons patients legally (non-criminally) overuse or underuse prescribed 
opioids have rarely been described in non-cancer pain patients especially in sickle cell 
anemia patients.  
 
Fishman et al. (49) compiled several factors such as why patients might under-use opioid 
medications such as fear of addiction, forgetfulness, carelessness, complexity of the 
medication regimen, self-treatment of early withdrawal, use of medication for other 
symptoms (e.g., sleep, anxiety) lack of education regarding illness/treatment, and social 
stigma. In this paper the authors discussed plans to address criminal over-use such as 
monitoring and employing opioid medications tagged with chemical markers or 
electronic/mechanical monitoring of drug containers. Gunnarsdottir et al. (50) identified 
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factors that act as barriers to cancer patients' use of analgesics: fear of side effects, 
fatalism about their disease, beliefs about the doctor-patient relationship, and fear of 
harmful effects. 
 
Because SCD patients have perhaps acute-on-chronic pain (5) which is defined as acute 
pain flares superimposed on underlying chronic pain, many patients may use not only 
short-acting opioids, but also long-acting opioids, and may use opioids chronically.  
Physicians may underprescribe opioids for SCD (51-53), may not trust patients to use 
opioids responsibly (53-56), and may inappropriately single out patients to screen for abuse. 
(57) Patients may not trust physicians to prescribe opioids liberally or appropriately, and 
may exhibit pseudoaddiction behaviors (58, 59) including hoarding and taking medicines 
from different physicians to get pain relief.  Like any patients using prescribed opioids, 
SCD patients may divert and/or manifest criminal behavior in their use of opioids, 
although this has been estimated to be rare (60,61). 
 
While a few reports of long-term opioid use for SCD have been published (62-64), no one 
has performed in-depth analysis of just how and exactly why sickle cell patients use 
prescribed opioids in general. Especially, no one has performed studies of time-specific 
and context-specific opioid use which give the ability to identify and evaluate the 
temporal pattern of changes in medication use and enable a closer assessment of the ways 
of using pain medicine that are present in most biopsychosocial phenomena (definitions 
are introduced in the method section under definitions). Current models of adherence do 
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not capture the time-specific behaviors of adherence, often important when patients are 
using as-needed opioids for pain. Sickle cell pain is unpredictable, and may be managed 
with both as-needed and scheduled opioids.  It represents an ideal disease in which to 
study time-specific and overall opioid adherence.  
 
Previous work has found patterns of adherence for drugs in general, which may apply to 
opioids.  Few have tested whether these patterns exist for opioid use. None have tested or 
even explore whether they exist for opioid use in SCD. We have preliminary data that 
prescribed opioid consumption is strongly correlated with pain intensity in SCD, and that 
opioid use is common in SCD and may be correlated with SCD outcomes. (5) Besides this 
preliminary data, the relationship between pain and patterns of analgesic use is unclear 
and studies that looked at non-adherence in sickle cell anemia populations were limited. 
No known studies to date have attempted to explore the links between time-specific 
adherence behavior and triggers in the lives of SCD patients. 
 
To address this gap in the pain management literature for SCD, and perhaps relevant for 
opioid use in the world of non-cancer pain disorders, there is a need to explore how 
patients use prescribed opioids in SCD, as well as reasons patients under-use or over-use 
prescribed opioids. 
 
The under-treatment of pain is often due to the reluctance of physicians to give SCD 
patients adequate dosages of opioid analgesia due to concerns about addiction, tolerance 
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and side effects. (65) Physicians tend to overestimate the prevalence of opioid dependence 
in patients with sickle cell crises. Yet the incidence of opioid analgesic addiction in 
patients with sickle cell disease has been reported as being no higher than three percent. 
(65) It has been found that under-treatment of pain can lead to 'pseudoaddiction' (66) where 
reports of pain by the patient are not recognized which often support the healthcare 
professionals’ perceptions of substance dependence. (67) The evidence suggests that a high 
percentage of sickle cell patients are perceived to be opioid dependent when in fact the 
percentage of sickle cell patients who are opioid dependent is no higher than the general 
population. (68) 
 
II. Purpose of the Study Protocol 
 
The immediate goal of this dissertation was exploratory qualitative and quantitative 
multiphase, mixed-methods research to develop a disease-specific research instrument 
designed to describe prescribed opioid adherence and opioid taking behavior in patients 
with SCD.  The research proceeds in 2 phases. Phase I explored and elicited themes. 
Phase II generated items to develop a draft survey, and complete the early steps of 
translational validity testing (face and content validity).  
 
 We acknowledge the premise of this study was exploratory.  In reaching the immediate 
goal of the dissertation, the dissertation research generated some descriptive information 
about opioid taking behavior in SCD patients.  
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We recognized opioid taking behavior may be classified as aberrant or non-aberrant.  In 
turn, aberrant opioid taking behavior may be classified as intentional or non-intentional.   
However, the target audience of this research was not those trying to distinguish between 
the two, or addictionologists, per se, although they may find the research helpful.  Rather, 
the research was directly targeted toward those interested in measuring and understanding 
adherence and medication taking behavior, including pharmacoepidemiologists, 
sociologists, psychometricians, psychologists, and health behavior researchers.   
 
III. Primary Hypotheses 
 
There are no a priori hypotheses for Phase I of this project, the mixed-methods study, 
which is intended to be hypothesis-generating study.  
However, with regard to opioid use, we expected that SCD patients would:   
1. Report all the patterns of overall adherence; including overuse over time, 
underuse over time, dropout use, and erratic use, previously described in general 
studies of medication adherence. 
2. Report previously unexplored time-specific or context-specific patterns of use and 
adherence. 
3. Cite many of the previously hypothesized or proven attitudes, beliefs, and 
contextual factors related to these patterns of use and adherence. 
 
 
 
 
13 
4. Cite previously unreported attitudes, beliefs, and contextual factors related to 
these patterns of use and adherence. 
 For Phase II, we hypothesized that the intended instrument would have high face and 
content validity. 
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CHAPTER 2 LITERATURE REVIEW 
 
I. Brief Introduction  
 
Sickle cell disease (SCD) is an inherited blood disorder of hemoglobin structure. It is a 
progressive disabling illness that leads to chronic hemolytic anemia, with severe clinical 
consequences. It occurs primarily in people of African ancestry. (1, 2) Symptoms of sickle 
cell anemia vary, but its main symptom is sudden pain throughout the body. Pains crises 
constitute the most characteristic clinical feature of sickle cell disease and are considered 
the most common reason for emergency department visits and hospitalizations of the 
affected patients. (3) The pain from sickle cell anemia can be acute (episodic), chronic, or 
a combination of both. Acute episodic pain was previously hypothesized as the major 
portion of pain in SCD. It is caused by vaso-occlusion of the microcirculation to the 
organ supplied- that is obstructed by sickled RBCs. But SCD Patients also have chronic 
pain, (4) unlike what was previously hypothesized.  The causes of this pain may be 
neuropathic as well as nociceptive, and little has been described other than the 
epidemiology of this pain. Pain in SCD is most commonly treated with opioids. Opioids 
are drugs that exert their activity on opioid receptors. They are considered the most 
potent analgesics.  
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II. Review Methods and Search Strategy 
 
 Databases  A.
 
We searched the topics of opioids, chronic pain and adherence measure studies in the 
primary medical literature through PubMed®, PsycINFO®, EMBASE, CINAHL, 
Cochrane Database, Ovid HealthStar and The World Wide Web was searched using the 
Google and Google Scholar search engines, covering the time period from January 1980 
to December 2012.  
 
 Search Terms B.
 
We used broad terms for indexed searching which are opioids, opiate, analgesics, 
narcotics combined with sickle cell. We then used the following search terms: ‘patient 
compliance’, ‘medication adherence’, ‘medication persistence’, ‘treatment compliance’, 
‘drug monitoring’, ‘drug therapy’,  ‘monitor’, ‘monitoring’, ‘drug’, ‘drugs’, 
‘compliance’, ‘persistence’ ‘medications’, ‘predictors’ ‘facilitators’ or ‘determinants’ 
‘relationship’ ‘and ‘barrier’ combined with the terms ‘questionnaire’, ‘survey’, ‘scale’, 
‘tool’, and ‘self-report’.  
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 Inclusion and Exclusion criteria C.
 
The following inclusion and exclusion criteria were used. 
We included studies that met all of the following criteria: 
1) Human subjects 
2) Evaluated adults (≥18 years old) with SCD. 
3) Were relevant to one of the Key Questions (adherence and adherence scale in sickle 
cell anemia, an article-measuring adherence using any adherence method and 
specifically self-reported questionnaires in the same patients, or their caregivers or 
both concurrently. 
4) Either evaluated or reported adherence assessment (for opioid adherence assessment 
instruments, monitoring instruments, and studies of survey assessment of opioid 
taking behavior) or clinical outcomes  
5) English language publications  
 
 Exclusion criteria D.
 
Studies only published, as conference abstracts were not included in my systematic 
searches. I omit the publication types of “letters,” “editorials,” and “comments.” I limited 
my analysis to studies of adults over age 18, since medication adherence for children may 
be very different from those for the majority of adults with chronic non-cancer diseases. 
Studies of non-human subjects and those without original data were excluded. We 
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excluded studies of patients with cancer pain or end-of-life conditions because of the 
unique circumstances that surround medication adherence for each of these populations.  
 
III. Results of Literature Review 
 
 Review of Adherence to Opioid in Sickle Cell Disease A.
 
My literature search identified no single study regarding scales measuring adherence to 
opioids in sickle cell anemia. Further, my literature search identified no single study 
regarding adherence to opioid in sickle cell anemia. We then searched adherence scaled 
medication adherence literature an in a population other than the sickle cell anemia  
 
We began by searching the literature for systematic reviews of adherence to medications 
to identify topics recently reviewed, and found a large body of literature on the 
medication adherence. Most studies evaluated adherence in general for those patients 
who were chronically on medications. A majority of the articles focused on three 
diseases: hypertension, diabetes, and hyperlipidemia, which are asymptomatic, for which 
long-term medical therapy is often necessary.  Below we provide a summary of my 
literature review in medication adherence. 
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 Self-Reported Adherence Scales  B.
 
I reviewed the literature to identify drawback and characteristics of available self-
reported medication adherence scales. A large number of self-reported medication 
adherence studies were identified. Recent systemic review of Lavsa et al showed that 
self-reported measures of adherence (including interviews, diaries, and questionnaires) 
were the most common way in which adherence was assessed.  Positive elements of the 
scale were summarized in this review. (123) In another review of Shi et al., the authors 
identified that a majority self-reported measures of adherence were moderately to highly 
correlated with the monitoring devices. (124) In two other reviews, the authors concluded 
that that self-reports measures are the most useful method in the research and clinical 
setting for assessing medication adherence practical interventions against non-adherence. 
(125, 126)  
 
The most commonly used medication adherence scales were: The Medication Adherence 
Questionnaire (MAQ; also known as Morisky), The Self-efficacy for Appropriate 
Medication Use Scale (SEAMS), Brief Medication Questionnaire (BMQ), The Hill- Bone 
Compliance Scale and Medication Adherence Rating Scale (MARS). However, no 
consensus exists regarding adherence scale selection or criteria. Overall, MAQ is the 
quickest scale to administer and the simplest for clinicians to score. Further, MAQ has 
been validated in the broadest range of diseases. (123, 125, 126) However, the current scales 
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have several problems and weaknesses. Below is an overall summary of the drawback of 
the existing scales (See Table 2).  
 
Table 2: Overall of limitations of the existing adherence scale 
 
 
1. No gold standard medication adherence scale exists, and no single scale is 
appropriate for every scenario. Several scales have many items worded 
specifically in regard to specific medications in specific diseases.  
2. Some were not specifically addressed or assess specifically medication adherence 
as a discrete construct but they were a generic health status measurement.  
3. They are not sensitive, and able to detect different types of nonadherence 
(momentary adherence, overuse, erratic use, others)  
4. Most for them were developed to be simple to administer and to be used initially 
and primarily in clinical setting. Few items scale may have low predictive ability 
of subsequent future adherence. 
5. Few items do not assess various biopyschosocial-spritual reasons. E.g. in MAR 
and Hills Bone Scales, Most reasons assessed focused on barriers to non-
adherence such as forgetfulness and adverse effects. 
6. Some of them developed to be based on a dichotomous yes/no response and not a 
graded response system. Such type of responses does not give idea about the 
frequency of the doing the asked actions/situations. (i.e. It will not give the fine 
distinction between frequent adherer and rare- adherer). 
7. The constructs upon which the tools were developed also vary. More recent tools 
focus on intentional and unintentional nonadherence, purposeful action, self-
efficacy and the influence of patient's beliefs about his/her conditions on 
adherence. 
8. Some of the published scales have low validity and reliability score. 
9. Some of the reported scales were not built based patient-reported care, which 
hugely influence design of items. 
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IV. Rationale for the Study 
 
While a few reports of long-term opioid use for SCD have been published, (31-33) No one 
has performed in-depth analysis of just how and exactly why sickle cell patients use 
prescribed opioids in general.Specifically, no one has performed studies of time-specific 
and context-specific opioid use which give the ability to identify and evaluate the 
temporal pattern of changes in medication use and enable a closer assessment of the ways 
of using pain medicine that are present in most biopsychosocial-spiritual phenomena 
(definitions are introduced in the method section under definitions). Current models of 
adherence do not capture the time-specific behaviors of adherence, often important when 
patients are using as-needed opioids for pain. Sickle cell pain is unpredictable, and may 
be managed with both as-needed and scheduled opioids.  It represents an ideal disease in 
which to study time-specific and overall opioid adherence.  
 
Previous work has found patterns of adherence for drugs in general, which may apply to 
opioids.  Few have tested whether these patterns exist for opioid use. None have tested or 
even explore whether they exist for opioid use in SCD. We have preliminary data that 
prescribed opioid consumption is strongly correlated with pain intensity in SCD, and that 
opioid use is common in SCD and may be correlated with SCD outcomes. (4) Besides my 
data, the relationship between pain and patterns of analgesic use is unclear and studies 
that looked at non-adherence in sickle cell anemia populations were limited. No known 
 
 
 
 
21 
studies to date have attempted to explore the links between time-specific adherence 
behavior and triggers in the lives of SCD patients. 
 
To address this gap in the pain management literature for SCD, and perhaps relevant for 
opioid use in the world of non-cancer pain disorders, this study attempted to explore how 
patients use prescribed opioids in SCD, as well as reasons patients under-use or over-use 
prescribed opioids. We interviewed SCD patients to investigate different medication 
adherence behaviors and to generate new hypotheses about adherence behaviors to 
prescribed opioids and corresponding contextual factors that may explain those 
behaviors. The purpose of this part of my study was to address gaps in the existing 
literature on how and why SCD patients use their prescribed opioid and to explore 
different adherence patterns of prescribed opioids in SCD patients through semi-
structured interviews.  
 
Following the qualitative study, we used its findings and themes as well as the existing 
literature to develop a survey tool that quantifies opioid utilization patterns and 
contextual factors in SCD.  We will pilot and administer the tool at least once, but realize 
full validation is beyond the scope of the current project. The purpose of this phase of my 
study was to gauge the prevalence of various kinds of opioid adherence behaviors and 
their contextual factors, and to begin testing a tool for future use in quantifying these 
behaviors in ours and other patients.   
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Together, the three phases of my mixed methods study will add in-depth information to 
the limited literature on opioid use in SCD and as formative research for further 
quantitative study. 
 
V. Study Objective  
 
 Primary Aim (Phase I) A.
 
1. Use qualitative and quantitative interviews of adults with SCD to: 
 
a. Explore adherence and opioid taking behaviors, both over time and at 
particular times. 
 
b. Identify and explore attitudes, beliefs, and contextual factors related to 
adherence and these opioid taking behaviors. 
 
c. Capture, describe, and interpret key themes from these opioid taking 
behaviors and contextual factors that may generate new concepts of 
adherence. 
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 Secondary Aims (Phase II and III) B.
 
2. Use the key themes, concepts, and results from the qualitative interviews and the 
literature to construct a quantitative instrument survey of opioid taking behaviors, 
and contextual factors related to these behaviors, in adults with SCD. 
3. Use results from Phases 1 and 2 to construct taxonomy of opioid use in adults with 
SCD. 
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CHAPTER 3 METHODS 
 
I. Study Design 
 
 Overview or Design Summary A.
 
Using a cross-sectional design and a mixed method approach, I conducted two phases of 
mixed methods (quantitative and qualitative components) study in order to generate and 
add in-depth information to the limited literature on opioid taking-behavior in SCD. The 
three phases were formative research for further quantitative study.  
I conducted direct semi-structured interview observations (n=20-30) and a subsequent 
cross-sectional structured survey (n = 50) of patterns of opioid use among adults with 
SCD. Between these two phases, I generated a pool of items and evaluated their face and 
content validity. Data was collected between Nov 2011 and May 2013. 
 
II. Stages of New Instrument Development 
 
The process of developing my new instrument went through the various stages of 
research to ensure adequate and accurate information related to instrument content or 
structure. There are three main phases in generating a new instrument developing 
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that instrument and validating the instrument. These three phases may in turn be further 
divided into 20 sequential, chronological steps of instrument development and validation 
of a new instrument in a previously unexplored field. 
 
Table 1 lists these three phases and links them to the 20 sequential steps. I constructed 
these sequential, chronological steps by adapting methodologies from 5 highly cited 
sources. [DeVellis, 2003, Sage Publications; DeVon HA et al. 2007, Journal of Nursing 
scholarship; Patrick DL et al. 2011; Passmore C, et al. Fam Med. 2002; Prior ME et al. 
2011, BMC Med Res Methodol] (135-139) I followed these steps.  The first five steps 
included reviewing relevant literature, framing the concepts, specifying domains, and 
conducting qualitative research. Specifically, one elicited key concepts using qualitative 
interviews to inform content and structure of the new instrument, and establish 
preliminary content validity of the new instrument.  
 
The second five steps were based on completion of the first five, and involved item 
generation and pre-validation development methodology. Specifically, the pre-validation 
stages of the new instrument included initial item generation, initial item reduction and 
question formatting, assessment of patient understanding of the draft instrument, and 
planning steps for instrument revision. The final10 steps involved validation of the draft 
instrument, including assessing coherence across items, discrimination, and all types of 
validity and reliability, (content validity, descriptive statistics, construct validity, criterion 
validity (concurrent and predictive validity), convergent validity, discriminant validity, 
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and reliability (internal consistency and test-retest reliability) with removal of poorly 
discriminating, unreliable or invalid items.  
 
For this research, Table 3 shows details of each step, the purpose of each step, and the 
status of this dissertation research relative to each step.  This dissertation research 
included completion of the first 10 of the 20 required steps of development and 
validation. 
 
 Project Status A.
 
I completed nine of the 9 steps of development and validation planned as part of this 
dissertation. Several steps were completed to create a pool of items.  I conducted a 
thorough literature review, examined existing scales, and applied my own clinical and 
research expertise. I consulted with expert, intelligent patients to obtain a rigorous review 
and revision. I adapted grounded theory to construct and analyze my interview.  
 
Table 3: 20-step new instrument development and validation methodology  
Phase # Step #  Purpose 
Phase I Step 1 Determining the context of use  
• Understand the disease or condition 
in the target population   
•  Consider the target population – 
cultural/language groups  
• Consider preliminary issues related 
to instrument content and structure 
(the possible range of instrument 
content and structure) 
• Consider the theoretical and 
qualitative methodological 
a. To considered the targets concept 
throughout the instrument 
development process.  
b. To ensure that the context of use in 
medical product labeling is clearly 
defined, and the approach for 
concept measurement is appropriate 
for the intended context.  
c. A hypothesized disease model can 
help can inform the evaluation of the 
suitability of existing instruments for 
the development program and/or the 
development of a research protocol 
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approach  
• Develop an hypothesized 
conceptual framework  
for eliciting concepts to be included 
in a new instrument. 
Phase I Step 2 Developing the research protocol for 
qualitative concept elicitation and analysis  
• Define the target sample 
characteristics  
• Select the data collection method -
individual interviews.  
• Determine the setting and location 
for data collection  
• Develop the interview guide— 
draft, pilot, revise  
a. To understand patients’ perspectives 
and experiences—including rare 
perspectives or uncommon 
experiences— be- cause 
understanding the entire range of 
patient experience and perspective is 
crucial for developing sensitive and 
comprehensive new instruments. 
b. To generate a pool of potentially 
relevant items for SCD pain-specific 
instruments, most studies focus on 
an inductive 'bottom up' approach 
using qualitative methods (e.g. one-
to-one interviews with the target 
population), which ensures items 
reflect the perspective of the 
majority of individuals in the 
population of interest [3,4]. Helps 
ensure that the final instrument 
measures the key concepts that come 
from the target population. 
Phase I Step 3 Conducting the concept elicitation interviews 
• Obtain institutional review board 
approval  
• Recruit participants; monitor 
sample characteristics to assure 
diversity of participation from the 
target population  
• Select and train interviewers  
• Conduct interviews—implement 
quality control measures  
• Record interviews  
•  Transcribe and clean transcripts  
a. To obtain patient quotes that 
provides a picture of patients’ 
experiences with the target concept 
and to show the relationship between 
the concepts, the words and phrases, 
and the final instrument. 
b. To translate meaning of the data into 
a set of items that can be scored to 
represent the targeted concept(s) 
quantitatively.  
c. To document evidence that will 
inform the content and structure of 
the new instrument. 
Phase I Step 4 Analyzing the qualitative data  
• Analyze qualitative data according 
to the theoretical grounded theory 
approach  
• Establish preliminary coding 
framework; update as data are 
coded  
• Establish coding procedures and 
train coders  
• Organize data using a qualitative 
research software program  
• Assess saturation  
• Interpret results  
a. To organize and catalog a patient’s 
descriptions of their experiences 
within the context of use.  
b. To develop concept codes ensures 
that the ideas generated from 
patients during the interview process 
have appropriate influence on the 
variety and labeling of the codes 
assigned and the overall organization 
of the qualitative results. 
Phase I Step 5 Documenting concept development and 
elicitation methodology and results  
• Provide objectives and context for 
use 
•  Describe target population  
• Provide hypothesized and revised 
disease model and any input from 
content experts  
• Provide conceptual framework and 
revisions made from preliminary to 
revised  
• Provide study methods via 
protocols and guides  
a. To provide to document the content 
validity of a new instrument.  
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• Provide summary of results, 
including evidence of saturation  
• Provide transcripts of interviews  
• Track origin and derivation of 
concepts captured in the instrument 
• Summarize qualitative data  
• Provide key references 
Phase II Step 6 Item generation: 
a. Systematic identification of 
existing related instruments 
meeting explicit eligibility criteria.  
b. Selection of additional instruments 
(e.g. generic instruments) to be 
administered alongside the new 
instrument.  
c. All items from the identified 
instruments form the initial 'item 
pool' (to which Steps 2-5 are 
applied).  
Steps 6 to 8 involve the synthesis of the 
products of research (i.e. validated instruments). 
The items that result from the systematic 
application of these steps form the basis of a 
new SCD pain-specific instrument.  
 
Phase II Step 7 Item de-duplication. Items are discarded if: 
a. They are literal duplications 
(identically worded items, or 
duplication of item content)  
b. Their content differs only by 
timeframe or attribution to a 
condition of interest (e.g. do you 
have difficulty... because of your 
condition)  
c. Their content overlaps with generic 
measures to be administered 
alongside new instrument (e.g. 
adherence self report measure)  
Identify redundant or poor questions and 
provide an early indication of the 
reproducibility of the responses. 
Phase II Step 8 Item reduction: 
d. Macro level: items discarded if 
associated with content themes 
(dimensions of health) that are not 
appropriate for inclusion in the new 
instrument (e.g. treatment 
satisfaction)  
e. Micro level: application of explicit, 
study-relevant criteria to select 
items for inclusion in draft 
instrument (actual content area)  
Further refinement to Identify redundant or poor 
questions and provide an early indication of the 
reproducibility of the responses. 
Phase II Step 9 Assessment of content coverage against a 
relevant pre-existing theoretical framework  
To provides clarity on the dimensions of health 
covered in the new instrument (i.e. how well the 
construct under measurement is represented by 
an instrument). 
Phase 
III 
Step 10 Exploratory pilot work with target population 
to assess comprehensibility, acceptability, 
relevance and answerability in order to inform 
instrument refinement (item removal &/or re-
wording) 
To explore of the target populations' views of 
the new instrument and the items it contains. 
Phase 
III 
Steps  
11-20 
Other validation steps: construct validity, 
criterion validity (predictive and concurrent 
validity), convergent validity, discriminant 
validity reliability. 
To ensure having valid and reliable instrument 
for the intended goal in the target population. 
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III. Design Rationale 
 
 Why Mixed Method A.
 
Because I was also interested in developing a tool that gauge and quantify the prevalence 
of various kinds of opioid adherence behaviors and their contextual factors in SCD, and 
to begin testing this instrument for future use in my and other patients, it was necessary to 
choose a mixed-method (qualitative and quantitative) design.  
 
A mixed methods research design defined as “a procedure for collecting, analyzing, and 
mixing quantitative and qualitative data in a single study to understand a research 
problem”. (140)There are six major types of mixed methods designs, which are the 
triangulation design, the embedded design, the explanatory design, the exploratory 
design, the transformative design and the multiphase design. (140)    
 
The descriptions of six designs are as the following: 1) the convergent parallel design, 
which seeks to obtain corresponding yet different data on the same subject matter; 2) the 
explanatory sequential design, a two-phase design that often begins with the collection 
and analysis of quantitative data and follows up with a qualitative design; 3) the 
exploratory sequential design, a two-phase design that often begins by using qualitative 
data to explore an event and then moves to a quantitative stage; 4) the embedded design, 
which mixes quantitative and qualitative data styles at the design level by embedding one 
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data style within a methodology framed by the other data style; 5) the transformative 
design, a design based on a transformative theoretical framework; and 6) the multiphase 
design, a design that combines both sequential and concurrent strands in a study. 
Of the six designs, only the multiphase mixed method design allows both concurrent 
(simultaneous) qualitative and quantitative components of data collection in a single 
phase, as well as multiple, sequential phases of data collection, each step informed by the 
prior phase(s). Thus, I chose to have a multiphase mixed method design because my 
project called for multiple phases (three) each using mixed methods: 
 
1- First Phase was an exploratory phase that began by collecting qualitative 
interview data along with some quantitative data from SCD patients. This phase 
set the foundation for the second and the third phases where the findings from 
Phase I were evaluated and used to generate items and form the development of 
the survey instrument for Phase II and III. (140-147)The role of the qualitative 
component of this phase was dominant.  
2- Second phase was evaluating face and content validity through collecting 
quantitative and qualitative data from a panel of clinical and research experts, 
colleagues and few patients. 
3- Third phase is piloting and pretest the new instrument where I will collect 
quantitative and qualitative about this opioid taking behaviors in SCD and 
preliminary data about validity and reliability of my new instrument. The role of 
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quantitative component of this phase is dominant. I planned to execute this phase 
but however, the plan was amended. 
 
 Why Grounded Theory Methodology B.
 
There are three major theoretical approaches to qualitative research: 1) phenomenology 
2) ethnography 3) grounded theory. (145-147) Grounded theory approach differs from 
phenomenology design where with the later focuses on studying existing concepts or 
theories of which I am aware but do not fully understand or not validated yet. (141-144) In 
addition, the grounded theory approach allow for the following features: a) development 
of new knowledge about a phenomenon through collection and analysis of data about that 
phenomenon without getting biased by existing phenomena; and b) simultaneous 
collection and analysis of data using a process known as constant comparative analysis. 
(141-144)  Since, my goal from the qualitative phases was to support the development of 
new model or theory about medication taking behavior and not validating existing 
theories, grounded theory methodology was particularly useful to answer my inquiries. 
Thus, I chose to follow grounded theory approach for my study.  
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 Why Individual Face-to-Face Interviews C.
 
Various qualitative data collection techniques are used to develop grounded theory, 
particularly interviews, focus group and observation. (141-143) Observation of patients’ 
environment (ethnographic study) or direct observing patients for medication taking 
behaviors is more reliable than the other two qualitative techniques. However, it was not 
feasible and practical with my limited resources. Focus group has the advantage of 
collecting information from group interaction among participants, which has the potential 
for developing greater insights. (143-147) However, the sensitivity of discussing the 
potential for addiction and diversion of opioids made us avoid using focus group and I 
decided to choose individual face-to-face interview.  
 
 Why Semi-Structured Interviews D.
 
I chose to do semi-structured interviews. The semi-structured interviews involved a series 
of open-ended questions chosen beforehand by the interviewer.  They provided 
opportunities for both interviewer and interviewee to discuss some topics in more detail 
and give the interviewer the freedom to probe the interviewee in order to elaborate on the 
original response within a specific time and specific key issues to be covered. (141-145) In 
addition, semi-structured interviewing (141) describes the “emic” or the insider’s view. 
This was considered an excellent method to examine patient perspectives of their 
illnesses. (148)   
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In contrast, I did not choose to do unstructured interviews. These interviews have very 
little structure. The interviewer (and probably the interviewee) must have free space and 
lengthy time to discuss openly every response in detail.  Further, there is no “script”-- the 
questions asked of each interviewee will not be the same.  Similarly, I chose not to use a 
structured interview.  Structured interviews allow only close-ended questions (e.g., 
answers must be “yes”, “no”, etc.). This method was not appropriate for an exploratory 
inquiry. 
 
IV. Phase I (Steps 1-5, Qualitative, Semi-Structured- Interview-
Dominant)  
 
In phase I, I collected both qualitative and quantitative data, however; the qualitative 
component of data collection was dominant. 
 
 Setting A.
 
This study was conducted on patients using the Ambulatory Care-Sickle Cell Anemia 
Clinic in Virginia Commonwealth University Health System. The Virginia 
Commonwealth University Health System is an urban, comprehensive academic medical 
center in central Virginia. 
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 Sample Size B.
 
The sample size for phase I was 21 patients, where saturation was achieved. 
As recommended for grounded theory research with a naturalist inquiry, at least 20 
individuals were defined in my disseration, they were recruited and interviewed, in-depth, 
in Phase 1. (141-143) Individuals were interviewed until redundancy of occurring themes 
was achieved. As I expected before executing the project, the saturation and redundancy 
of recurring themes were achieved by 21 interviews. (141-143) 
 
 Duration of interview     C.
                                                                     
Study participation consisted of a one-time, approximately 1.5 hour in-person interview 
 for Phase I.  
 
 Sampling D.
 
During the study, a purposive, heterogeneous sample design was employed to recruit 
SCD patients in the three phases of this study.  
Because the purpose of this phase in this project was to acquire new and detailed 
knowledge on a topic, and because random sampling does not necessarily decrease 
respondent bias in the interpretative paradigm of qualitative research, I decided that using 
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purposive methods for participant selection was the most suited sampling for the purpose 
of this study. (146, 147) 
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 Data Collection E.
 
A single semi-structured qualitative interview and quantitative interview was used for the 
first phase of this study. Literature review and expert opinion was gathered informally to 
provide supportive and background information for my interview guide. Three patients 
were interviewed as a pilot for Phase One interviews. Interview questions and procedures 
were assessed and modified. Pilot participants’ interview data was not used in the 
analysis. 
 
This study focused on a narrow subject area (opioid medication adherence and pain).  
Subjects were first asked open-ended questions, which allow free response by patients 
(see attached Interview Guide) (See Figure 1). Interview questions were centered on pain 
descriptions, and on instances of use of prescribed opioids, as well as reasons, situations, 
or circumstances that challenged or facilitated their utilization of prescribed opioids. 
Interviewees were asked probing questions based on responses to the open-ended 
questions. I used these open-ended and close-ended questions to generate hypotheses, by 
seeking to elicit the interviewee's experiences and obtain related information from those 
experiences. Overall, the interview questions created an open-ended context for 
participants to talk about his/her experiences.  
 
In addition, after the semi-structured interview that included a series of open-ended 
questions and probing questions (according to their responses), subjects were asked 
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close-ended questions. I used these close-ended items adapted from the literature to 
identify and classify adherence behavior categories based on 6 previously described 
categories in the literature. (149)In addition, I used close-ended survey questions to pilot 
some survey questions for the subsequent quantitative survey.   
The interview was audio-recorded.  Throughout the interview, researchers took detailed 
notes on subject responses, and the audio recording as well as the detailed notes, were 
subsequently transcribed for further qualitative analysis.  
In order to make sure that the interview fit the proposed time (90 minutes), I tested the 
interview guide and the preliminary survey on two co-workers for time and found it time-
appropriate.  
 
After completing approximately three of the planned interviews, I reviewed and 
discussed the data collected to determine whether the interview questions were sufficient 
and appropriate to capture the emerging themes and findings.  A key question driving the 
reviewers was whether there were emerging patterns of adherence or non-adherence, 
including overuse or underuse, and emerging reasons for use, and/or whether these could 
better be captured by adjusting questioning.  
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Figure 1: Developing My Interview Guide
 
 Quantitative Component of Phase I F.
 
 
The quantitative components of this phase was: 1- Brief Pain Inventory (BPI-SF); 2- 
Short-Form McGill Pain Questionnaire (SF-MPQ); 3- Adapted closed ended items from 
previous adherence; and 4- Information extracted from the electronic medical record. 
 
I administered the short form of BPI-SF to measure pain intensity and resulting 
interference with life activities. BPI-SF was a brief and easy to use tool for the 
assessment of pain in research settings (See the attachment). The BPI-SF uses simple 
numeric rating scales from 0 to10 that are easy to understand. On the BPI-SF, mild pain 
is defined as a worst pain score of 1 - 4, moderate pain is defined as a worst pain score of 
5 - 6, and severe pain is defined as a worst pain score of 7 – 10. The BPI-SF has been 
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used effectively to measure the severity and interference of pain in patients with sickle 
cell disease. The BPI-SF takes only 2-5 minutes to administer. (150) In addition, I assessed 
pain characteristics by using the SF-MPQ.  The SF-MPQ is structured to assess 
qualitative and quantitative aspects of pain, including location, intensity, quality, and 
temporal dimensions. Subjects were asked to rate the current intensity of each pain-
related adjective by circling “none, mild, moderate, or severe.” Participants rated these 
items on a 100-mm Visual Analog Scale. The Visual Analog Scale consists of a 100-mm 
line with “no pain” written at one end and “worst imaginable pain” written at the opposite 
end, and will be used to assess spontaneous pain. The distance in millimeters from the no 
pain end to the location of the mark gives a measurement of pain intensity.  The SF-MPQ 
took only 2-3 minutes to administer. (151) 
 
In addition to the open and close-ended questions, subject descriptive information was 
extracted from the electronic medical record, including demographics, type and timing of 
prescriptions and refills, prescriber history, clinic visits, emergency department visits, 
hospitalization and substance use diagnoses.  
 
 Interviewer G.
 
 
Interviewers for the phase 1 of this study included me as a graduate student, and included 
a research assistant that assisted with language interpretation when require, since I uses 
English as a second language.    
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 Data Analysis Process for Qualitative Interviews H.
 
In accordance with a naturalistic approach and in light of the exploratory nature of the 
study, I used the grounded theory approach to guide the data analysis. I did not have any 
specific expectations for the data before the analysis start. Rather, I expect that concepts 
and themes related to opioid taking-behaviors would emerge from the texts through 
inductive content analysis and the constant comparative method. (144-147) 
 
The interviews were audio recorded and transcribed. The transcriptions of the interviews 
were summarized and used for analysis. The qualitative interview data was not quantified 
but was used to explore the range and variety of perceptions and phenomena. I started the 
process of qualitative analysis during the early stages of data collection. This early 
involvement in the analysis phase helped us move back and forth between concept 
development and data collection, and helped change the interview guide. (144-147) 
 
Using the approach of the grounded theory, (See Figure 2) inductive reasoning was 
applied to the emergent themes in the data, within the participants’ voices, to help build a 
new theory and a new theoretical framework. (144-146)The theory development process 
took place throughout the research process to inform the study’s data collection, coding, 
and analysis to build emergent themes into theory. (144-147) (See Figure 3) Again, here I 
was not deriving variables/categories from existing theories or previous related studies, 
and I had no intention of verifying existing theories; rather, I immersed myself in the 
interview transcripts and let the categories emerge on their own.  
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I defined a coding unit as “a segment of text that can give a concept and can be coded 
under one criterion category”. (148) Responses to each interview were unitized before they 
are coded. Concepts were grouped and related to form abstract categories. Relationships 
between categories were identified to develop “formal theory”. Based on data from the 
first few respondents, the scheme was significantly revised three times and was tested by 
3 coders until inter-coder agreement reached acceptable levels”. (147) 
 
Figure 2: Analysis for Qualitative Components 
 
To systematically build theory, I followed three phases of coding: an initial open coding 
phase, followed by subsequent axial and selective coding phases. (147, 148) Through each 
phase of the analysis, I followed a structured pattern to assist with thorough, accurate, 
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organized, and efficient coding. First, I coded the data using the margins of the interview 
transcripts to assign tags or labels to segments of text. After coding, I developed a 
codebook. The codebook was organized and contained definitions of the identified codes. 
Following the reviews, the research team met to discuss the findings, to analyze the data 
collectively, and continue the process of theory development.  A conditional matrix was 
created connecting context, conditions, properties, dimensions and consequences of the 
discovered phenomena.  
 
For the issue of trustworthiness (internal validity, external validity, reliability, and 
generalizability) of the qualitative results of my project, were reported and discussed in 
terms of the four criteria suggested by Lincoln and Guba: (144) credibility, dependability, 
transferability, and conformability, and were used to evaluate the trustworthiness of 
research work conducted within an interpretive paradigm.  
 
During this study, I carefully designed and controlled the data collection and data 
analysis procedures to ensure the credibility of the research results. Furthermore, 
credibility was established mainly through member checking and peer debriefing. The 
peer debriefing process involved in the coding development steps ensured the credibility 
of the research by reducing the bias of a single researcher.  
The transferability of the qualitative part of my project was made and ensured by “rich 
description and reporting of the research process” (144) and detailed documentation of the 
data processing in a Codebook.  
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Figure 3: Constant comparison technique using grounded theory 
 
 
As suggested by Lincoln and Guba, (144) conformability was primarily addressed and 
established through a conformability audit. I gave a detailed documentation of data 
handling and my research notes (recording decisions, queries, working out, and the 
development results). By referring to these materials, I audited my own inferences and 
interpretations, and other interested researchers reviewed the research findings, which 
provided means for conformability checking.  
 
The dependability of the research findings in this study was established by the transparent 
coding process and inter-coder verification. Coding consistency in this study was 
addressed by including three iterations of coding conducted over a period of one 
semester.  
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V. Phase II (Steps 6-9, Item Generation and Translational Validity)  
 
Between the two phases of patient data collection, I generated a pool of items and 
evaluated their face and content validity. In this phase, I collected both qualitative and 
quantitative data from a panel of clinical and research experts, colleagues and few 
patients.  
 
To complete steps 6-10 planned for the completion of this dissertation research, overall 
translation validity (content and face validity) for my draft instrument was measured 
through: a) use of panel of clinical and research expert (in the field of pain management); 
b) examination of the instrument by few intelligent and expert patients’ and colleagues’ 
feedback prior piloting the instrument; and c) further of evaluation of face validity and 
content during the pilot study phase of data collection.  
 Transforming Qualitative Interview Results to Instrument Items A.
 
 
Transforming qualitative findings to instrument items was a critical and important step 
therefore systemic in-depth approaches to the assessment of content validity were 
followed including priori and posteriori procedures. The priori approach was conducted 
by specifying my instruments’ content domain. The posteriori procedures were conducted 
by having a panel of judges assess the content validity (will be discussed further below). 
For priori procedures for domain specification, I followed linguistic-transformation 
approach (152, 153) that helped in delineate the instrument content domain of items. In this 
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approach, a passage from written material is transformed by the use of certain rules for 
generating items. The content domain was specified. Certain categories within the 
content domain were identified and linked by my conceptual framework. Items were 
easily grouped by changing the items in one or more of the created categories. Items are 
very specific in the way in which the content domain was defined and how items are 
generated. 
 
Key themes and concepts from thematic analyses of these interviews were used to guide 
the development (item writing) of a draft quantitative survey.  I started with multiple 
quotes, group them into themes, and generated items for each theme. Using common 
recurring emergent themes yielded that I identified as important dimensions of 
understanding opioid-taking behavior, I based the individual item wording on actual 
statements made by participant during the qualitative interviews. I included any key 
important themes directly addressed participants’ values and perceptions of prescribed 
opioid. Because I wanted my work to reflect accurate language of participants’ 
worldview, I included the same words of any relevant experience the participant used to 
express their current understandings of the issues I addressed.   
 
Further, to ensure that my items address patient’s reported experience within the reported 
context, I documented the early steps of coding which allowed us to trace initial origins 
of items or language, as well as later iterations of emergent or evolving concepts. In 
addition, an inductive approach to developing concept codes (based on grounded theory) 
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help ensure that: a) ideas generated from patients during the interview process have 
appropriate influence on the variety and labeling of the codes assigned and the overall 
organization of the qualitative results; b) ideas generated before the patient interviews are 
not superimposed on or adversely bias the data. Please see Table 4 for an example of my 
transformation of qualitative themes to instrument items. 
 
Table 4: Development of Selected AOTBA items from themes emerged during the 
qualitative interviews  
Theme from qualitative interview Domains/Dimensions Generated Item in the draft instrument 
A. Underuse of Prescribed Opioid Due to: 
 
1. Fear of addiction 
 
During the last week, I took LESS 
prescribed opioids because: 
 
1. I thought I might become addicted or 
hooked on the medication 
 
2. I wanted to avoid addiction to my 
medicine. 
2. Side effects  1. I know I will experience bad side effects. 
2. I do not always know what side effects 
will happen to me. 
 
3. I know I will experience unpleasant side 
effects.  
 
4. I can't seem to bear side effects if I don't 
take some less of pain medicines.  
 
5. The pain medication made me feel bad. 
3. Forgetfulness  1. I do forget to take my medicine. 
 
2. I forgot when I last took my medication 
and was scared to take another. 
4. Carelessness 1. I do not worry about taking my 
medicine, so I just take less. 
2. I am careless at times about taking my 
medicine 
5. Social stigma 1. I was embarrassed or ashamed of taking 
pain medicine in front of others. 
2. I was afraid that others would judge me, 
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even when having severe pain. 
3. I was afraid that people would treat me 
differently if they knew I took pain 
medicine. 
6. Cost of medication 1. I couldn't afford to pay for taking pain 
medicine.  
 
2. I did not have money to purchase the 
medication (or its refills).  
 
3. 1. I had no insurance to pay for my 
medicine. 
Overuse of Prescribed Opioid Due to: 
 
 
 
1. Forgetfulness  
 
During the last week, I took LESS 
prescribed opioids because: 
 
1. I sometimes have trouble 
remembering if I already took 
my medication(s). 
2. I forgot when I last took my 
medication and felt that I should 
take more just in case. 
2. Uncontrolled and Unbearable 
(excruciating) pain 
 
1. I have a need for medication 
because I constantly have 
unbearable pain. 
2. I have a need for medication 
because my crisis pain is very 
severe. 
3. I have a need to take medication 
because I cannot handle the pain 
without them. 
3. Maintaining Functionality at 
work/ school 
1. I thought I would lose my job 
because of my pain. 
2. My prescribed dose does not 
help my ability to do well at 
school or work. 
3. I was afraid I would fail doing 
tasks for my work. 
4. My prescribed dose made my 
school life difficult. 
5. My prescribed dose made my 
work life difficult. 
6. I cannot function very well with 
my prescribed dose of pain 
medicine. 
7. Using any less, I still could not 
function at work with less side 
effects. 
8. I need to function at school. 
4. Meeting Obligation and 
Responsibilities 
1. I had to deal with social 
obligations or responsibilities. 
2. My pain makes it hard for me to 
take care of kids. 
3. I find it difficult to find others 
who can take care of my kids. 
4. I would not be able to maintain 
my family social life. 
5.  There seemed to be more good 
than bad about using pain 
medicine for me to meet my 
responsibilities. 
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 Content Validity B.
 
Content validity is “the extent to which an instrument measures the important aspects of 
concepts that developers or users purport it to assess”. (135) A preliminary appraisal of 
content validity was performed to assess the draft of AOTBA scale for clarity, relevancy 
to the domain of interest. Content validity was established by a) a priori descriptions of 
the psychometric development of the instruments and b) Evaluation by a panel of three 
researchers and by the calculation of a content validity index (CVI). (154) An expert was 
asked to rank the items on an index of content validity (CVI), showing the proportion of 
agreement by the panel, was calculated for each item and the total instrument. The scale-
content validity index (S-CVI) was determined by assessing the proportion of expert 
reviewers who score items as a three or four on the relevancy scale, where 1 = not at all 
relevant and 4 = highly relevant, to the total number of items on the scale. The item-
content validity index (I-CVI) is determined by assessing the proportion of relevance of 
each item to the number of expert reviewers. This index should be as close to 1.0 as 
possible to be acceptable. (154) Many agreed that for a scale to have exceptional content 
validity it should have an I-CVI of .78 or higher and an S-CVI of .90 or higher. (155)  See 
Table 5 and 6 for an example of how I used CVI methods. 
 
For the content Validity indices from expert reviewer, all reviewers rated items in term of 
wording clarity and relevance. For clarity, items were rated on a four-point scale: 1= item 
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is not clear, 2= item needs major revisions to be clear, 3= item needs minor revisions to 
be clear, 4= item is clear. For relevancy, items were rated on a four-point scale 1= item is 
not clear/representative of content domain. 2= item needs major revisions to be relevant, 
3= moderately relevant or 4= highly relevant 
 
 Face Validity C.
 
Face validity defined as an instrument having the appearance of measuring the content of 
interest. (135)  In my project, face validity was determined by: 
A) Having three colleagues review the instrument. (135,136) They were asked to read 
the instrument and evaluate the content and look at the measure and decide 
whether or not it appears to reflect the concept the researcher intends to measureǁ‖ 
to look at the measure and decide whether or not the test measures the desired 
domain of interest. See Table 5. 
 
B) Interviewing few expert intelligent patients (before piloting the instrument) about 
their perceptions of the instruments. (135, 136) Participant feedback served as a 
measure of face and content validity too. See Table 7 for an example of questions 
that were asked to get patient feedback. 
 
In addition, participant feedback during field-testing provided additional data to increase 
instrument face and content validity. 
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After receiving comments from colleagues, expert faculty and expert patients, I 
considered and addressed appropriate comments received and presented the revised final 
draft instrument for final review to the advisory committee. Once all authors reached 
consensus, the final instrument was submitted to IRB. 
 
Table 5: Drafts of the CVI for expert reviewer ratings of the wording clarity and 
relevancy  
 Wording Clarity  
Rated items on a four-point scale: 1= item is not 
clear, 2= item needs major revisions to be clear, 3= 
item needs minor revisions to be clear, 4= item is 
clear 
 
Yes=Items will be rated as 3= moderately clear or 4= 
highly clear 
 
Relevancy 
1= item is not clear/representative of content domain. 
2= item needs major revisions to be relevant, 3= 
moderately relevant or 4= highly relevant 
 
Yes=Items will be rated as 3= moderately relevant or 
4= highly relevant 
  
Comment 
Item Expert 
#1 
Expert
#2 
Expert 
#3 
Expert in 
Agreement 
I-
CVA 
Expert 
#1 
Expert
#2 
Expert 
#3 
Expert in 
Agreement 
I-
CVA 
 
1 No Yes Yes 2 0.67       
2 Yes Yes Yes 3 1       
3 No No No 0 0       
4 No No Yes 1 0.33       
5            
6            
7            
8            
9            
10            
            
Note: Yes=Items will be rated as 3= moderately relevant/clear or 4= highly relevant/clear are considered in the table No= item rated as 
2 and lower will not be considered in the table. 
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Table 6: Drafts checklist for expert opinion overall feedback on AOTBA instrument 
 
1=Not Appropriate 2= Slightly 
Appropriate 
Moderately 
(Quite) 
Appropriate 
Highly 
Appropriate 
Comment 
Appropriate ness of 
instrument Format 
     
Appropriate ness of 
instrument Order 
     
Appropriate ness of 
instrument Length 
     
Appropriate ness of 
instrument 
Complexity level 
     
Appropriate ness of 
instrument 
Readability 
     
 
Table 7: Drafts checklist for participants’ feedback 
 Yes No Suggestions/comments? 
Did you feel that all the questions on 
this page were readable? By readable, 
I mean could you understand all of the 
terms or words in the question. If no, 
which items did you feel were not 
readable? 
   
Did you feel that all the items on this 
page were clear? By clear, I mean 
could you understand what all of the 
questions were asking? That is, did 
they make sense to you? If no, which 
items did you feel were not clear? 
   
Did you feel that any of the items on 
this page were ambiguous or double-
barreled? By ambiguous or double-
barreled, I mean were any of the 
questions confusing or seemed to be 
asking more than one thing? If so, 
which items did you feel were 
ambiguous or double-barreled? 
   
Did you feel that any of the items on 
this page were sensitive either for you 
or you would think for participants 
taking this survey? By sensitive, I 
mean were any of the questions likely 
to make either you or a participant feel 
uncomfortable to answer? If so, which 
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items did you feel were sensitive? 
Did you feel that all of the items on 
this page had complete choice 
categories? By complete choice 
categories, I mean that each question 
had all the choices that should be 
available for that question. If not, 
which items did you feel were 
incomplete in their choice categories? 
   
Did you feel that any of the items on 
this page were not with the correct 
scale? By not with the correct scale, I 
mean were any of the questions with a 
group of questions that asked 
something different? Did any 
questions seem out of place? If so, 
which items did you feel were not with 
the correct scale? 
   
Now, thinking about the survey as a whole ... 
Did the format seem appropriate? If 
not, what should be different? 
   
Did the order of the scales 
(categories), questions, and choices for 
each question all make sense? If not, 
what seemed out of order? 
   
Did the length of the survey seem 
appropriate? If not, why not? 
   
Did the survey seem too complex?    
Did the survey seem to be too 
repetitive throughout? 
   
How easy was this for you to 
complete? How likely do you think it 
would be for others to complete? 
   
Do you think that there should be any 
additional questions added or taken 
out of the survey? 
   
Did the survey seem to have merit? 
That is, did it seem to go along with 
my overall purpose (The purpose of 
this study is to assess opioid taking 
behaviors and their reasons)? 
   
Additional comments………..    
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 Instrument Items and Content  D.
 
The exact content of the draft items that comprised my survey of opioid adherence and 
reasons for adherence was finalized, I used analogous patterns, themes, and templates 
used by McCracken, et al, (156) who studied how patients view their pain medications. 
McCracken conducted qualitative research to construct a set of 78 items regarding beliefs 
and concerns about pain medication. Item and scale analyses resulted in a 47-item 
measure, the Pain Medication Attitude Questionnaire (PMAQ) (156) that assesses 7 areas 
of patient concern: addiction, perceived need, unfavorable scrutiny by others, adverse 
side effects, tolerance, mistrust in the prescribing doctor, and withdrawal. As discussed 
below, the survey aimed to assess adherence for a particular time as well as over a period 
of time, and worded items and responses differently to reflect these two types of 
assessments. 
 
My draft instrument was designed based on preliminary qualitative research, designed to 
produce three categories of measurement:  two of the “what” of opioid taking behavior, 
and one of the “why” of opioid taking behavior.   
 
The two “what” measures, one of behavior over a prolonged time, and one of momentary 
behavior, each seek to classify opioid taking behavior into mutually exclusive categories 
based on (temporal and momentary) patterns of use.  This categorical approach used a 
battery of questions to first characterize all opioid taking behavior, and then other 
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questions to richly quantify the frequency of behaviors. The goal was a set of adherence 
scores that represent the type, level, and direction of (non) adherence.  
 
Further, the “why” measure, again conceived based on qualitative research, uses the draft 
survey instrument to capture concepts related to or predictive of opioid taking behavior in 
the target population (SCD) —to capture the other health behaviors/attitudes of SCD 
individuals, comprehensive with respect to patient concerns.  Concepts include how 
patients behave in relationship to their prescribed opioid medication and their disease. 
The goal was to measure the concepts most significant and relevant to SCD and 
prescribed opioid medications in SCD. The survey then included items to quantify the 
frequency of occurrence of each of these behaviors/attitudes.  The goal was to create 
quantitative scores in each of these behavioral/attitudinal items/domains. 
 
VI. Structure of AOTBA Instrument and Format of Responses 
 
My instrument was divided into three brief sets of survey questions, each with a different 
purpose and response format. Formats included dichotomous questions (two possible 
answers yes/no), multiple-choice closed ended questions, partially closed multiple-choice 
questions and scaled questions. 
 
 Part 1  A.
The first part of the questionnaire included some questions that have a dichotomous 
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response format, which means only two mutually exclusive responses are provided. 
Others are multiple-choice closed ended questions. The purpose of the questions was to 
obtain classification and demographic information and respondent characteristics.  
Example: 
1. Are you: 
 Female 
 Male 
2. Do you smoke cigarettes? ___Yes ___No 
3. What is the highest level of education that you have completed? 
 
 Grade school 
 Some high school 
 High School Graduate  
 Some College  
 College Graduate (Bachelor’s degree) 
 Professional degree 
 
 Part 2  B.
 
The second part of the questionnaire included some partially close-ended questions. I 
asked the respondent to choose, among several possible categories, the response that most 
closely represents their behaviors and the frequency of repeating that behavior. Although 
the survey items were comprehensive and highlights of the themes emerge from the 
interviews, other themes or data potentially emerge from piloting the survey and since the 
purpose here was to pilot test the first version of the instrument (with the aim of later 
formulating a multiple choice or closed version of   questions. Accordingly, I left a space 
for other reasons and behaviors. 
Example: 
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1. Which of the following statements best describes the way that you take your as-needed (short-
acting) pain medicine over the last week month?  
a. I usually took my medication as prescribed  
b. I usually took LESS medicine than prescribed  
c. Over the last month, I usually took MORE medicine than prescribed 
d. Over the last month, I sometimes took MORE medicine than prescribed and sometimes 
LESS medicine than prescribed.   
e. Over the last month, I usually took my medicine more than prescribed when I had little 
pain and less than prescribed when I had (great) pain.   
f. Over the last month, I stopped taking my medicine. 
g. Other…. 
 
 Part 3 C.
 
 
The purpose of the third part of the questionnaire was to quantify behaviors and reasons 
for these behaviors. Thus, several scales, which are presented (worded) as a set of 
statements, not questions. The wording of items in the instrument reflected the exact 
themes or wording in the qualitative thematic analysis. This part of instrument was 
divided into several brief sets of subscales. Each subscale had different dimensions and 
each dimension had different items. These series of items were developed to express a 
wide range of behaviors and their reasons. All the statements were phrased in terms of 
how often particular events occurred. The nature of response options ran between “never” 
and “always” on a 5-point scale as descriptors of amount or frequency. Each of these 
response categories have a score ranging from 1 to 5 (1=Never, 2= Rarely 3= Sometimes 
4= Often 5=Always) along an underlying frequency continuum (See Table 8). In this part 
of the scale, I will ask the respondent to select (locate) one answer to rank their (level) 
amount of frequency. The advantage of having more than two choices in the scale was to 
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allow for more choices that would permit a finer distinction in the intensity of the 
frequency.  Some statements going from negative to positive, then a number of items in 
the questionnaire were designed to have 1 as the most positive alternative and 5 as the 
most negative. 
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Example: 
 
Which of the following statements best describes the way that you took your pain 
medicine during the past week? Please mark the one statement below that best describes 
how you took your pain medicine in the last seven days. Please mark tables, one for 
short-acting (as needed) and one for long-acting (scheduled) pain medication. Please 
note that “as prescribed” means according to the directions on the bottle 
 
Table 8: Example of drafted items in AOTBA  
 
 
 Short-Acting Opioid Long-Acting Opioid 
 Never 
  
Rarely 
  
Sometime
s 
  
Often 
  
Always 
  
 
Never 
  
 
Rarely 
  
 
Sometimes 
  
Often 
  
Alw
ays 
  
1. I 
consult 
my health 
care 
providers 
before 
making 
some 
changes ¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
2. I may 
change 
the way I 
take my 
pain 
medicatio
n when I 
am 
dealing 
with 
difficult 
situations  ¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
3. I may 
take less 
pain 
medicine 
than usual 
to finish ¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
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school/wo
rk 
assignmen
t. 
4. I may 
take more 
pain 
medicine 
than usual 
to finish 
Househol
d chores 
/duties. ¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
5. I take 
more pain 
medicine 
than usual 
because 
my crisis 
pain is very 
severe. 
¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
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 Mode of Instrument Administration D.
 
The instrument is planned to be a self-administered survey, with guidance by writing 
specific instructions on how to answer the question. 
 
VII. Definitions: General Definitions of Patterns of Adherence 
 
Definitions of problematic use of prescribed opioids are not standardized across studies, 
(66, 67) but problematic use is typically defined as overuse. Problematic use seems to 
encompass both criminal use of opioids and non-criminal, but still “problematic” use.  
Criminal use may occur in patients prescribed opioids, but is not my interest in this study. 
Rather, I was interested in opioid nonadherence, i.e., non-criminal opioid overuse and 
non-criminal opioid underuse. Overuse was defined as taking more opioid than 
prescribed.  Underuse is qualitatively different from overuse, and may have different 
causes and associated behaviors. Many opioids are prescribed to be taken PRN (as 
needed) up to a maximum dose. Patients may choose, for many reasons, not to take their 
opioid medication, or to take as little as possible of it, even though they report that their 
level of pain negatively impacts their life. I was therefore define underuse of opioids as 
taking less than the dosage allowed by prescription and still reporting either inadequate 
pain relief, or reporting (in the interview) that pain impairs ability to engage in normal 
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daily activities. (68) The definition of underuse or over-use is not based on how frequently 
a patient fills a prescription. (68) 
 
 Patterns of Overall Adherence for Long-Acting Opioids A.
 
Long-acting opioids are generally prescribed to be taken regularly, not as needed.  For the 
purpose of this study I have defined the following terms:  
 
Adherence to long-acting opioids: use as prescribed [prescribed dose, frequency and 
duration] for 80%-100% of doses. 
 Underuse non-adherence: taking less long-acting opioid than prescribed [in terms of 
dose, frequency, or duration] and still reporting inadequate pain relief or that pain 
impaired their ability to engage in normal daily activity. 
Overuse non-adherence: taking more long-acting opioid than prescribed over a given 
time interval.  
Erratic adherence: mixture of underuse and overuse over a given time interval.  
Dropout adherence: discontinuation of use after beginning. 
 
 Patterns of Overall Adherence for Short-Acting Opioids B.
 
Use of short-acting opioids is usually as needed, not prescribed as timed doses. 
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Adherence to short-acting opioids: is defined as use as prescribed [prescribed dose, 
frequency] when needed. “Needed” may be defined as pain of a given intensity or 
duration, or pain that impairs ability to engage in normal daily activity, but must be self-
defined by patients. 
Overuse non-adherence: taking more [dose, frequency] short-acting opioid than 
prescribed. 
Arbitrary adherence: mixture of underuse and overuse over a given time interval.  
Dropout adherence: discontinuation of use after beginning. 
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 Patterns of Time-Specific Adherence for All Opioids C.
 
Time-specific adherence: is related to ways of opioid use [in term of prescribed dose, 
frequency and duration] at a specific time of the day; it is not related to situation or 
location, however, it is related to time unit, specific hour, specific part of the day along 
the 24-hour day, for example: [night/day time], [breakfast, lunch time or dinner time] or 
[sunrise, sunset, dusk, twilight, or dawn times]. Patterns include: 
Time-specific Adherent: opioid use as prescribed [prescribed dose, frequency and 
duration] for 80%-100% of prescribed/expected doses at a specific time of the day.  
Time-specific Underuse: opioid use [dose, frequency, or duration] at 0-79% of 
allowable/prescribed at a specific time of day and still reporting inadequate pain relief or 
that pain impaired their ability to engage in normal daily activity. 
Time-specific Overuse:  opioid use [dose, frequency, or duration] at >100% of 
allowable/prescribed at a specific time of day.  
Time-specific Erratic adherence: mixture of underuse and overuse at a specific time of 
day.  
Time-specific Dropout adherence: discontinuation of use after beginning using at a 
specific time of day. 
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 Patterns of Context-Specific Adherence for All Opioids D.
 
Context-Specific Adherence: is related to ways of opioid use [in terms of prescribed 
dose], in specific locations, conditions, and/or situations [that are not related to unit of 
time or part of the day]; it is related to what happened before or during the process [steps] 
of deciding to take one specific dose of opioid. This type of adherence could be related to 
emotional conditions, sudden circumstances, anticipated conditions, unexpected 
incidents, social events, public or community occasions, or responsibilities (such as work, 
finishing assignments, or sitting for an exam). Patterns include: 
Context-specific Adherent:  at a specific instance, specific location and specific situation, 
use of the appropriate prescribed dose for long-acting or allowable dose for short-acting 
opioid when needed. 
Context-specific Overuse:  at a specific point of time, specific location and specific 
situation, temporal (episodic) use of more than the appropriate prescribed dose for long-
acting, or more than the allowable dose for short-acting opioid when needed. 
Context-specific Underuse: at a specific point of time, specific location and specific 
situation, temporal (episodic) use of less than the appropriate prescribed dose for long-
acting, or less than the allowable dose for short-acting opioid when needed. 
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XIII. Subject Selection  
 
In the proposed study, a successive and purposive, heterogeneous sample design was 
employed to recruit SCD patients for the phase 1 and is planned to be used in phase 3 of 
this study.  
 
 Inclusion Criteria  A.
 
The inclusion criteria for phase I of this study were:  
1- SCD diagnosis (four Hgb types: SS, SBothal, SC or SB+thal) 
2- African-American patients (self-identified) 
3- Pain for > 30% of days in the last month  
4- Received three outpatient prescriptions for at least one Schedule II or Schedule III 
opioid medications from Virginia Commonwealth University Health Care System 
(VCUHS) within the previous 12 months (by chart review and medical record 
[EMR] system). 
5- Between the ages 18 and 65 years. 
6- No known hearing or visual impairment (by chart review). 
7- Fluent in English.  
8- No serious psychiatric diagnosis (by chart review and electronic medical record 
[EMR] system). 
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9- No history or current drug use problem (by chart review and electronic medical 
record [EMR] system). 
 
 Exclusion Criteria  B.
 
Patients were excluded when they are not capable of being interviewed for the semi-
structure interview or for taking the survey (e.g., dementia, mental retardation, illiteracy). 
Subjects were excluded if the chart shows evidence of dependence on any psychoactive 
substance or of Emergency Department (ED) or hospital use on the day of the interview. 
Subjects were excluded also if they contact the investigators or study personnel after 
enrolment is complete. Pediatric patients were excluded, because they are suspected to 
differ substantially from adults in both their clinical course and healthcare utilization 
patterns. Patients on chronic exchange transfusion were excluded because of effects on 
hematologic factors and pain. Patients who are not oriented to person, place and time 
(Mini-Mental Status Exam <24), (165) and unable to answer questions were excluded, 
because of inability to comply with interview completion. At any time, included subjects 
were able to withdraw. 
 
XIV. Ethical Considerations  
 
The VCU IRB reviewed the study. The usual ethical standards were followed including 
written informed consent.  An incentive of $45 was provided to clients in appreciation or 
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their time for phase 1 and a $25 patient incentive is planned to be used phase 3 of this 
study. A light snack was offered to clients before, during, or after interviews. Travel 
vouchers were offered to patients needing transportation. Prior to being screened and 
interviewed, patients were asked to sign a formal written informed consent form, which 
describes the nature and purpose of the study, and indicated that participation in the study 
was voluntary. Patients were told that if they are interested, they could sign a written 
informed consent before screening. All of the participants volunteered to answer all of the 
questions that were posed. As a condition of treatment at VCU, patients sign 
authorization forms allowing pre-screening of their medical records for research 
purposes.   
 Subject Recruitment Plans and Consent Process A.
 
1. Recruitment Plan 
 
The same recruitment plan was used for phase 1 and 2 in this study. The source of 
recruitment was direct recruiting via Adult Sickle Cell Clinic Sickle of Virginia 
Commonwealth University (VCU) Medical Center in Richmond, Virginia. The sample 
was recruited using a method that was designed to reduce the likelihood of systematic 
selection bias. All patients that came to the outpatient clinics during selected time periods 
were given written information about the study.  A sample of patients was selected for 
screening.  
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Recruitment times were coordinated with clinic schedules to obtain a representative 
sample of outpatients with regard to sickle cell Hgb phenotype, age, gender, and 
treatment/follow-up regimens. One day before the outpatient clinic day (Thursday or 
Friday), the provider reviewed the list of patients who are scheduled to have medical 
appointment with Dr. Smith to determine who is qualified as a potential subject for this 
study.  I was trained to pre-screen all available charts for eligible patients and placed 
study information on their chart. The next day (in the outpatient clinic day), when 
patients come to the clinic, those who meet the initial screening criteria were invited to 
participate in this study. Patients were approached and invited by the principal 
investigator or the recruiter in a private setting, during their routine scheduled visit to the 
clinic, and were asked verbally if they are interested in hearing about a new study called 
the “Understanding Adherence to Prescribed Opioids in Sickle Cell Disease.” Patients 
were given a study information sheet. After reading the information sheet, full details 
about the study was presented and all questions answered. Participants signed the 
informed consent form before starting the screening and the interview. Patients 
completed the study interview in private room at VCU health system. Contact 
information was obtained from patients who were willing to hear about the study or 
wanted to participate but did not have time on that clinic day. These patients were then 
contacted at a more convenient time. 
 
Following signing formal written informed consent form, patients were screened for 
eligibility using a short structured questionnaire (screening interview). The information 
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for those that were not recruited or not eligible was destroyed immediately. The 
enrollment visit was conducted in a private room at VCU Health System. Eligible 
participants were given more details about the project and then formal written informed 
consent was obtained (see attached consent form). Participants were recruited from 
November 2011-May 2013. 
 
2. Participants 
 
The majority of study patients were from the Richmond, Virginia and areas around it, as 
these areas have high population of African Americans who are visiting the Adult Sickle 
Cell Clinic Sickle from Virginia Commonwealth University (VCU) for treatment. The 
only source of recruitment was direct recruiting via Adult Sickle Cell Clinic Sickle from 
Virginia Commonwealth University (VCU) Medical Center in Richmond, Virginia. 
 
3. Sample Enrichment Features: 
 
As much as possible, patients were chosen to represent a wide range of the SCD 
population in terms of gender and frequency of pain. Patients were identified using data 
extracted from the VCUHS electronic medical record (EMR) system. Data from the EMR 
revealed more than 350 SCD patients. Painful conditions for which opioids were 
prescribed were ≥ 30% of the days (identified by self report). I attempted to enrich the 
invited sample for patients who are more likely to be at risk for problematic use of 
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prescription opioid medications by sampling those with specific characteristics as in table 
9 and 10.  
 
Table 9: Sample enrichment features for Phase 1 
 
 
 
4. Risks and Benefits 
 
The risks to subjects involved in this study were minimal.  Subjects participated in semi-
structured interview about a sensitive topic, use of potentially addictive and abusable 
substances, although the intent was to ask about non-criminal use.  No subjects 
experienced discomfort when sharing personal information.  All patient data was de-
identified. No subject interview reported confidential information, identified by the 
subject including demographic data.  Subject identifying information was stored 
separately from their results information once transcribed and analyzed. There was no 
way to match subjects with their identifier characteristics.  Only the interview analytic 
team had access to the identity of individuals, and identifiers were kept separate from the 
remainder of the data. This data was filed separately and remains under lock and key in 
offices where only the team works. These procedures were required by VCU IRB.  
                               Gender 
 
Pain frequency  
Female Male 
> 50% of the days N=10 N=10 
> 30-50% of the days N=10 N=10 
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I worked to ensure that interviews are conducted in a fashion that minimized the stress or 
discomfort a subject may experience while reporting information.  The subject was able 
to withdraw from the interview at any time and could refuse to answer any particular 
question asked in the interview.  No names were used during interview as they were 
being recorded (subjects were given a study number instead). I was experienced with 
handling interview data.   
 
 Baseline Data Collection  B.
 
I collected baseline information as part of the interview. Baseline information included 
past medical history and demographic characteristics, pain-related variables, treatment-
related variables. 
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 Resources C.
 
I spent a large proportion of my time collecting information. I was responsible for 
coordinating the advisory committee meetings, developing dataset to collect data, and 
collecting the data by reviewing medical files and by conducting semi-structure 
interview. In addition, I was responsible for conducting data analysis, interpreting the 
results, and writing the first draft of the manuscript. The investigator was responsible for 
protecting the privacy of the subjects by de-identifying all data collected, so that no 
investigator or outside party could match data with a particular research subject. 
Occasionally, research assistants helped in interviewing subjects or collecting 
information. 
 
XV. Study Procedures 
 
 Screening for Eligibility (for Phase I and planned for Phase III) A.
 
The only source of recruitment was direct recruiting via Adult Sickle Cell Clinic Sickle 
of Virginia Commonwealth University (VCU) Medical Center in Richmond, Virginia. A 
random sample of patients was selected for screening. Patients were approached and I 
invited them into a private setting, during their routine scheduled visit to the clinic, and 
asked verbally if they were interested in hearing about a new study called the 
“Understanding Adherence to Prescribed Opioids in Sickle Cell Disease.” If they agree, a 
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brief description of the study was read to them. Subjects received a letter signed by the 
principal investigator inviting them to this study and describing study details. Patients 
were told that if they are interested, they should speak to me following their visit. I 
introduced the study using the following script. “This study was designed to find out 
about patterns of prescribed opioid use at home in patients with sickle cell disease and to 
find out about the reasons of using prescribed opioid in different pattern. You are being 
asked to participate in this study because you have been diagnosed with sickle cell 
disease, and may meet the study entry requirements. If you are interested and eligible to 
participate you will be interviewed today, or at any another convenient date/time. If you 
are interested, I will need to ask you some questions to determine your eligibility.” 
Following oral and informed written consent, patients were screened for eligibility using 
a short structured questionnaire (screening interview). The enrollment visit was 
conducted at the Adult Sickle Cell Clinic at VCU Medical Center. Eligible participants 
were given more details about the project and then a formal written informed consent was 
obtained (see attached consent form). Participants were recruited over nine months’ 
period from November 2011to May 2013. 
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 Research Material B.
 
Medical Records: For Phase 1 and 3, data were extracted from VCUHS electronic 
medical records (EMR) system. A minimal amount of data was obtained from the 
medical records to limit attempts to enroll non-eligible patients. After consent, medical 
records data regarding medications, health status, ER visit, and concurrent illness was 
obtained.  
 
Digital audio recorder was used for recording the interview for Phase 1.  
Interview guide: semi-structure interview guide and preliminary survey. Please see the 
attached interview guide. Transcripts: include transcription of audio file into written form 
documents. I conducted the Semi-structure Interview and coordinated for Phase 2 and 
plan to coordinate Phase 3. Pre-screen form, recruitment form, screening form and data 
collection form was used for screening purposes and for collecting the other related 
research data in the Phase 1 and is planned to be used for Phase 3. (Please see the 
attachment):  
Subjects received a recruitment letter signed by principal investigator inviting them 
officially to the study and describing briefly about study details during their routine 
scheduled visit to the clinic for both phases. 
  
  
 Privacy of Participants C.
 
After getting permission from patients’ health providers, I approached individuals during 
their clinic visit and provided them with study details. I moved to a private area to discuss 
sensitive information. The interview was held in private rooms. Subjects enrolled in the 
study received a study identification number. No attempt was made to match subjects by 
name with any data collection material after data collection. Recruitment materials 
include a letter signed by principal investigator inviting them to this study and describing 
briefly about study details.  Only de-identified data was used. All de-identified 
information was maintained in a HIPAA-compliant manner. Patient data was entered into 
a computer database (including audio digital electronic files); these data files are 
password-protected.  
 
 Compensation Plan D.
 
One hour and a half minimally was allotted for a given interview visit. Subjects received 
financial compensation of $45.00 for Phase 1 and $25 for Phase 3 and cab/bus vouchers 
(for those in need). 
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 Consent Process E.
 
The study required that subjects complete an interview and an informed consent was 
collected using the attached consent form. 
 
 Safety and Adverse Events  F.
 
There was no risk to subjects involved in this study.  Subjects participated in semi-
structured interview about a sensitive topic, use of potentially addictive and abusable 
substances, although the intent was to ask about non-criminal use.  Subjects did not 
experience discomfort when sharing personal information.  All patient data was de-
identified. Subject interview was necessity report confidential information, identified by 
the subject an including demographic data.  Subject identifying information was stored 
separately from their results information, once transcripts have been made and themes 
coded of the transcripts and matched with identifier characteristics.  Only the interview 
analytic team had access to the identity of individuals, and identifiers were kept separate 
from the remainder of the data (this data was filed separately and remains under lock and 
key in offices where only the team works).   
 
 Safety and Compliance Monitoring G.
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1. Data and Safety Monitoring 
 
Phase 1 of this study was a qualitative and quantitative interview study. Phase 3 will be a 
quantitative survey interview. The research involved no more than minimal risk to the 
subjects. All patient data was de-identified in Phase I and will continue to be de-
identified in Phase 3.  
 
This study included subject participation in interviews and surveys. Patient medical 
records were used partly to pre-screen patients for eligibility. As part of conditions for 
treatment, patients signed a medical authorization for this reason. Retrospective medical 
history, interview and survey de-identified data were used. All de-identified information 
was maintained in a HIPAA-compliant manner. All patient data was entered into a 
computer database (including audio digital electronic files); these data files are password-
protected. The same data and safety monitoring procedures were used for the second 
phase (quantitative) of the study. 
2. Medical Monitoring  
 
I worked to ensure that interviews were conducted in a fashion that minimized the stress 
or discomfort a subject could have experience while reporting information.  The subject 
was able to withdraw from the interview at any time and could refuse to answer any 
particular question asked in the interview.  No names were used during interview as they 
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are being recorded (subjects was given a study number instead). I was experienced with 
handling interview data.  All patient data was de-identified. 
 
3. Definitions of Adverse Events 
 
Subjects participated in semi-structured interview about a sensitive topic, use of 
potentially addictive and abusable substances, although the intent was to ask about non-
criminal use.  Subjects experienced no discomfort or emotional disturbance when sharing 
personal information.   
 
XVI. Statistical Analysis 
 
 Sample Size Determination and Power A.
 
Phase 1: The planned sample size was 20-30 patients, or until saturation is achieved.  
However themes saturation was achieved after conducting 21 interviews. 
 
  Interim Monitoring and Early Stopping B.
 
See above. Early stopping in Phase 1 of this study was related to early achievement of 
saturation with 21 patients. I did not expect to have to stop the study on the basis of 
unanticipated harm to subjects.    
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XVII. Data Analysis  
 
 Analysis for Phase I and Phase II A.
 
Qualitative data analysis was done by coding and categorizing for common themes in 
interview transcripts using organizing features in Microsoft Office (Word and Excel). I 
identified all of the statements the subjects offered about how they used their opioid 
medication and their reasons for using prescribed opioid. Statements and words within 
each explanation were grouped into sub-themes, and statements that did not fit into one 
of these explanations were grouped and given an appropriate label.  Then I sorted the 
statements into types of explanations. For example, statements about opioid use may be 
coded as overuse, underuse, appropriate use, arbitrary use, or dropout use. Similarly, 
statements about reasons for certain types of use were sorted as biological, psychological, 
environmental, or social factors. Statements were coded as “psychosocial” when they 
combine the two categories social and psychological factors. Theme names were assigned 
by mutual consent of at least two analysts.  Categorization and coding of statements was 
confirmed/validated by a third analyst who was blind to the first two analysts’ assigned 
themes, codes, and sub-themes. 
 
In addition to empiric thematic analysis, analysis were made to classify adherence 
behavior over time based on previously described 5 overall adherence categories: 
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adherent, underuse, overuse, arbitrary adherence (mixture of underuse and overuse), and 
dropout adherence (discontinuation of use after beginning). Although no prior idea about 
medication taking behavior, I classified adherence behavior that were time-specific or 
context-specific, into several categories in order to categorize behavior at specific times 
or in specific contexts as a) inappropriately under-using b) inappropriately over-using, or 
c) using appropriately. These theoretical classifications have not been previously used.  I 
determined that adherence behaviors can be classified this way based on the context of 
the answers given, leading to quantification via a survey. 
 
  Statistical Methods  B.
 
Descriptive statistics (frequencies and proportions; means ± standard deviation) were 
used in Phase 1 and Phase 2 as appropriate to describe characteristics of the sample.  
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XVIII. Data Handling and Record Keeping 
 
 Confidentiality and Security A.
 
This research was conducted with the participants’ Protected Health Information (PHI). 
The retrospective collection of baseline data for this study involved no more than 
minimal risk to the subjects. All patient data was de-identified immediately after linking 
charts data with interview data. The PHI was not disclosed for purposes other than 
approved. The PHI was not reused or disclosed to (shared with) any other person or 
entity, except as required by law, for authorized oversight of the research study, or for 
other research for which the use or disclosure of the PHI would be permitted under the 
Privacy Rule.  
 
Information obtained was recorded in such a manner that human subjects cannot be 
identified, directly or through identifiers linked to the subjects; and no disclosure of the 
human subjects' responses occurred outside the research study. The information for those 
that were not recruited was destroyed immediately. Subjects enrolled in the study 
received a study identification number. There was an adequate plan to protect identifiers. 
Identifiers were destroyed (immediately after linking charts data with interview data for 
each patient).  Subject identifying information was stored separately from their results 
information. Once transcripts were made and themes coded of the transcripts responses 
were matched with identifier characteristics only when necessary.  No attempt was made 
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to match subjects by name with any data collection material after data collection. Only 
the interview analytic team has access to the identity of individuals, and identifiers were 
kept separate from the remainder of the data (this data was filed separately and remained 
under lock and key in offices where only the team works).  No names were used during 
interview as they are being recorded. All information were maintained in a HIPAA-
compliant manner. All patient data was entered into a computer database (including the 
audio digital electronic files); these data files are password-protected. Some patient data 
was obtained from existing medical records. The data collection sheet (see attached 
appendix for collection form) for each patient was assigned a study number and no 
identifying information (such as medical record number, name, initials, or exact date of 
birth) was recorded on the data collection sheet. All data was stored in a locked and 
secure cabinet. Also, no identifiers were collected, published or presented. The interviews 
were held in a private room.    
 
 Training  B.
 
I am a PhD student at the VCU School of Pharmacy; I have completed my B.S. and M.S. 
in pharmaceutical sciences. I have participated (as a trainee researcher and trainee data 
analyst) on several research projects located within the American medical system.  I have 
finished all the required and research-related courses, IRB training, HIPPA training, 
interviewing training which prepare me to carry out this research. I am experienced with 
handling interview and survey data. 
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 Subject Stipends or Payments C.
  
Subject incentives include refreshments, transportation expense coverage (if needed), and 
stipends of $45 for Phase1.  
 
XIX. Attachments (Appendices)  
 Pre-Screening Form A.
  Recruitment Form B.
 Screening Form (MMSE) C.
 Copy of the VCU- IRB Approval, Recruitment Invitation Letter/brochures D.
consent, and HIPPA Authorization and Informed consent Form  
 Special procedures protocols  E.
 BPI Form  F.
 McGill Pain  G.
 Interview Guide  H.
 The preliminary Surveys I.
 First Draft of AOTAB Scale  J.
 Revised Draft of AOTBA scale K.
 Summary of Themes Related to Domain 3  L.
  
  
CHAPTER 4 RESULTS 
 
I. Phase I Findings 
 
 Demographics and Clinical Characteristics A.
 
The total number of patients recruited into the study was 22. One patients experienced 
excruciating pain just before starting the interview and withdrew from the study. The 
total number of patients analyzed was 21. 
 
In addition to the interview, key clinical and demographic information on each patient 
was gathered at the time of the visit. A summary of demographics and participants’ 
characteristics is Table 11. All descriptive statistics were used to summarize and describe 
the data. All analyses were done using JMP 10. 
 
As shown in Table 11, approximately 57% (n=12) of the participants were women. 
Patients ranged in age from 18 to 58 years. Of the 21 patients, 5 (24%) participants were 
married. More than half (57%) of my participants have the SS genotype of SCD. While 
approximately one-third (33%) of my participants have the SC genotype of SCD. When 
asked about rating their pain intensity on the average in last 30 days, the 
  
mean reported pain intensity was 5.5 (SD=1.7). A higher proportion (62%) of my sample 
reported more than >50% of pain days in the last 30 days. More than half (52% (n=11)) 
of the participants were on both long-acting and short-acting prescribed. Notably a higher 
proportion (62%) of my participants has either college or some college education. 
Approximately 57% of my sample reported their income to be in the range of $0 to 
$25,000. Approximately 24% of my samples are smokers. Similarly, around 24% of 
sample reported drinking alcohol.   
Table 11: Demographics and Characteristic of Participants  
 
Variables	   Frequency	  %	  (n	  =	  21)	  
Age	  Mean	  (SD)	   35.4	  (11.4)	  years	  
Gender	   	  
Female	   57%	  	  (12)	  
Marital	  Status	   	  
Married	   24%	  	  (5)	  
Education	   	  
High	  school	  or	  less	   38%	  	  (8)	  
College	  or	  some	  college	   62%	  	  (13)	  
Household	  income	   	  
$	  0	  to	  $25,000	   57%	  (12)	  
$25,001	  to	  $50,000	   19%	  (4)	  
$50,001	  and	  Over	   24%	  	  (5)	  
Genotype	   	  
SS	   57%	  (12)	  
SC	   33%	  (7)	  
SB+thal	  	   5%	  	  (1)	  
SBothal	   5%	  	  (1)	  
%	  Pain	  Days	  	   	  
≥	  30-­‐50	  %	   38%	  	  (8)	  
>50	  days	  %	   62%	  (13)	  
Average	  Pain	  intensity	  (1-­‐10)	  Mean	  (SD)	   5.5	  (1.7)	  
Prescribed	  Opioid	  Regimen	   	  
Short-­‐acting	  (PRN)	  Only	   52%	  (11)	  
Both	  short-­‐	  and	  long-­‐acting	   48%	  (10)	  
Drink	  Alcohol	   	  
Yes	   24%	  (5)	  
Smoke	  Cigarette	   	  
Yes	   24%	  	  (5)	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 Qualitative Findings, Phase I B.
 
For phase I, the final sample consisted of 11 men and 10 women, average age 36 years, 
ranging from a diverse background of socioeconomic and educational levels. Qualitative 
thematic analysis uncovered several patterns of opioid-taking behavior and several 
related biopsychosocial-spiritual phenomena, some hypothesized and some not.  These 
patterns and phenomena portrayed a new six-domain conceptual framework for 
prescribed opioid taking-behavior in SCD: 1) Pain and its consequences; 2) Impact of 
Prescribed opioid on biopsychosocial-spiritual function. 3) Prescribed Opioid-Taking 
Behavior and their biopsychosocial-spiritual determinants on opioid-taking behaviors; 4) 
Aberrant behavior; 5) Physician prescribing behaviors and attitudes; 6) Hypothetical 
targets for interventions to improve prescribing and opioid taking-behaviors. Further, the 
data portrayed explanatory factors that could be classified into various levels or domains 
based on models proposed in prior research. Factors included intra-patient (biological, 
spiritual, psychological) and extra-patient (social support, provider relationships, 
institutional norms, culture, legal and governmental policy) domains. 
 
1. Findings Related to Domain 1:  Impact of Pain and Its Consequences on 
Biopsychosocial-Spiritual Function in Patients with Sickle Cell Disease 
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Patients reported their perceived feeling of being a burden on family members; that pain 
negatively impacts maintenance of family relationships, obligations, friendships; and that 
pain inhibits social interactions, reduced participation in social or community obligates, 
interfered with activities of daily living, interfered with work and school productivity, 
cognitive abilities, and emotional well-being. Patients described their pain  as causing 
mistrust by physicians caring for them (especially emergency). Patients also described 
their pain  as differing when they lived in cities with special sickle cell care. Specific 
negative emotional states included stress, feelings of guilt, and severe mental and 
physical exertion.  
2. Findings Related to Domain 2:  Impact of Prescribed Opioids on 
Biopsychosocial-Spiritual Function in Patients with Sickle Cell Disease 
 
Based on my qualitative study, participants reported positive, negative, or variable effects 
of prescribed opioids. Prescribed opioids had some negative effects on patients such as 
isolation, dependency on others and stigma. However, positive effects countered included 
feelings of independence from a pain-centric lifestyle and avoidance of pity or sympathy. 
Furthermore, personal pain management experiences created divergent effects on 
relationships, moods, activities of daily living, functioning, productivity in the 
school/workplace, fulfillment of social and spiritual obligations, and overall world-view.  
See Table for the emerged themes related to these domains. 
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Table 12: Summary of Impact of Opioid on Biopychosocial-Spritiual 
• Planning for increased vigilance for activities based on prior experience 
with medicationSp 
• Stress relief 
• can manage pain at home (prevent trips to ER, bring fast relief, 
convenience & normality all achievable) 
• Backup plan for any other health aches as self-treatment 
• Anticipation of pain due to diligence for taking oral prescribed opioids 
• Make one stay at home 
• Personal responsibilities are easier to meet. 
• Stigma that goes with using opioid and having to deal with those that 
abuse opioid. 
• Long acting drugs decrease need for short acting drugs. 
• Mental fatigue 
• Having to worry about dependency/overdose impact of opioid vs. impact 
of taking a medication overall - heightened paranoid/OCD over times. 
 
3. Findings Related to Domain 3:  Prescribed Opioid-Taking Behaviors and their 
Biopsychosocial-Spiritual Determinants in Sickle Cell Disease  
 Qualitative thematic analysis revealed three phenomena First SCD patients exhibited 
various opioid-taking behavior patterns including adherence, overuse, underuse, and 
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erratic use Second, a wide variety of biopsychosocial-spiritual factors hindered or 
motivated opioid use: pain intensity; side effects; fear of addiction; perceived stigma or 
judgment by others; senses of responsibility, productivity, hopelessness, or obligation; 
stress; social role pressure; social desirability; bullying; and anticipatory fear of adverse 
outcomes; and Third, behaviors varied based on the time of day, week, month, or year, 
and based on context at times of doses.   
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4. Findings Related to Domain 5 and 6:  Advices for other providers 
i. Advice for health care providers 
 
The interviewees gave several pieces of advice  for the healthcare providers responsible 
for patients with sickle cell disease( see Tables 13 and 14). They also gave advice for 
fellow patients and suggested interventions to improve prescribing and opioid-taking 
behaviors. See Table13. 
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Table 13: Summary of Participants Advice for their Health Care Providers 
1. ER doctors should be more informed about disease (Environmental, leading to psycho, AKA 
bad relationships) ---in emergency situations, inadequate care is provided, patients may not have 
listened to patients because they know what kind of medications works for them (bio-psycho-
social, environmental stigma, patients believe they know what is biologically beneficial for 
them)  
2. Patients should be trusted (psycho-environmental, there must not be a lot of trust displayed by 
physicians towards patient)  
3. Patient-centered prescribing is effective: Listening to patients will improve medication 
prescribing according to their preferences, health status and functioning (again, high level of 
patient awareness, they don’t think they’re helpless or stupid. Psycho-Environmental---they 
believe their condition would be mollified under their own jurisdiction).  
4. Utilize patients’ experiences and perspectives about SCD disease and medications to guide in 
prescribing which opioid agent/dose/frequency is most effective for them (psycho-
environmental…potentially bio, but not verifiable, perhaps a placebo effect through 
psychological well-being?) 
5. Emphasize on taking long-acting prescription as directed (bio-environmental…suggesting that 
not enough information is provided?) 
6. Trust patients in order to maintain optimum and favorable patient-physician relationships 
(enviro-psycho, apparently there is mistrust of physicians too, mistrust on both sides? Patient 
dissatisfaction/lack of explanation/lack of trust could lead to misuse) 
7. Stories about selling prescribed opioid pr (selling medication, misuse, taking advantage of 
healthcare providers, trying to defend themselves, warning physicians of misuse)..? (ß What is 
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this?) 
8. their questions answered or needs met.) 
9. ER doctors should understand patients (environmental, perception throughout all advice given is 
that patients truly think they know best, and that there is mistrust on both sides resulting in 
ineffective treatment. Maybe if physicians listened to patients they wouldn’t be compelled to 
misuse if they had more drugs. Dosage is not “one size fits all”).  
10. Place emphasis on securing prescriptions to prevent drug abuse (by whom? The patient?)	  
Advices for physicians and health care providers 
1. Focus on optimizing the patient-physician relationship; ensure that your patient trusts you.  
2. Work hard to ensure that your patient understands how his/her medication works. Emphasize the 
need to take medication as directed, particularly to potentially reduce substance abuse. Listen to 
their concerns regarding medication, make adjustments to their medication if it is to their benefit, 
and trust your patient.  
3. Treat your patient with respect and do not assume that they lack intelligence based on their 
socioeconomic background. Provide both medical and emotional counsel for your patient. 
4. Work to educate nurses and emergency room staff on SCD.  
5. Be aware that there is drug misuse in the hospital, and that sometimes patients are under pressure 
from friends or family members to share or sell medication. Work with patients to secure 
medication.  
Advices for society/government/other environmental influences 
1. The government should invest in additional SCD research. 
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Table 14: Summary of Advices for fellow patients  
 
 
 
Advices for fellow patients 
1. Manage pain more effectively by taking medication on time and as directed, particularly long-
acting opioids. Do not abuse medication.  
2. Promote self-wellness to reduce/avoid pain: limit activity, get rest, eat healthily and drink plenty 
of fluids, particularly water (consider getting an IV to ensure hydration). 
3. Understand the mechanism of sickle cell disease, and how what happens at a cellular level 
translates to pain on a macro level. Realize and accept that severe and even unexplained pain is 
typical of SCD.  
4. Trust physicians, they would never hurt a patient intentionally. Do not be afraid to communicate 
your concerns and ask for better explanations. Work with your physicians if you think there is 
something wrong with your prescription. 
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5. Overview of Global Themes That Emerged During Phase I for Domain 3 
 
This dissertation and instrument development part was only be focused with the results of 
domain 3, Prescribed Opioid-Taking Behaviors and their biopsychosocial-spiritual 
Determinants of Opioid-Taking Behavior in Sickle Cell Disease. See Appendix I for a 
summary of all theme emerged from qualitative data. 
i.Reasons for Taking Less of Prescribed Opioid of Taking  
 
 
For those participants who took less or no prescribed opioids continuously or  
episodically, reasons from refraining from opioid use are listed in Table 15. 
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Table 15: Reasons for Taking Less Opioid than Prescribed 
1) Feeling no pain or low pain intensity 
2) Forgot to take the pill(s) (inattentive) 
3) Conscious decision to endure pain based on feeling capable of handling pain without 
need for opioids 
4) Attempt to handle/endure/deal with/carry pain without need for opioids based on 
insecurity about level of incoming pain 
A) Episodic 
B) Continuous 
5) Nonchalance regarding prescribed opioids 
6) Hesitation & indecision with regards to taking medication (i.e., choosing between 
responsibilities or lessening pain) 
7) Forget the time intervals/frequency (inattentive) 
8) Leaving medicine at home (unintentionally) 
9) Social commitments 
10) External influences 
A) Family and/or close friends’ discouragement (inner circle) 
B) Society’s discouragement 
C) Physical environment (e.g., weather, physical location) 
11) Worries of impact of associating family with negative stigma 
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12) Reduced perceived pain through use of opioids 
13) Reduced perceived pain through pleasant outlook & demeanor 
14) Fear of feeling worse due to effects of taking opioids (side effects, personal bias  
towards taking medication) 
A) Uncertainty 
B) Concern (i.e., “what if”) 
15) Sense of hopelessness regarding effects/effectiveness of opioid use 
16) Using other remedies for managing pain and using opioids as a “last resort” with low 
priority 
17) Use of opioids hindering activities of daily living, family and social responsibilities 
18) Safety of self and others upon taking opioids (e.g., driving under influence,  
accidentally starting a fire after cooking) 
19) Becoming a burden to families or burden transfer of responsibilities to family  
members 
20) Need to be productive throughout day 
21) Fear of addiction 
22) Negative attitude towards taking opioids 
23) Financial burden of buying medication or its refill 
24) Availability 
A) In market or local phrmacy 
B) With patient’s stock  
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i. Lack of transportation 
ii. Running out before next appointment 
25) Worries about running out of medication early 
26) Completely separate self from negative stigma of being a “drug seeker” [avoiding stigma 
before it is attached] 
27) Attenuate stigma to perpetuate better image as an opioid user 
28) Danger of carrying opioids (fear of opioids being stolen) 
29) Personal preferences/judgment, perceptions, beliefs towards opioids (benefits of  
opioids not worth the risk for self) 
30) Fear, worries, and concerns of being judged in any fashion (e.g., as looking weak,  
foolish, crazy, cold, unproductive, slow) by others when under the effects of opioids  
31) Bullying related to SCD and opioid use 
32) Self-mistrust about self-management with opioids and strong inclination to be  
cared for by healthcare professionals 
33) Perception of experiencing SCD to a lesser degree relative to other SCD patients 
34) Confusion/uncertainty regarding severity of pain and stress 
 
 
ii. Reasons for Taking More of Prescribed Opioid of Taking  
 
For those participants who took more prescribed opioids continuously or episodically, 
reasons for taking more of prescribed opioid use are listed in Table 16. 
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Table 16: Reasons for Taking More Opioids than Prescribed 
1) As an excuse to take a break from responsibilities (e.g., work)  
2) As a routine to function “normally”  
A) Housework 
B) Attending school and related responsibilities (e.g., assignments, exams, 
 Greek life) 
C) Work and related duties 
D) Family and social obligations and etiquette (e.g., family gatherings, church, 
parties, maintain relationships etc.)  
3) Perform activities of daily living (Ex: going to the bathroom, getting up and  
going back to bed) 
4) To avoid pain and anticipated pain associated with movement, preceding  
signal and/or environment 
5) Not experiencing/perceiving/believing negative effects and outcomes 
6) Concealing pain (avoiding pity, sympathy, ridicule etc.) 
7) For safety of self and others 
8) Perception that benefits outweigh the disadvantages 
9) Influenced by family and community 
10) Indirect influence of family and community 
11) Avoidance of hospitalization 
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A) Long wait-times (vs. immediacy of higher dose) 
B) Financial burden 
C) Avoidance of being seen as “drug-seeker” 
D) Preference for self-management 
E) Perception of being healthier than “other” patients with SCD 
F) Perception of taking time away from other patients that require  
hospitalization 
12) Belief of self-sufficiency with respect to taking more opioids instead of  
requiring other means of management 
13) Perception of ineffectiveness of prescribed dose 
14) Avoid stress - psychological 
15) Increased frequency or level of pain than usual 
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iii. Notable Quotes Related to Domain 3 
Please see Table 17 for notable selected participants’ quotes related to opioid taking 
behavior.  
 
Table 17: Notable themes and participants quotes from qualitative interview data 
 
Emergent Theme Participants 
Taking less opioid in 
order to meet family 
obligation 
 
Participant# 2: “I don't like it, because, when I take it, it 
takes me two days to get back into everything; into doing 
the things for the kids and taking care of the household…I 
wouldn't take it if I had to do a lot with my children, but it 
does make you sleepy”  
Taking less opioid 
due to vulnerability 
(opioid makes others 
take advantage of 
users) 
 
Participant# 20: “I do not take my meds cause the kids 
take advantage. They always want [to] take advantage of 
it. Cause they know it makes me drowsy, and it puts me to 
sleep, so they kind of take advantage of that“  
Taking opioid in 
anticipation of pain 
Participant #21: “there was a time when I was less 
experienced, I might anticipate that it would come back. 
And I might take it, you know, as a precaution. Um, but 
nowadays, I've gone through it enough times to know that 
each crisis is different and there's no way of anticipating 
when you're gonna hurt, not gonna hurt. So, I mean, I just 
take it when I need it.” 
Taking more tablets Participant #21: “I take more of the long-acting,..and 
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of long-acting and 
short-acting opioid 
per one dose and 
more frequently. 
more of the immediate-release, probably take it more 
frequently and probably take more tablets in one dose.”  
Taking opioid as 
precaution or taking 
more before going to 
social gathering, 
outdoor activities or 
church 
Participant # 12: “Medicine during church, I make sure I 
take it before I leave home . . . so I don’t have to take 
while I’m in church. Or worry about like if I’m in . . . 
gathering outside, it going to be a while. So normally I’m 
going to take the medicine before I leave. But if it’s time 
for me to take it, we still got to . . . (pause) gathering with 
the people . . . I go and get me something to drink, open 
my uh my container take my medicine . . .  Go about my 
business”    
 Participant #11: “Mm, depends on the activity or the 
situation . . . Oh, outdoor, I'll take more . . . Outdoor, I'll 
take more. Family gathering, same amount. If I'm at 
church, I'll take more, cause I-I do get a little excited . . . 
before . . . yeah, as a preventative. And then, after, if I, 
depending on how I feel. But, usually, for both my 
answers that I mentioned, usually I take more beforehand, 
and then I just try- I try to gauge just how I feel during and 
after, see how much of–cause you know, church, that's 
before-before, and during. I-I don't have to worry about 
during, it's usually before and after, because it's just a 
block of time between dosages, usually . . . I usually try do 
it beforehand . . . “ 
Taking more of opioid Participant # 10: “I'll probably take more during the day . . . 
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during the day to finish 
responsibilities 
Um, usually I'm trying to get more done during the day . . . 
And, moving around, you know, I don't want to be in pain . . 
. Or, I don't want to think about it, so I'll take more during the 
day so, maybe I'll get more relief, and . . .  Not worry about 
it.” 
Taking more of the 
short-acting when 
having excruciating 
pain 
Participant #21: “What do I do differently?...Uh, yeah, 
always take the medicine when I'm in pain. I don't, I mean –
sometimes if I'm in an unusual amount of pain, I might take a 
bit more of the immediate- release. Not the extended-release, 
but the immediate-release.”  
Participant # 33: “Cause I'm having severe pain . . . And I'll 
take it a little sooner than it says on the bottle . . . Well, it 
says every 3 hours on the bottle, I might take it every 2 
hours… Mm-hmm, when I have severe pain.”                                                                             
Taking long-acting 
earlier when having 
excruciating pain 
Participant # 6: “Um. With the long-acting, I wait at least 8 
hours . . . If the pain is really bad, then, uh, I might take it, 
uh, a little bit sooner, I might take it um, you know, 7 ½ 
hours. You know, 7 [hours] . . . Sometimes if it's like real 
bad. Normally, uh, just at the 8-hour mark . . . Um, okay, 
well that was the long-acting . . . OK, the short-acting, um, I 
take it, pretty much like I said, twice a day. Normally it's like 
8-10 hours in between when I take it. Like I said, unless I 
have breakthrough pain, or have, uh, a major crisis or 
something going on, I take it a lot sooner, but, um . . . The 3-
hours. Uh, it's always the 3-hour mark…At least, yeah, I 
don't take it, uh, sooner… But, uh, normally at least the 3-
hour mark.”                                                                                                
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Refrain from using 
opioid at the first 
feeling of pain and 
prefer to wait longer till 
having more pain. 
Participant # 7: “I'll wait, I think I'll wait kinda late because 
it seem[s] like if you go ahead and take it when you first feel 
the pain, it can work faster, but with me, I'll wait 'til I'm 
really in pain to take the medicine.” 
Forgetfulness of taking 
long-acting opioid 
Participant # 3: “Difficulty taking my scheduled 
medication. Like, when I'm-I'm out and about, shopping and 
doing some things that I don't [do at home] and I might 
forget it at home, or, um, just forgot. “                                                                                                   
Side effects as a Factor 
that make it difficult to 
take medication 
 
Participant # 6: “Right, uh. I have to think about that. Um, 
well. Definitely there's a time where I was working. I was a 
courier, and, um, normally on Saturdays, my, um, my 
schedule would be earlier . . . And, um, I would start, uh, 
around 12 o'clock, my route. And, uh, normally I wouldn't 
take, uh, the medicine, uh, in the mornings like I normally 
do. So, uh, but the time I normally finish my route and all 
that, it would be, kind of, mid-evening. And, um, and so that 
kind of made it difficult for me to take it as prescribed. Um . 
. . As far as the time, and you know. When I need to take it, 
um, because I was working. And, um, for the wait until I was 
hope, I could let, you know my body rest and things like that. 
Plus, sometimes it can make you drowsy, and doing this job 
on the road, so sometimes on Saturdays when I was working 
as the courier . . . Um, that would make it difficult, but . . . 
Um, just the time. It would be considerable later than I 
normally do . . . Yeah, uh, like I said, it was night. It'd be 5, 
6, 7 [o'clock] even, before I take my first dose of medicine, 
you know. You know, so that's way off when I normally take 
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it. It's way off. It would normally be my time to take it again, 
but it would just be my first time, so.”                                                   
Participant # 2: “Hmm, the only think I know is it makes it 
difficult for me, is I have nausea . . . Nausea, or vomiting–
it's-it's miserable to take. And you know this is what's going 
to happen, and you're already not feeling good, and you gotta 
strain. No, I don't wanna take it then . . . It's just the nausea. 
That's the only thing that I could seethat I could remember 
thatthat refused me from not taking it. And then, sometimes, 
when I think, and this was a while back, when I think the 
dosage is just too-too much, that it makes me more, like, out 
of it, drugged up, than I would, I would, if I know that's what 
it's gonna do to me, then I won't take it. I don't like to be 
sleep and f– I don't like that . . . I don't like the feeling . . . 
And it's more so I don't like to have nothing that's in control 
of me, I like to be in control all the time . . . So, that would 
make me refuse, from taking it. That and nausea, those are 
the only two things.”  
Participant # 7: “You know, you don't wait til the pain gets 
severe to take the medicine,–… But I wait til I'm hurting –if 
I'm hurting, and then I take my medicine, instead of taking it 
as soon as I feel the pain…Mm-mm. I just. [sigh] It's just 
gonna have me doing funny things…I might run through the 
house and say, um, ...[strange things]. One time I was in a 
crisis, and I was saying, 'Yessir! Yessir!' [both laugh]…No, 
because, um, when I'm like that, whatever my son is doing, 
he's gotta stop; like, say he's on the internet or on the phone, 
he'll say, 'Now lemme call you back because my mother, she 
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 Results of Preliminary Survey C.
 
After I finished each interview, I administered a preliminary survey of 11 questions about 
opioid taking behaviors and their factors.  
 
In the current study, one of the measures for opioid adherence was measured by 
patient self-report of prescribed pain medications taken during the previous seven days. A 
one-item self-report questionnaire with five options was adapted from previous research. 
done took her medicine and she sick and I gotta keep an eye 
on her cause she's gonna get into stuff.'…And then 
sometimes it makes me active; I get in the kitchen and I get 
[to] cooking stuff and everything, and, I don't need to be 
going through that, because, just imagine if my son wasn't at 
home, and just imagine if he's at work or something, and I 
get into some kind of activity, and something happens. Just 
imagine, I'm cooking on the stove and suddenly I [have] got 
a fire…You know. And that-that's not a good situation. “            
Fear of ineffectiveness, 
providers mistrust and 
lack of knowledge about 
opioid as factors of non-
adherence behaviors  
Participant #21: “in days when I was younger, um, I could 
see how fear that the medication wouldn't work [would be a 
reason]…Um. Not understanding how the medicine works. 
Not understanding how the extended-release and the, um, 
immediate-release, how one works with the other…Uh, not 
trusting the doctor. Uh, and he knew what he was talking 
about… Um. I could see how those factors in my younger 
days, I would have taking my medication willy-nilly. Um, 
but me personally, I mean, if I'm not in pain, I won't take it.” 
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The five analgesic-taking options included: 1) regularly took all pain medications, 2) 
regularly took some prescribed pain medications, 3) took all prescribed pain medications 
after an increase in pain, 4) took some medications after an increase in pain, and 5) did 
not take prescribed pain medication most of the time. Adherence was defined in this item 
as “regularly taking all pain medications as prescribed by the physician.” If a patient took 
all prescribed pain medication regularly, he/she would be further categorized as adherent. 
All others were categorized as non-adherent. Only one-fifth of participants (19%, n=4) 
fully adhered to prescribed analgesics. Among the four non-adherent patterns Figure 4, 
the largest subgroup was “took some medications after an increase in pain” (81%, n = 
17). 
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Figure 4: Distribution of participants’ answers to a survey questions related to 
taking as-needed pain medicine during the last seven days 
 
 
 
 
 
For the remaining 10 questions, I received a wide range of responses and frequencies to 
each question.  For question 2 which asked about taking short-acting opioid based on 
provider verbal agreement, most respondents (62%) indicated that they do not take it as 
prescribed and exhibited various non-adherence behaviors. The most frequently reported 
non-adherence behavior was taking more and less than prescribed followed by (19%) 
“Take less”. See Figure 5.  
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Figure 5: Distribution of participants’ answers to a survey questions related to 
Overall Short-acting Opioid Taking Behavior based on provider verbal agreement 
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For question 3 which asked about taking short-acting opioid based on the direction on the 
bottle, most respondents (90%) indicated that they do not take it as prescribed and 
exhibited various non-adherence behaviors. The most frequent (57%) reported non-
adherence behavior was taking more and less than prescribed followed by (29%) “Take 
less”. See Figure 6.  
 
Figure 6: Distribution of participants’ answers to a survey questions related to 
Overall Short-acting Opioid Taking Behavior based on the direction on the bottle 
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For question 4 which asked about taking long-acting opioid based on provider verbal 
agreement, most user respondents (24%) indicated that they do not take it as prescribed 
and exhibited few non-adherence behaviors. The most frequent reported non-adherence 
behavior was taking less than prescribed. See Figure 7.  
 
 
 
Figure 7: Distribution of participants’ answers to a survey questions related to 
Overall Long-acting Opioid Taking Behavior based on provider verbal agreement 
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For question 5 which asked about taking long-acting opioid based on the direction on the 
bottle, there was an approximate 50% split between user respondents. However, the most 
frequent (14%) reported non-adherence behavior was taking less than prescribed. See 
Figure 8.  
 
 
Figure 8: Distribution of participants’ answers to a survey questions related to 
Overall Long-acting Opioid Taking Behavior based on the direction on the bottle 
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For question 6 which asked about the frequency of taking of short-acting (SA) opioid in 
anticipation of pain or complication, most participants (90%) indicated any of 
“sometimes”, “often” or “always” as how frequent they did take their SA opioid for this 
reason. While 10% of the participants indicated either “never” or “rarely” did take their 
SA opioid for this reason. See Figure 9.  
 
Figure 9: Frequency of taking short-acting (SA) opioid in anticipation of pain or 
complication 
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For question 7 which asked about the frequency of taking of short-acting (SA) opioid due 
to kinesophobia, most participants (66%) indicated any of “sometimes”, “often” or 
“always” as how frequent they did take their SA opioid for this reason. While 34% of the 
participants indicated either “never” or “rarely” did take their SA opioid for this reason. 
See Figure 10. 
 
 
Figure 10: Frequency of taking short-acting (SA) opioid due to Kinesophobia  
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For question 8 which asked about the frequency of taking of short-acting (SA) opioid due 
to stress, most participants (90%) indicated any of “sometimes”, “often” or “always” as 
how frequent they did take their SA opioid for this reason. While 10% of the participants 
indicated that they “rarely” did take their SA opioid for this reason. See Figure 11. 
 
Figure 11: Frequency of taking short-acting (SA) opioid due to stress  
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For question 9 which asked about the frequency of taking more of short-acting (SA) 
opioid when dealing with temporary situations, most participants (90%) indicated any of 
“sometimes”, “often” or “always” as how frequent they did take more of their SA opioid 
for this reason. While 14% of the participants indicated that they “rarely” did take more 
of their SA opioid for this reason. See Figure 12. 
 
Figure 12: Frequency of Taking MORE of SA Due to dealing with temporary 
situations (taking exams, finishing assignments, or dealing with specific work duties) 
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For question 10 which asked about the frequency of taking less of short-acting (SA) 
opioid when dealing with temporary situations, most participants (81%) indicated any of 
“sometimes”, “often” or “always” as how frequent they did take less of their SA opioid 
for this reason. While 19% of the participants indicated either “never” or “rarely” did 
take less of their SA opioid for this reason. See Figure 13. 
 
 
Figure 13: Frequency of Taking LESS of SA Due to dealing with temporary 
situations (taking exams, finishing assignments, or dealing with specific work duties) 
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For question 11 which asked about the frequency of taking less of short-acting (SA) 
opioid due to unplanned activities, most participants (86%) indicated any of 
“sometimes”, “often” or “always” as how frequent they did take less of their SA opioid 
for this reason. While 14% of the participants indicated that they “rarely” did take less of 
their SA opioid for this reason. See Figure 14. 
 
 
Figure 14: Frequency of Taking LESS Due to unplanned activities 
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II. Phase 2 Findings 
 
 Writing and Evaluation of the items A.
 
First, I transcribed all of the interviews.  I developed specific categories according to the 
general themes that emerged from my qualitative analysis. Each individual quotation was 
assigned to the appropriate division. I evaluated each quotation for both its explicit and 
implicit concepts. A general consensus was utilized for the following: 
1. Each quotation was evaluated in order to place it in the appropriate category, 
based upon its general interpretation.  
2. Each quotation had multiple facets. Three research colleagues’ members 
explored each possible interpretation. 
3. All final themes and their respective categories were approved by the members. 
 
I developed a number of statements to articulate each individual aspect of every 
quotation, which became the themes.  Each group member wrote statements on the same 
common themes, but expressed them in their own voice, using the linguistic 
transformation approach. 
 
The statements were then analyzed for brevity, clarity, relevance, redundancy, ability to 
represent the original theme, simplicity of language. More than 500 survey items were 
initially proposed and reviewed. After deliberation by review panel, 162 items were 
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chosen to be included in the first draft survey. These items reflected all of the original 
themes. It was determined that each of the selected items was necessary in order to reflect 
the complete spectrum of my themes. 
 Review Panel B.
 
I formed a panel comprised of three clinical and research experts in pain management of 
non-cancer pain and three patient experts living with SCD and trained in a medical 
science. The purpose of this panel was to confirm that each item in the survey was unique 
and appropriate. 
 
The panel reviewed each item for redundancy and relevancy, and determined whether the 
meaning of each item expressed adherence or non-adherence and could be characterized 
as continual or momentary in nature. For an item to be accepted, it was required that two 
of the three panel members agree that the item was not redundant, attained the same 
degree of relevancy, and was consistent with momentary or overall adherence/non-
adherence. Each panelist’s comments were evaluated to determine consistency in their 
responses and the reasons why they reached each conclusion (See Figure 15). 
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 Scale-Content Validity Index (S-CVI) and Item-Content Validity Index (I-CVI) C.
or AOTBA Scale  
The scale-content validity index (S-CVI) was determined by assessing the proportion of 
expert reviewers who score items as a three or four on the relevancy scale, where 1 = not 
at all relevant and 4 = highly relevant, to the total number of items on the scale. This is 
determined by assessing the proportion of relevance of each item to the number of expert 
reviewers. Almost all the items have I-CAV equal 1.00. Also, the S-CVI index was 0.989 
for relevancy and 0.971 for clarity. Both these readings (findings) are very acceptable for 
content validity and indicate that AOTBA scale has exceptional high content validity.  
 
Table 15: CVI for Expert Reviewer Ratings of the Wording Clarity and Relevancy  
item # 
 
Relevancy 
1= item is not clear/representative of content domain. 2= item 
needs major revisions to be relevant, 3= moderately relevant or 4= 
highly relevant 
 
Yes=Items was be rated as 3= moderately relevant or 4= highly 
relevant 
Note: Yes=Items was be rated as 3= moderately relevant/clear or 
4= highly relevant/clear are considered in the table No= item rated 
as 2 and lower was not be considered in the table. 
 
Wording Clarity  
Rated items on a four-point scale: 1= item is not clear, 2= item 
needs major revisions to be clear, 3= item needs minor revisions to 
be clear, 4= item is clear 
Yes=Items was be rated as 3= moderately clear or 4= highly clear 
Note: Yes=Items was be rated as 3= moderately relevant/clear or 4= 
highly relevant/clear are considered in the table No= item rated as 2 
and lower was not be considered in the table. 
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7 Yes Yes Yes 
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26 Yes Yes Yes 
3 
1 Yes Yes Yes 
3 1 
27 Yes Yes Yes 
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29 Yes Yes Yes 
3 
1 Yes No Yes 
2 0.67 
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 Acting Based on the Feedback D.
 
Based on the expert panel review, each item was reworded or eliminated based on the 
aforementioned panel review. The revised AOTBA scale was returned to the panel for a 
final review and approval.  They were asked to evaluate the overall appropriateness of the 
instrument format, order, length and level of complexity. 
The AOTBA scale was designed to reflect the panel’s evaluation of its applicability to the 
patients to be surveyed. The scale was formatted and printed for its initial administration. 
I selected three patients based upon the following criteria: 
a. The use of  different opioid regimens (long-acting, short-acting, or use of both) 
b. Gender ( the importance of the inclusion of at least 1 subject of the opposite sex) 
c. Literacy level 
d. Competency on the MMSE  
 
1. Editing of the Scale: 
 
The authors wrote each statement included in the scale. These statements were then 
edited by the research assistant for brevity, clarity and grammar and spelling.  An expert 
senior colleague (a family nurse practitioner for SCD patients) reviewed each statement 
for correct grammar including: the agreement between subjects and verb, consistency in 
verb tense, simplicity and readability. She edited the statements to ensure the items met 
English grammar standards, with subject-verb agreement and consistent use of tense for 
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each item. The complexity and length of items were also changed to simplify the 
language used in each item.  
 
The wording of the items was discussed among the authors, the research assistant and the 
senior experts. The final wording for each item was chosen so that each statement would 
be interpreted in the same way across all participants.  
 
A health education specialist reviewed and simplified the items in order to ensure their 
readability and simplicity. Each item was edited to match the literacy level of fifth grader. 
The health education specialist then recommended the following tools:   
1. Readability statistics through Microsoft Word  
2. Plain Language Thesaurus For Health Communication  
 
These tools were used to modify the wording of the statements and increased the validity 
and reliability of all items in the scale. The health education specialist read the revised 
statements and met with the researcher for approval of the final wording.  
 
The scale was then presented again to the panel and the panel members individually 
wrote their final comments on the items to ensure that the statements met all criteria as 
outlined above. With the help of a panel of three Expert Patients trained in medical 
sciences, I further identified redundant or poor questions and provided an early indication 
of the reproducibility of the responses. 
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2. Detailed Summary of Scale Feedback and Editing 
 
The following items were accepted without modification by Clinical and Patient Experts 
as being appropriate and essential to the scale and utilizing simple and clear language: 1, 
2, 5, 17, 25, 37, 45, 47, 55, 65, 66, 69, 75, 82, 83, 84, 85, 86, 87, 88, 109, 112, 114, 120, 
134, 135, 139, 140, 147 and 158. A number of items were removed from the scale 
entirely due to redundancy, confusing wording, inapplicability or other problems with the 
item.  Items 3, 4 and 6 were removed because they were noted to be redundant with item 
5 by Clinical Expert 2.  Items 14 and 15 were removed because they were noted to be 
redundant by Clinical Expert 2 and poorly worded and inapplicable by Patient Expert 2. 
Clinical Expert 2 also noted that item 15 was poorly worded. Item 18 was also eliminated 
because Patient Expert 2 suggested that it may not be necessary and the issue was 
addressed in items 19 and 20. Item 21 was also removed from the scale as it had a 
number of issues. Clinical Experts 1 and 2 commented that it was not appropriately 
worded. Patient Expert 2 also noted that it was redundant with items 117, 71 and 72 and 
Patient Expert 1 found it to be confusing.  
 
Items 23, 40, 74, 144 were deleted from the scale based on review by the authors, but was 
received no comments from the expert panelists. Item 29 was removed due to poor 
wording noted by Clinical Expert 2 and a vague meaning noted by Patient Expert 2. 
Clinical Expert 1 suggested that item 30 was not clear and the item was deleted from the 
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scale. Item 41 was also not included because Patient Expert 2 noted that it was not 
pertinent to the scale. Clinical Expert 3 suggested that item 43 was too close to item 42 
and the item was deleted. Clinical Expert 3 also noted that item 48 was too similar to item 
47 and Patient Expert 2 said that it was too closely related to 49; therefore item 48 was 
not included in the scale. Clinical Expert 3 found that item 51 was repetitive with item 
50, so it was removed. Both Clinical Expert 3 and Patient Expert 2 found item 54 to be 
another redundant item (similar to item 57) and it was subsequently deleted. Item 71 was 
dismissed because it was noted by Patient Expert 1 to be poorly worded and by Patient 
Expert 2 to be redundant. Patient Expert 2 also suggested that item 78 was too similar to 
items 61-64 and it was subsequently removed from the scale.  There were grammar issues 
in item 90 noted by Patient Expert 2 and it was also found to repeat the meaning of item 
91, therefore it was deleted. Clinical Expert 3 and Patient Expert 2 both noted that item 
95 was not applicable and it was removed from the scale.  These two panelists also found 
that items 97, 98 and 99 were not strong and meaningful statements and may be answered 
by other items. These three items were not included in the scale. Patient Expert 2 also 
found that items 101, 103 and 104 was not necessary and these were removed. Both 
Clinical Expert 2 and Patient Expert 2 found item 108 to be redundant with item 106, 
therefore 108 was not included. Patient Expert 2 suggested that item 121 be removed 
because it was too much like items 47, 49,51,54,56, therefore it was deleted. Item 126 
was deleted because Clinical Expert 1 said that it was unclear. Clinical Expert 1 also said 
that item 132 was unclear and Patient Expert 2 said that it was redundant; therefore it was 
subsequently removed from the scale. Patient Expert 2 pointed out that item 133 did not 
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have meaningful content and it was removed. Item 137 was found by Patient Expert 2 to 
need revision and was deleted.  Item 141 was noted by Patient Expert 2 to be redundant 
with items 136-137 and therefore it was removed. Patient Expert 2 commented that items 
149, 150 and 152 are all redundant and they were deleted. Clinical Expert 3 noted that 
item 149 was also redundant with item 144.  Patient Expert 2 said that item 151 was 
vague and it was deleted. 
 
The remaining items were given further consideration with respect to commentary from 
Clinical and Patient Experts and were modified according to their comments. The 
following is a summary of the comments. For item 7, Clinical Expert 2 suggested that 
"the medicine" should be added after "do not take”. Patient Expert 2 proposed that item 7 
be deleted, and suggested the rewording "I fill the prescriptions I receive from my health 
care provider but I do not take them." Patient Expert 2 suggested for item 8 the rewording 
"I do not fill the prescriptions I received from my health care provider on time." Patient 
Expert 2 also reworded item 9 to "I do not fill the prescriptions I receive from my health 
care provider " The same patient expert suggested item 10 be reworded to "I am able to 
follow the agreement regarding pain meds that I made with my prescriber to the letter (or 
faithfully)." For item 11, Patient Expert 2 suggested that the wording of the first part be 
changed to "I can describe accurately" or "I can state exactly". The same patient expert 
also proposed that the wording for item 12 be changed to “before I make any change in 
the way I take my pain medicine”.  Clinical Expert 2 suggested that for item 13, “the” 
should be added after “follow” and that 12 and 13 can be combined. Clinical Expert 2 
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also noted that in item 16 “advice” should be added after “my HCP’s” and Patient Expert 
2 noted that “instructions” should be added after “providers”. Clinical expert 2 pointed 
out that 19 and 20 should begin with “I choose NOT to” and Patient Expert 2 suggested 
that these two may be redundant. Patient Expert 3 noted that the wording for item 20 
should be changed to “I choose not to take a certain medication because of side 
effects/stigmatized/tolerance/dependence”. Patient Expert 1 said that item 22 was not 
applicable for short-acting medication and Patient Expert 2 noted that items 22 and 23 are 
too similar. Patient Expert 2 said that item 24 was not applicable for short-acting 
medication. For item 28, Patient Expert 3 said that “as” should be removed and “there 
are” should be added.  Patient Expert 1 suggested that item 32 is a redundant item and 
that in item 33, “to manage my pain” should be moved from the end of the statement to 
after “myself”. Item 38 was said to be redundant by Patient Expert 2 and inappropriate by 
Patient Expert 1, since nothing is ever written about non-pain symptoms in scripts. 
Patient expert 2 recommended that items 39 and 40 be combined to "I remove some pain 
medication from the original bottle for convenience and/or emergencies."  
 
In item 42, Patient Expert 2 proposed that "prescribed" be deleted because the patient 
cannot change the prescribed instructions. Instead, the following rewording was 
suggested by the patient expert: "I change the way I take my pain medications from the 
prescribed instructions when I am dealing with difficult situations." Clinical Expert 2 
noted that items 42 and 58 should be reworded to be more generalized because they are 
explicitly detailed real-life situations. Clinical Expert 3 noted that item 44 was redundant 
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with item 47. Patient Expert 2 said that the topic in item 46 was addressed better in other 
items. Patient Expert 1 said that item 49 was redundant with 48 and that item 50 was 
redundant with item 47. Patient Expert 2 and Clinical Experts 2 and 3 agreed that items 
52 and 53 were too similar. Clinical Expert 2 also included the word “opinion” after 
“influence”. Clinical Expert 2 recommended that “changed” be switched to the present 
tense for item 56, Patient Expert 2 suggested the item be deleted, and Patient Expert 3 
suggested that the date range be changed to “months to a couple of months“. Clinical 
Expert 3 said that item 57 was redundant with item 54 and Patient Expert 2 said that it 
was redundant with item 58. Patient Expert 2 also said that item 59 overlapped too much 
with item 60. Clinical Expert 1 noted that item 61 may or may not be appropriate for the 
scale. Patient Expert 2 said that item 64 was redundant with both items 49 and 60.  
 
Patient Expert 1 said that item 67 was vague and Patient Expert 3 suggested that 
“emotionally” or “physically” should be added after “better”. Patient Expert 2 said that 
item 72 was redundant with 21, 71, 117 and 118. Patient expert 1 said that in item 72 
"after consulting with physician" or "without" should be added. Patient Expert 2 noted 
that items 73, 74 and 75 were all the same question. For item 76, Patient Expert 2 
suggested the rewording "I changed the way I take my pain medications because I used 
other prescribed non-pain medications" and Patient Expert 3 noted that the item did not 
apply. For item 77, Clinical Expert 2 suggested that “do” is changed to “does” and 
Patient Expert 2 changed the wording to "I changed the way I take my pain meds because 
my doctor does not believe or understand my pain." Patient Expert 2 said that item 79 
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was unnecessary and that item 81 may be redundant with items 82-88. Patient Expert 1 
recommended that "after consulting with physician" or "without” be added to item 89. 
Patient Expert 1 said that items 92 and 93 were vague and Patient Expert 2 said that items 
92, 93 and 94 were all redundant. For item 94, Patient Expert 1 said that the item did not 
make sense and Patient Expert 2 commented that the “patient must learn responsibility.” 
Patient Expert 2 also said that items 96, 97 and 98 were too similar and that item 96 was 
the best of the three. Patient Expert 2 also thought that Item 100 was redundant. For item 
102, Clinical Expert 2 suggested the rewording from "instead of consultation with" to” 
without talking with".  
 
Patient Expert 2 read items 109 and 110 to be essentially same question, and that item 
111 was similar to items 90-95 and 113-114, and that item 113 and 114 are also too 
similar. For item 115, Patient Expert 2 proposed the rewording “I cut back or stop taking 
my pain medication when I feel better even if I still have some pain." Patient Expert 3 
said that item 115 should be clarified based on whether the pain is mild or severe because 
“it makes a difference how many pills I would cut back”. Clinical Experts 2 and 3 and 
Patient Experts 1, 2, and 3 all reworded item 118 to include "it" after "when" and "else" 
after "something". Patient Expert 2 objected to item 119 by questioning "Why take in 
first place if moral dilemma?" Clinical Expert 2 and Patient Expert 2 both said that item 
122 should be supported with examples. Patient Expert 2 recommended that “s” be 
removed from “times” in item 123. Patient Expert 2 also suggested that in item 124 "or 
on an as-needed basis” should be removed and that it was redundant with items 47, 49, 
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51, 54, 56. Clinical Expert 2 said that item 124 is poorly worded. Clinical Expert 2 said 
that item 125 was confusing and Patient Expert 2 suggested that "type of" be deleted and 
"pain" be added after "prescribed", and "severity I have at the moment" be deleted. 
Patient Expert 1 and 3 noted that both items 127 and 128 are not applicable for short-
acting medications and items 129, 130, and 131 are not applicable for long-acting 
medications. Clinical Expert 1 noted that items 129 and 130 might have answers that vary 
based on etiology of pain. For item 136, Patient Expert 2 said that it was a redundant 
item, Patient Expert 3 said it needed supporting examples and Clinical Expert 1 said the 
scoring was questionable.  
 
Patient Expert 2 said that item 138 was not of the appropriate reading level for the scale 
and that “I take a different number of pills at different times of day than what is written 
on my prescription.” Patient Expert 2 said that item 142 was redundant with items 143 to 
144. Patient Expert 3 said that item 145 does not apply to long acting medications and 
Clinical Expert 1 said that item 148 does not apply to long acting medications. Patient 
expert 1 said that questions 146 and 147 were too similar. Patient Expert 2 said that items 
153 and 154 were redundant. Patient Expert 1 said for item 155 that there is no maximum 
and that item 156 is not applicable for short-acting medications. Patient expert 
commented that item 156 is unclear and that for item 157, PRN medications don’t have 
specific day’s supply. Patient Expert 3 noted that item 159 is not applicable for long-
acting medications and that example should be given for item 160. For item 162, Patient 
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Expert 2 added "for pain" after "I take medicine" and Patient Expert 3 noted that other 
medications and treatments be apply.  
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1. Qualitative Comments of the Clinical expert Panel and Patient Panel  
 
I met with the expert panel to describe the evaluation process for the scale. Each member 
was asked to review the item for readability and relevancy.  
Upon completion of the review, the panel submitted the quantitative rating of the item 
along with qualitative comments. After panel review of the survey tool, I reviewed all 
qualitative comments and suggestions.  
 
Documentation of comments and suggestions was placed into appropriate excel sheet.  
Covered items included appropriate grammar (the agreement between subject and verb 
[singular and plural], use of adjective, missing basic verb, missing pronoun);, 
redundancy; synthesis of two or more statements; separation of one item into two 
statements; simplification of words to fifth grade reading level, word order within the 
statements; additional words to clarify statements;  agreement in verb tense within 
statement, revised the statement but keeping its intent; consideration of combination or 
separation  of responses to similar influences on medication taking behavior , adding 
example for more clarifications. 
 
Some items could be classified as either overuse or underuse, or could be classified as 
momentary or overall adherence. Consistent with the logical formula (tautology), if only 
statement A is true then the opposite of statement A (which is statement B) cannot be 
  
 
141 
assumed, however; if both statement A and B are true then a combination of statement A 
and B are also True. If only A or B is true and the other is not true, then a combination of 
A and B cannot be true. Therefore, substitution of two separate statements instead of one-
combined statements is logically valid and justified. 
 
With as-needed medications, it is difficult to assess adherence versus non-adherence, and 
overuse versus underuse as the same patient may respond with opposite reply to the same 
question at different times. The experts recognized this conundrum and this was reflected 
in their assessment of the items. Some thought that the statement indicated adherence 
while other thought it indicated non-adherence; some thought it indicated overuse and 
others that indicated underuse. Therefore, I decided to eliminate the items from the scale 
where the experts did not a gree on what  the item represented ( adherence or 
nonadherence). 
 
The disagreement among the clinical expert because patient behavior varies due to 
several factors: etiology of the pain, prescriber instructions, effectiveness and side effects 
of the medications.  Sometimes prescriber write prescriptions that allow the patients to 
modify the number of pills they take at one time. This is dependent upon level of pain 
which varies from mild to moderate to severe. At other times, prescribers allow patient to 
take both a milder PRN opioid (which offers less sedation, but also provides less 
analgesia) for mild pain and a stronger opioid (more sedative properties but also more 
analgesic effect) for severe pain.  
  
CHAPTER 6 DISCUSSION 
 
I. Review of Goals and Methods 
 
The primary purpose of this project was to explore and describe the opioid taking 
behavior in adult Sickle Cell Disease (SCD) patients and to describe the comprehensive 
biopyschosocial-spiritual reasons for these behaviors.  
 
For phase I, the final sample consisted of 52% (n=11) men and 48% (n=10) women with 
a mean age of 36 years, ranging from a diverse background of socioeconomic and 
educational levels. Medical history and psychological variables were assessed at baseline. 
Relevant medical history predictors included history of pain days and history of 
analgesics medications.  
 
This multi-phase mixed method study described the opioid taking behavior and the 
reasons for adherence to prescribed opioid of 21 SCD patients in the Adult Sickle Cell 
Anemia Clinic at Virginia Commonwealth University Health System (VCUHS) in the 
Richmond, Virginia.  
 
Adherence was described and assessed by the investigator following an extensive semi-
structured interview and preliminary survey regarding adherence behavior. I used 24 
  
questions in an open-ended, face-to-face interview and preliminary survey to collect 
data about adherence to the prescribed opioid regimens. 
 
The discussion of my findings is organized by the major concepts described opioid taking 
behavior and their reasons (pain, stress, knowledge, beliefs, side effects etc.).  There is 
currently no published literature about adherence to prescribed opioids in SCD for 
comparison. Therefore, I offer alternative explanations and comparisons of the current 
results with past research on non-cancer pain conditions. The discussion also includes 
commentary on the data collection method of adherence. The limitations are also 
discussed. Preliminary implications for clinical practice are presented and finally, 
directions for future research are proposed. 
 
II. Summary of Findings 
 
Qualitative thematic analysis uncovered several patterns of opioid-taking behavior and 
several related biopsychosocial-spiritual phenomena, some that I expected and others that 
I did not.  These patterns and phenomena portrayed a new six-domain conceptual 
framework that addresses the complex individual, relational, environmental, cultural, and 
systemic issues surrounding opioid taking-behavior in SCD. From this six-domain 
framework, I organized the explanatory factors into a new method of classification, 
which included two overarching domains: intra-patient (biological, psychological, 
spiritual), extra-patient (social support, provider relationships, institutional norms, 
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culture, legal and governmental policy). This classification provides a roadmap for future 
research. The explored six domains offer guidance in understanding a complex 
explanation of the effect of pain, its pharmacotherapy, and medication taking behaviors 
on an individual’s health that simultaneously bridges all healthcare domains. 
 
 Unanticipated Findings  A.
 
My experience suggested that a) the only reason for taking opioids in SCD patients is 
pain, b) SCD patients would report taking more of prescribed opioid due to excruciating 
pain, c) the pain-free patients would not report taking prescribed opioid, d) SCD patients 
would exhibit few behaviors of opioid taking behavior. I found, however, that this was 
not the case in my SCD patient sample. One of the major findings in this study was that 
as a whole, my patients showed various types of opioid-taking behaviors with various 
forms of non-adherence, and many different reasons for non-adherence. Further, one of 
the most striking findings was that the patients demonstrated arbitrary behaviors of opioid 
use. Although this finding is consistent with previous adherence literature in other 
diseases condition such as asthma, I did not expect to find it sickle cell with pain 
medicines.  
 
 Opioid taking behavior  B.
 
The sample reflected a heterogeneous group of individuals with various socioeconomic 
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backgrounds. All subjects in this sample had SCD and many individuals were very ill. 
Participation in this research was restricted to individuals with SCD pain with prescribed 
opioids, unique from many descriptive research studies on SCD pain. 
 
This research was focused on the behavior of opioid taking behavior, which was explored 
in detail. A wide range of opioid agents and dosages were prescribed.  In this sample, 9 
(48%) subjects were prescribed long-acting opioids with short-acting opioids PRN (as 
needed), and 12 subjects (52%) were prescribed only short-acting opioids PRN. The 
percent of subjects prescribed short- and long-acting opioids does not represent the actual 
distribution of the clinic’s current patients (include VCUHS clinic’s numbers). It is also 
higher than most research samples, where only a minority is prescribed long-acting 
opioids, (171-173) but lower than the 88% reported by Ferrell and colleagues. (174)  
 
Surprisingly, in the one-item self-report adherence questionnaire, only one-fifth of 
participants (19%, n=4) fully adhered to prescribed analgesics. Among the four non-
adherent patterns Figure 4, the largest subgroup was “took some medications after an 
increase in pain” (81%, n = 17). 
  
 
 Underuse and delay in opioid taking behavior C.
 
Underuse and delay in taking opioid medication to treat pain was reported; 19% of 
subjects (n=4) reported not taking opioids even though pain was experienced, and 48% of 
subjects reported delaying opioid use by an hour or longer. 
 
In this study, participants varied in their use of long-acting and short-action opioid, with 
fewer adherents to short-acting opioid. Half of the participants did not use their long-
acting opioid every day.  This is consistent with previous studies reporting high levels of 
non-adherence of short-acting and long-acting opioid among cancer patients. (171,174)  
 
All patients included in the current study were prescribed short-acting PRN opioids. 
However, 10%-29% either discontinued their use or took less than prescribed. In their 
reporting, subjects varied the dosages of short-acting medication they took during the day 
and there was a within-subject difference in the type or dosage of short-action opioid. 
The low (10%-29%) reported use of PRN is also consistent with other samples in cancer 
literature. (171,174) One interesting finding was the participants reported using short-acting 
opioids because it was time to take it, implying that even though the medication was to be 
used for breakthrough pain, some individuals put themselves on a regular schedule of 
short-acting medication with a lower interval than the available schedule. 
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In this sample, although all patients reported having more than 29% of pain days in the 
last month with level 5.5 as an average of pain intensity on a scale of 1-10, overuse of 
prescribed opioids was ranging from 5%-10% and may be related to reported pain level. 
This was consistent with findings in cancer patients, where patients reported using only 
half of their available short-acting opioid when experiencing severe pain.  
 
The highly varied pattern of non-adherence with short-acting PRN opioids and the less 
varied use of long-acting opioids proved to be a consistent finding in the literature. 
Conceptually, several explanations may account for this finding. Use of long-acting 
opioid is simpler, generally twice a day dosing at scheduled times, and no decision or 
evaluation of symptom experience is required. The fewer doses per day, the more likely 
the medication is taken, which is a consistent finding in medication adherence studies. 
However, it is proposed that, conceptually, the use of a short-acting PRN opioid may not 
an adherence issue. PRN, short for pro re nata in Latin, meaning “in the circumstance” in 
English, implies that patients make the decision of when to take the medication. In fact, a 
PRN opioid prescription is not meant to be used at 100%; if 100% of the PRN is used, it 
is an indication for dose increase or drug change. As discussed in Chapter 1and 2, 
individuals with pain may believe that the management of symptoms is a distinctive 
behavior choice and different from following recommendations for management of their 
disease. Whereas management with hydroxyurea or long-acting opioid may be thought of 
in terms of adherence, management of symptoms is uniquely tied to an interpretation of a 
sensation and thus is essentially under the individual's own making power. 
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 Reported Factors D.
  
In this study, I explored biopychosocial-sipritual factors that are not commonly explored 
or examined in the current pain literature in relation to pain and opioids. These included 
pain intensity, stress, fatigue, accurate education about opioids, beliefs about reporting 
using opioids, side effects, and many other reasons. See appendix K.   
 
1. Education 
 
The sample did not demonstrate accurate knowledge about opioid use. The variance in 
the awareness and knowledge about opioid use may be sufficient to provide a meaningful 
explanation of varying behavior. Although accurate understanding of opioids is critical in 
appropriately taking medication, this factor may not be sufficient to drive behavior. 
Given the current clinical guidelines and accepted standards of care, it would be clinically 
ethical and logical in future research to correct any inaccurate understanding of 
medication use. However, there may be a role in future research on SCD pain to test 
interventions designed to improve knowledge of opioid side effect management.  
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2. Beliefs 
 
This study explored the beliefs and attitudes held by the patients about using opioids. 
Various attitudes and beliefs toward taking opioid were reported. Below in the 
discussion, I provide a classification of the different attitude reported. The various 
attitude and beliefs were consistent with what was previously reported in the literature. 
(175,176) This finding is most likely related to the fact that all patients included in the 
sample were taking opioids for many years. I found that non-adherence is more likely 
reported if the patient also reports a low perception of the need for taking his/her opioid. 
This perception may arise due to the preconception about SCD is incurable diseases.  
 
3. Side effects  
 
Given the wide array of responses to a general question in the interview regarding side 
effects, it is recommended that a specific side effect questionnaire be used in future 
research. Various side effects reported in this sample were present in all patients. Opioid 
side effects are consistently cited in the literature as a factor contributing to under use. 
(177) However, in this study, physiological side effects were not an important factor. One 
explanation is that in this sample, side effects were well controlled, reflecting practice in 
an academic medical center. Another possibility is that individuals with severe side 
effects stopped using opioids completely and were not included in this study. 
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Side effects should be considered as creating a feedback loop both as a result of opioid 
use and as an influence on future use of opioids. Specifically, increased opioid doses or 
overuse resulting in increased side effects. Increased side effects then lead to reduced 
opioid use. (49,50) Although conceptually the occurrence and management of side effects 
remain important in research about SCD pain, the influence of side effects needs to be 
investigated as both an outcome of opioid use and as a potential influence on future 
opioid use. 
 
4. Importance of pain relief 
 
The importance of pain relief was a common concern for subjects taking both long-acting 
and short-acting opioids. Interestingly, importance of pain relief ranged from not at all to 
the most important motivation for taking the opioid. Although this has previously been 
identified as a factor influencing the experience of SCD symptoms, this is one of the first 
reports discussing the importance of pain relief. 
  
One of the major research aims of the study was to explore the relationship between pain 
severity and opioid use. As I expected, not all subjects increased their use of opioids on 
the days when their pain was more severe. Fifty percent of subjects increased their use of 
the short-acting opioid when pain increased, 40% took the same amount regardless of 
pain severity, and 10% of subjects had inverse relationships between pain severity and 
PRN opioid use. This finding has interesting implications.  About half of the subjects 
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with pain due to SCD used their pain level as a guide to medication use, the common 
clinical recommendation. Yet, at least a third of participants displayed arbitrary o 
counterintuitive behavior, taking more short-acting opioid with less pain or using less 
short-acting when pain was worse. Using less short-acting opioid when pain is worse may 
reflect that the patient is "giving up" or feels despair. If the medicine is not helping, why 
take more. Using more short-acting opioid when pain is less severe is more difficult to 
explain and is an intriguing phenomenon that has not been discussed previously in 
literature.   
 
This supported my finding that related to many reasons not associated with pain behind 
changing opioid taking behavior. Contrary to Ward and colleagues, (175) my findings 
show that opioid use and changing opioid taking behavior is not simply related to the 
reported level of pain.  
 
5. Satisfaction and pain management outcome 
 
This study found a number of important connections between adherence and outcome. 
Although it is not of direct interest in my study to attempt to describe whether prescribed 
opioid is related to outcome improvement, a majority of participants reported that taking 
the opioid according to the prescribed instructions improved the amount of pain relief. 
Interestingly, some participants reported that adherence with prescribed long-acting 
opioids helped in improving their pain relief by reducing the frequency and severity of 
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pain most of the time. However, this relief may not help to keep them to maintain 
adherence in the future. In contrast, I found that participants who denied any non-
adherent behaviors to their short-acting were satisfied with their prescribed opioid. The 
exact nature of the relationship between adherence and pain management outcome has 
not been examined in previous research. As a result, the clinical observation that SCD 
patients with greater alleviation of pain tend to also be more adherent was not supported.  
This may indicate that reported level of pain in the past may be a sign of future reported 
behavior. 
 
I found that participants taking the long-acting opioid, who described themselves as 
experiencing lesser negative effects from opioids, and who attributed their main use of 
opioid to pain (biological factor), were more likely to be adherent to their short-acting 
prescribed opioid regimen. In addition, participants taking short-acting opioids who 
attributed their opioid use to many biopyschosocial factors were more likely not to adhere 
to their regimen. As a result, the clinical speculation that patients with less reported pain 
may be more or less adherent with their opioid regimen was not supported. This finding 
may be due to possible differences in the nature of their pain or may be based upon prior 
understanding and awareness of how they are supposed to use their prescribed opioids.  
 
Participants that reported autonomous adjustments of their dosages tended to take short-
acting opioids. They also were more among participants that attributed behavior to by 
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psychosocial-spiritual factors such as stress rather than simply biological factors such as 
pain and side effects.  
 
 
 
 Erratic and arbitrary behaviors  E.
 
Previous research that has shown that failure to adhere to previous treatment regimens is 
one of the best predictors of future non-adherence. (178) In my study, patients that reported 
experiencing frequent side effects or fear of addiction reported refraining from taking 
their prescribed opioid. This finding was more consistent with previous findings that 
patients were more likely not to take their prescribed opioid if experiencing side effects 
or if they had certain beliefs about medications. (177) 
 
It is possible that non-adherence or overuse of opioids is partly due to the possibilities 
that opioids are not effective in providing adequate pain management. This finding is 
consistent with what was expected.  
 
Arbitrary behavior is an unexpected finding, and it is unclear why a patient would 
continue to demonstrate such behavior so consistently. It is always a possibility that 
participants may not have been honest in reporting of non-adherent behaviors, which may 
account for these unusual findings.  
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Interestingly, participants that reported experiencing less stress adhered better to their 
prescribed opioid regimens. This result is consistent with other studies showing that 
higher levels of depression consistently predicted poorer adherence. (179) It is possible that 
such findings would have been statistically significant with a larger sample size.  
 
 Physician-patient relationship F.
 
In my sample, some SCD participants indicated that adherence to prescribed opioid 
regimen improved their relationship with providers while others expressed how their 
providers helped them to improve adherence. The impact of patient-physician 
relationship on opioid adherence was modeled and studied previously in literature. This 
body of literature has shown that a strong relationship may promote adherence and 
improve outcome. (180) 
 
III. Domain 1 Findings: The effect of pain and its consequences on 
biopsychosocial-spiritual function in patients with SCD 
 
In Domain 1, patients reported their perception of the impact of pain in their lives. Firstly, 
patients explained that their pain caused mistrust by physicians caring for them 
(especially in emergency situations). Patients also described their pain differed when they 
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lived in cities with specialized sickle cell care. This perception could be due to the stress 
of living in an environment without appropriate facilities or treatments, which are not as 
advanced or effective as cities equipped with specialized care. As previously described, 
my qualitative interviews about pain in SCD suggest simultaneous effects of numerous 
explanatory factors bridging multiple domains from individual care to healthcare policy.  
The implication of these findings is that interventions affecting numerous aspects of the 
patient’s life will be required to improve the pain of individuals diagnosed with SCD. 
 
IV. Domain 2 Findings: The effect of prescribed opioids on 
biopsychosocial-spiritual function in patients with SCD 
 
Based on my qualitative study, participants reported positive, negative, or variable effects 
of prescribed opioids. Here, variable effects refer to those effects that may be perceived 
as positive in one situation and negative in another. The same effect can be viewed 
differently by individuals in different circumstances. Example is that side effects of 
medication cause patient to stay home.  Some patients view this as positive (not going to 
the ER), whereas others view it as negative (isolation from friends and family). 
 
Because multiple resources in the literature pertaining to opioid use focus extensively on 
the biological impact of opioids, (177) there exists a paucity of research regarding the 
impact of prescribed opioids on other life aspects that affect overall well-being. These life 
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aspects may be divided into five main domains: Biological, Psychological, Social, 
Spiritual, and Miscellaneous (Extrinsic Factors). Furthermore, there exists cross-
classification (e.g., Psycho-social, Bio-Psycho) for some facets of life. One example of a 
multi-class life aspect would be work. Work has psychological (sense of achievement on 
self-esteem), social (sense of camaraderie with coworkers) and miscellaneous (financial) 
components that may be affected by opioid usage. There are also some strong inter-
domain drivers: the social stigma of shame and past negative experiences with taking 
opioids in front of others may drive psychological appraisal of one's illness as well as 
how they feel their medication is best taken. This would in turn affect their behaviors. 
 
As a note, the Miscellaneous (Extrinsic Factors) domain serves as a gray area 
placeholder, where the appropriate domain fit is unclear for particular life aspects. These 
life aspects may still have impact on the other four domains. Financial impetus, for 
example, may not reside neatly into the biosocial-psychological spiritual categories; 
however it has a profound impact that changes responses within them. 
 
In defining certain classifications, I recognize that some of these measures might be 
subjectively brought to attention by patient interviews, or subjectively judged by 
physicians. This further demonstrates the difficulty of defining a gray area. 
 
One of the reported effects of taking opioids is that personal responsibilities are easier to 
meet. Although the perceived onset of action differs among my participants, most or all 
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agree that it lessened the burden and responsibilities of SCD patients. 
A negative effect of taking opioids is that these patients must encounter those that abuse 
medications and their associated stigma. It is very likely that abusers of opioids attempt 
to use SCD patients for their medication and the SCD patients then are labeled with the 
stigma of being associated with that group. 
 
 The effect of biological factors on other factors A.
 
The physiological effects of opioids appear to be the main mediator of the indirect 
biopsychosocial-spiritual effects, consequently altering future opioid-taking behavior. 
Physiological mechanisms serve as the link between opioids and other factors affecting 
medication taking behavior. For instance, genetic predisposition that aggravates certain 
side effects may partially influence how an individual perceives his or her medication as 
well as the actions they take seeking or avoiding social interaction. For all domains, 
patients may intensify or minimize pain by genetic predisposition. (181) Therefore, opioid 
use is partially dependent on biological factors.  
 
 Purity of the Model B.
 
While a theoretical model may not explain every aspect of an individual’s life, the 
domains included in this study can provide a framework for describing opioid taking 
behavior in SCD patients. Taxonomies serve to improve a general understanding and 
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classification taxonomy for future research. I believe that some aspects of these domains 
may fit into multiple domains. For example, vomiting and nausea are common side 
effects of opioids caused by biological stimuli. However, continued experiences with 
vomiting and nausea may cause an expectation bias that aggravates or reduces the side 
effects, therefore placing it partially into the psychological domain. 
 
To my knowledge, this is the first research based on patient interviews that can inform 
the debate about the appropriateness of the use of opioids in SCD, and contribute to the 
foundation of evidence-based practice. 
 
 Basis of Patient Responses C.
 
There are four ways that a patient typically responds to a new, life-changing diagnosis 
and its associated treatment: integrate (blend with existing lifestyle), assimilate (change 
lifestyle to be like those of others patients), augment (assimilate and do extra treatment), 
and rejection (reject the treatment and any lifestyle changes). 
 
V. Domain 5 Findings:  Advice for providers and fellow patients 
 
The participants were both verbose and consistent in their responses with regard to advice 
for the healthcare providers responsible for patients with SCD.  
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According to advice from my interviews; there was a nearly unanimous desire for 
physicians to listen to patients. This advice was presented from biological, psychological, 
social and environmental perspectives.  
One participant stated that patients “know what kind of medications work for them”. The 
perception here is that patients want more attention from physicians because they attest 
that they know their bodies and experiences best, and believe that their biological needs 
will be best met when their own opinion is taken into account. From a psychological 
perspective, there is a high level of self-worth, the patient strongly believes he or she is 
correct and wants that validation by his or her doctor. Statements like this allude to the 
possibility that patients are dissatisfied with the relationship they have with their 
physician, and therefore, do not trust the care-giving environment.  
 
A recurring theme in the interviews is that those experiencing pain are most aware of 
how much medication they need. One participant suggested that physicians “[u]tilize 
patients’ experiences and perspectives about SCD . . . in prescribing which opioid agent, 
dose, [and] frequency is most effective for them.” Statements like this suggest social and 
environmental dissatisfaction with the amounts of prescription prescribed by physicians. 
This also presents the desire to further the patient-physician relationship. Patients 
furthermore appear to believe that many physicians do not trust them, and fearing drug 
abuse, limit their prescriptions.  
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Another common response was that patients want to be trusted by their physicians. Many 
patients believe that they are not trusted and that they are denied the dosages needed to 
effectively treat their pain, because physicians believe they will abuse the opioids. 
Patients attest to this abuse with “stories about selling prescribed opioids” in which 
patients would relate that other individuals would misuse their prescriptions. Perhaps this 
is to defend themselves, but the acknowledgement here is that if physicians listened more 
to what their patients wanted and made accommodations based on individual visits and 
histories, there would be less abuse than the perceived “blanket dosage” which assumes 
that standard amounts of narcotics are effective for various individuals with different 
levels of pain.  
 
In order to improve physician-patient relationships, it would be beneficial to provide 
more dosage options and reduce outward suspicion towards clients. There appears to be a 
general consensus among the participants of this study that the people who will be 
benefitting from taking medication feel that they are under the scrutiny of caregivers. (180) 
 
Interviewed patients were asked to give advice to others living with SCD. Advice was 
given in the realm of biological, psychological and social domains, with emphasis placed 
on the effect of medication on one’s spiritual life and the interconnectivity of all realms 
of a patient’s life and wellbeing. Responses reflected knowledge of interviewees 
regarding how their disease worked (presumably from education at the clinic), and was a 
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reflection of awareness regarding perceived efficacy of reducing pain caused by SCD. 
Several items were dedicated to urging fellow patients to take medication as indicated.  
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VI. Other Important Findings Related to Domain 3:   
 
 Preferences for taking prescribed opioid based on pain intensity  A.
  
Previous studies showed that use of prescribed opioids depended mainly on pain 
intensity; (49, 50,171, 172) however, in my study, SCD patients vary in their preferences for 
when to take their prescribed opioids. Some reported they preferred to wait until reaching 
high levels of pain intensity before taking the initial dose, some will take prescribed 
opioids for any mild or moderate levels of pain (either for momentary pain or in 
prevention of pain escalation), while some take prescribed opioids in anticipation of pain.  
This behavior may be due to a variety of reasons.  Some may simply not like taking 
medications.  Others may believe the pain will subside on its own; others may not want to 
deal with potential side effects at the moment; others may not be thinking clearly because 
of the pain and medications already in their system.  Behaviors may vary from physician 
and patient expectations even with office visit counseling.  Theory and practice may 
rarely coincide so the physician and researcher may want to anticipate such behavior as 
normal.  Understanding this may help practitioner avoid frustrations of what may seem to 
abuse or abnormal behavior.  Also this will help the researcher design and implement 
educational programs for physicians and patients. 
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 Beliefs about how opioids work B.
 
Some patients, who reported taking prescribed opioids upon initially feeling mild pain, 
believe that taking the medication immediately will provide more rapid relief than when 
taken at a later point in time or upon more severe pain. In contrast, other patients that 
reported waiting some period of time before taking prescribed opioids believed that they 
do not yet need them and consider taking opioids upon early pain onset as misusing them. 
 
This belief may be derived from the concept of loading doses in the initial stages of pain 
management to prevent severe pain later: as indicated by one patient, a nurse taught them 
to “nip pain in the bud”. The concept of loading dose is common in areas where effective 
drug doses have a narrow therapeutic index (anticonvulsants, aminoglycosides, etc) but 
not in pain management. (182) Anecdotally, I have observed the benefits of administering 
high doses at the beginning of pain to decrease opioid use later.  This may also lead to 
decreased medical costs (decreased ED/hospital visits) and increased quality of life.  
 
A pain management researcher may adapt this concept in hospital and ED setting. A 
practitioner may consider this in the hospital/ED and may encourage patient in outpatient 
settings within prescribed guidelines use the concept of loading dose when crisis hit.  
 
 Intentional non-adherence in taking prescribed opioids when severe pain arises C.
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Patients reported deliberately not adhering to their prescribed opioid regimen by taking 
more when having excruciating pain. These patients openly admit to non-adherence with 
respect to their prescribed opioid regimens and justify their actions as normal behavioral 
responses to pain. This may indicate a common practice in which patients are not 
concerned about possible negative repercussions because they know themselves better 
than the physician.  As stated earlier, the combination of pain and medications in 
patient’s system may prevent logical thinking.  Practitioner may need to understand SC 
pain is different from other non-cancer pain in quality, regularity, and intensity, thus 
these behaviors are not indicative of aberrant behavior.  A researcher may consider future 
research to explore this behavior and how to use it effectively. 
 
While this is not the effective dose, patients preferred having higher strength of 
prescribed opioids in order to avoid prematurely running out of their medication and/or to 
exert more precise control in adjusting their dosage. 
 
 Taking Several Short-Acting Medications Simultaneously D.
 
Observed clinically and supported by my qualitative interviews, patients typically 
classify pain by severity and may ask clinicians to prescribe additional, alternative opioid 
medications by type of pain so that they may tailor their pain management plan of using 
prescribed opioids. As a result, routine practices of pain clinicians in my clinic involve 
prescribing multiple opioid medications so that patients may somewhat individually tailor 
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which agent to use based on intensity of pain, in order to allow for personalized, patient-
centered care. For example, clinicians may advise patients to use Percocet for mild to 
moderate pain and save Dilaudid for severe pain. Based on pain severity and their 
preferences, many participants autonomously adjust their use of different opioid agents. 
Interestingly, my interviews revealed that some SCD patients take various short-acting 
prescribed opioids simultaneously. This is due to the mistaken belief that different 
prescribed opioid agents will work synergistically in relieving pain. The converse is true; 
these short-acting medications compete mainly for the same opioid receptors. Thus, 
patients decrease overall efficacy of their prescribed opioids. Although there is no theory 
to support taking more than one short-acting med simultaneously, patients report pain 
relief not achieved with one or the other medication individually.  The practice may be 
due to subjective effect attributed to the combined effect of the short acting medications. 
All opioids work the same in theory but patient response varies for a number of reasons.  
Again, further basic and clinical research may be required to explain this observed 
finding. A practitioner may want to be aware that patients may explore unconventional 
regimens and are achieving successful outcomes.  
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 Use of OTC and herbal medications in addition to prescribed opioids E.
 
In my study, some SCD patients reported using over-the-counter (OTC) medications, 
such as Advil, Motrin, and Tylenol, along with prescription opioids for different reasons. 
First, these patients want to avoid the negative biopsychosocial side effects associated 
with taking high doses of prescribed opioids. Second, some patients are aware that OTC 
medications work using different mechanisms and wish to attain more complete pain 
relief by using a combination of OTC medications and prescription opioids. Third, some 
patients exhibit a negative attitude toward prescription opioid use, so they try to use OTC 
medicines in minimizing use of opioids (though they must occasionally use prescribed 
opioids despite their reservations). Previous studies have shown potential interaction 
between opioids and herbal medications.  Effects of one or the other may be intensified or 
decreased. Practitioners may want to have this information readily available for their 
patients that take herbal or OTC medications.  In practice, a table may be developed to 
insert in patient chart to assist practitioner and patient.  A researcher may help develop 
table of the most important interactions with the most commonly prescribed opioids. 
 
 Efficacy and satisfaction of prescribed medications F.
 
Throughout the interviews conducted, patients exhibited various levels of satisfaction 
with their prescribed opioid regimens. Most patients felt satisfied with their daily regimen 
with exception of times of excruciating pain, while a few were partially dissatisfied and 
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suggested changes to their prescribed opioid regimen.  Based on my sample size, I would 
not claim that that this is a valid, reliable and representative method of measuring the 
satisfaction of opioid efficacy in the general SCD population. Nevertheless, from my data 
we  reached the following conclusions: a) opioids are working in this subset of patients, 
b) their regimens are effective, and c) practitioners are meeting the patients’ needs. While 
few patients were unsatisfied, it is important to understand why in such cases.  Usually it 
is because the regimen is not working.  The cause of the ineffectiveness should be 
determined and addressed by practitioner. It is also possible that patient expectations are 
too high, that side effects have increased, their bodies have become tolerant, or other 
reasons.  Accordingly, practitioners may need to routinely evaluate the efficacy of the 
regimen.  Continued research is important to explore better ways of measuring 
satisfaction and reasons for satisfaction. 
 
 Initial responses to pain G.
 
SCD patients in my sample expressed different ways of initially responding to pain. Most 
patients would prefer to take their prescribed opioids simultaneously with home remedies 
(heat, bath, sleep, deep breathing, etc.) because they attribute their practice to “nipping 
pain in the bud.” This refers to their practice of stopping the pain before it escalates and 
becomes unbearable. Some prefer trying alternative remedies (such as herbal 
supplements and OTC medications) before resorting to stronger medication such as 
prescription. A few patients addressed waiting until reaching severe pain because either 
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they misjudged the quality, escalation, and type of pain or they are not ready to take the 
medication due to pending duties or responsibilities. Very few patients reported taking 
prescribed opioids first due to past experiences of failure with the other initial responses 
to pain. Future research needs to determine why SCD patients responded differently to 
initial pain and determine whether it is attributed to genetic, biological, or psychological 
etc. factors. With proper research, I could predict how people may respond to pain 
allowing practitioners to better prescribe effective regimens including opioid and non-
opioid therapies. 
 
 Reasons for Waiting for Initiating Medication Use H.
 
SCD patients in my qualitative phase conveyed reasons for waiting in initiating 
medication use. Often there was dislike with regards to biological side effects (e.g., 
hallucinations and uncharacteristic/atypical actions). Several patients indicated safety 
concerns (e.g., driving while experiencing hallucinations) as a reason for deferring 
medication use, while others indicated reluctance in becoming a burden to family 
members (i.e., family members have to give more attention to the patient). It is possible 
that reasons for delaying initial use of meds has more to do with avoiding side effects and 
negative consequences than achieving pain relief.  Sometimes patients consciously 
choose to endure pain in order to continue working, driving or to fulfill other duties.  
Further drug research may be indicated to discover agents with the efficacy of opioids but 
free of side effects. Perhaps modifications of a current entity or a new moiety altogether 
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will help.  When prescribing, practitioners may consider sometimes pain management 
may not be the patient’s primary goal.  Depending upon the intensity and quality of pain, 
pain management may be secondary to other responsibilities and duties.  The ultimate 
goal of therapy (drug or other) is to increase quality of life.  It should not be assumed that 
quality of life is increased only by decreasing pain when so many other factors may be 
involved. 
 
 Refraining from Taking Prescribed Opioids When Having Mild Pain: I.
 
Some participants in my study considered taking prescribed opioids for mild pain as an 
unsafe nuisance whose disadvantages outweighed the benefit of alleviating mild pain. 
They would express annoyance at how opioids would change their “system” (biological, 
lifestyle, behavioral, psychological, and social life norms) and present more of a danger 
than a safeguard. Reasons as reported by participants for such behavior were: a) fear of 
opioid dependency, b) concern about side effects and toxicity, c) wariness about taking 
the medication earlier than prescribed and being perceived as an opioid abuser, d) 
excessive worry about harmful effects of opioids, e) believing the opioid needs more time 
to take effect, and f) having a negative attitude towards taking opioids. For example, 
some participants repetitively expressed, “I'm not the type of person who takes 
medication easily.” As stated previously, other factors are involved in patient’s quality of 
life not pertaining to pain relief. Researchers may want to further define these factors in 
future research.  For example, “What is quality of life and what factors contribute to in in 
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patients with SCD?”  It is easy for practitioners to focus on pain relief and may lose sight 
of these other factors when prescribing.  Practitioners may want to have such a 
conversation with their patients periodically and use the results to help develop individual 
regimens.   
 
 Reasons for Waiting Before Taking Subsequent Doses: J.
 
Some participants in my study described a number of unusual (curious) behavior in 
which they try to maximize the interval between doses by waiting as much as they can 
tolerate until they reach the level of unbearable pain and feel “really need it 
[medication].” The reasons behind this behavior were similar to reasons mentioned for 
refraining from using prescribed opioids. Those participants who exhibited such negative 
attitude often described reluctance, hesitation, or avoidance to taking their medication at 
all.  
 
 Reasons for Taking More Prescribed Opioids in Terms of the Recommended K.
Interval between Doses 
 
On the other hand, some participants will increase their intake of prescribed opioids 
during periods of unbearable/intolerable pain due to the stress of being in pain for a long 
time. They may perceive excessive pain as a medical emergency that triggers a 'fight-or-
flight' response and fight the pain using more of their medication. Some of the 
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interviewees justified decreasing regularity of the time intervals between doses of opioids 
by pitting the severe, excruciating pain against beliefs that more frequent dosage of 
medication would not cause more harmful/toxic effects and side effects experienced 
would be tolerable/acceptable. These participants were much more at ease with 
modifying their drug regimen and were more liberally lenient with their prescribed opioid 
use.  As discussed earlier, excruciating pain in combination with effects of meds already 
in patients system may lead to unclear thinking.  Patients that would not normally take 
frequent doses may do so under the influence of pain and meds. Researchers may 
consider trying to determine at what point does pain relief becomes the determining 
factor in quality of life in patients with SCD.  Such research may help explain these 
unusual behaviors.  If practitioners had this information readily available, individualizing 
therapy may become easier. 
 
 Self-Gratification and Taking Advantage of Opioids (Self-Enabling Behavior) L.
 
Some participants hold a flexible range to themselves about the acceptable amount of 
medication that they may take because of the availability and accessibility of their 
prescribed medications through their physicians, and because of looser personalities. 
They try to self-gratify their want to be painless without exerting self-control or 
constraint and show inconsideration towards clinicians' instructions and their health. This 
epicurean/self-enabling behavior may occur without physical craving to taking 
medication.  Some SCD patients use their disease as a justification for taking opioids.  
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Their experience has shown them they are capable and may even require a higher dosage 
than a “normal” person.  Some patients exhibit pride in the ability to take more meds than 
others.  It is similar to the pride some have at being able to “drink others under the table.”  
Some of this is tolerance, while some may be a psychological issue peculiar to SCD 
patients.  Research may be indicated to ascertain how this relates to appropriate treatment 
of SCD.   
 
 Impact of Prescribed Opioids on Family Members M.
 
SCD patients reported different stories and anecdotes regarding how they became a 
burden to their families while under the influence of the prescribed opioids. Additionally, 
they described this bothersome nature; some said that their families felt scared, 
concerned, and anxious about their medication use.  A lot of time is spent educating 
patients and practitioners about appropriate therapy when using opioids.  My results show 
the possible need to educate families also. Little research has been are done on the effects 
of opioid use on family members. On the surface, the effects seem similar to that of 
family members of addicts and alcoholics.  On a deeper level, the sources of shame, for 
example, are different because addiction may involve illicit activities.  US culture looks 
down upon addicts or alcoholics for various reasons. Some may be shared by family 
members of SCD patients, while other reasons are unique to this subset.  Though sickle 
cell disease is recognized as a disease (some still argue the point regarding addiction), the 
African American community has its own issues of shame concerning this disease. If 
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SCD patients are not taking their opioids appropriately because of the reaction or 
perceived reaction of family members, investigators may want to examine these 
phenomena more closely.  Practitioners may want to take into consideration family 
dynamics when developing patient regimens.  Similar situations exist with other disease 
states.  For example, new diagnosed diabetics may have family members trained to 
administer insulin if the patients are considered unable to give themselves the medication.  
The same may be true for some SCD patients and their families. 
 
 Downward Social Comparison N.
 
Some of my SCD participants exhibited the phenomenon of downward social 
comparison. This refers to their tendency to compare themselves to others whom they 
believe are in a worse situation in terms of health status in order to separate themselves 
from perceived stigmas associated with other SCD patients and improve their feelings 
about themselves and their health condition. This concept was introduced by Wills in 
1981 [ref]. For example, some participants took a moral high ground, repeatedly stating 
that they would not abuse or take advantage of their prescribed opioids like other SCD 
patients, and assert or claim that many other SCD patients typically do.  The shame of 
SCD in the African American community was mentioned in detail in earlier point.  If 
SCD patients are not taking their opioid med appropriately due to this phenomenon, 
research may be indicated.  Promising oneself to never abuse opioids to prevent 
appearing as someone who is an abuser or perceived abuser may make oneself feel better 
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than someone else.  The fact is, no one plans to become tolerant/dependent/addicted.  It is 
easy to promise oneself never to take opioids inappropriately when one is well but it may 
be more difficult during a crisis.  I have already mentioned the effects of excruciating 
pain and the effects of meds in the patient’s system on adherence.  I have also briefly 
discussed the stigma within the African American community. These may be issues for 
psychologist/sociologist to examine further in hopes the results may guide practitioners. 
 
 Comparing Personal Use of Opioids to Others O.
 
In addition to asserting their differences to other SCD patients, some interviewees also 
cited similarities and comparisons to other SCD patients, cancer patients, and patients 
with non-cancer pain. When asked about whether they perceived they take higher or 
lower doses of prescribed opioids than cancer patients, many participants said they were 
prescribed similar drug regimens. Meanwhile, others stated that they felt or thought they 
took more pain medicine relative to any other set of patients with cancer or non-cancer 
pain.  I am not sure why some perceived their dosage more different than other subsets of 
opioids users and what they are basing their responses on. Possibly, it is an assumption 
about how they perceived their health status.  It is also possible that they have a 
relationship with someone in those other subsets of SCD patients who use less or more of 
prescribed opioid. It is possible that it is the result of downward social comparison or 
other phenomenon. This may be an issue for psychologist or sociologist to examine in 
hopes of guiding practitioners. 
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 Prescribed Opioid Consumption During Crisis Days P.
 
Although many SCD patients inconsistently consume prescribed opioids along typical 
days with or without pain, most of the prescribed opioids are heavily consumed during 
unpredictable crisis days. The BPSS situations may be the source of this inconsistency in 
medication use. Further research need to investigate the in detail the full description and 
the source of the inconsistency during typical days. Researchers may need to address the 
allowable consumption of opioid during crisis days.  
 
 Uncertainty of How to Use Medication as Prescribed Q.
 
Along my interviews, I asked participants to recall the written instructions on their pill 
bottles and the doctor's verbal instructions. I found that many patients were uncertain 
about the number of pills to be taken per dose, the frequency of doses per day, the 
interval of time required between doses, the maximum allowable doses per day, and the 
acceptable agents to be used concomitantly. This could imply that the non-adherence 
found in my sample to pain medicine regimens could be attributed to this partial 
uncertainty of how to use the medications. 
 
Non-adherence due to patient’s inability to follow practitioner’s instructions is not 
uncommon.  I am not sure if these issues any different than patients of other disease 
  
 
176 
states. Therefore, I cannot attribute the problem to SCD. Researchers need to further 
investigate if these issues are different in other disease population. In future research, I 
can determine the rate of non-adherence due to lack of understanding practitioner’s 
instructions in this population and compare it to other studies.  
 
 Variability of prescribed Immediate-Release Opioids R.
 
In my sample, the highest frequency (number of times a day) of taking immediate-release 
opioids reported was 12 times a day, the lowest frequency reported was 0 times a day, 
and the average frequency was 8 a day, which does not correspond to the average number 
of times actually prescribed. This variability represents a form of non-adherence. This 
form of non-adherence may be attributed to different pain severity and experience among 
participants. 
 
 Changing Regularity of Taking Prescribed Opioid S.
 
Regularity of taking medication is defined as a description of a way of taking medication 
with regards to taking medication as-needed or on a fixed schedule. Surprisingly, some 
participants naïvely use their as-needed opioids on a regular, fixed schedule instead of 
taking them as required (based on their episodic judgment and perception of level of 
pain).  
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1. Misunderstand, “dunno” 
 
For some of those patients who reported taking their as-needed medications with set 
intervals of time between doses, this behavior could be attributed to their lack of 
knowledge in how their immediate-release opioid should be used. Moreover, such 
unawareness could happen as a result of miscommunication among physicians, 
pharmacists, nurses or patients. This may be due to past experience.  If patient knows 
opioid will last 4 hours, they may naturally set-up a schedule of taking medication every 
four hours to prevent the possibility of future pain.  Has anyone asked the patients why 
they do this?  
 
2. Pain Avoidance and Pain Anticipation (Premonition) 
 
For some other patients, as-needed pain medication was taken regularly in anticipation of 
pain. Whether this anticipation was as a result of feeling an “aura” and preceding signal, 
fear of unpredictable pain, fear of consequences of pain, or other fears (e.g., nosophobia, 
thanatophobia), the result of such feelings was exaggerated pain avoidance leading to 
overuse of immediate-release opioids. 
 
3. Dependence 
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Unknowingly, some patients may start to become dependent on their prescribed opioids 
through the nature of sickle cell anemia pain in terms of quality, intensity, regularity, and 
frequency, as well as the physical dependence on taking opioids for pain management 
over an extended period of time. This emerging dependence behavior may be naively 
founded on good intentions by the patient in coping with the unique characteristics of 
SCD pain. 
 
 Knowledge and Perception of Prescribed Opioids and Adherence T.
 
My findings in this study indicate that patient knowledge and awareness may cause 
different adherence behaviors. As an aside, there is a cultural (familial, community, and 
governmental) show of little effort regarding attentiveness to medication and its most 
practical applications. Embodiment of this sentiment may ultimately result in sub-optimal 
care, lowered attentiveness from both patients and providers, and lower awareness of 
correct prescribed opioid usage. Some patients are aware of the risks involved with taking 
opioids, including side effects, toxicity, and risk of dependence, and some 
pharmacological aspects (onset and duration of action). Practitioner may want to keep in 
mind the role of different source of knowledge in non-adherence.  How many to take, 
how often to take and the impact of opioids?  Non-adherence in SCD may be due to 
different reasons than that of non-symptomatic disease states such as diabetes and/or 
hypertension.  For example, the pain of SCD is a reminder for the patient to take their 
pain meds.  If a diabetic forgets their oral medications, they probably will not have 
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symptomatic signs to remind them to take the meds.  Practitioners may want to keep in 
mind not only the typical causes for non-adherence but also the motivation provided by 
the desire for pain relief plus the unwillingness to endure side-effects as mentioned 
earlier.  Therefore practitioner needs to educate their patients of the importance of taking 
their meds as instructed especially during a crisis.   
 
 Types of Patient Attitudes  U.
 
Based on my qualitative study, participants exhibited attitudes towards two facets of 
taking opioids: (1) general associations with medicines, and (2) specific associations with 
opioid medicines. An ambivalent to negative attitude was prevalent among general 
associations with medicines, as participants would describe wanting to limit the amount 
of (harmful/unnatural) chemicals going into the body. This attitude was extended towards 
physical aspects, such as difficulty in swallowing the large opioid tablets, or social 
aspects, such as public and self-perception of dependency on a drug. On the other hand, 
specific associations with opioid medicines imparted much stronger positive or negative 
outcome attitudes. Experiences with biopsychosocial effects, for example, drowsiness 
and possibility of addiction, daily functioning, and social stigma, often polarized 
participants' attitudes. 
 
Ultimately, associations with both prescribed opioids and medicines in general, such as 
those outlined above, form an overall opinion towards taking prescribed opioids. This, in 
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turn, may affect patients' final opioid-taking behavior until new experiences alter existing 
attitudes. 
My participants showed 4 different types of overall attitudes towards prescribed 
opioids:  
(1) Positive (mild to extreme) 
Ex: I have no problem using prescribed opioids and medicine in general, and 
favor use of prescribed opioids for their biopsychosocial effects. 
(2) Negative (mild to extreme) 
Ex: I do not like using prescribed opioids or medicine in general, nor do I support 
use of prescribed opioids for their biopsychosocial effects. 
(3) Ambivalence (weakly or strongly) 
Ex: I do not like using prescribed opioids and am OK with using medicine in 
general, but do not mind use of prescribed opioids and medicine in general 
because I need them to function. 
Ex: I am OK with using prescribed opioids and using medicine in general but do 
not like their biopsychosocial effects. However, I do not mind use of prescribed 
opioids because I need them to function. 
(4) Apathy 
 
Ex: I feel indifference towards prescribed opioids and medicines in general. 
Interestingly, my qualitative results show that the positive, negative, and ambivalent 
attitudes affected opioid-taking behavior among my participants. I observed that positive 
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and ambivalent attitudes were more likely to stay strictly adherent to the prescribed 
regimen. Regardless, these behaviors were still prone to non-adherent behavior (overuse 
and/or underuse). Some participants with positive attitudes tended to experiment with 
their opioid-taking behavior, while some participants negative attitudes tended to abstain 
from opioid-taking behavior. Furthermore, some participants expressing ambivalent 
behaviors were prone to erratic opioid-taking behavior, sometimes taking more and 
sometimes abstaining from prescribed opioids. 
 
 Origins of Differences in Attitude Regarding Prescribed Opioids and V.
Adherence 
 
Many participants showed a negative and hesitant attitude towards prescribed opioids, 
while a few had a greatly positive and enthusiastic attitude towards taking prescribed 
opioids. On the other hand, many participants also described different attitudes among 
healthcare providers. Further research is needed to investigate the reasons behind 
differences in attitude among SCD patients. 
 
 Frequent Episodic Judgment and Mental Fatigue  W.
 
Frequent decision-making may result in mental fatigue in SCD patients. Because SCD 
patients must cope with chronic pain on top of daily activities and life events, the process 
of judging whether or not to take pain medicine is a complex one that stresses mental 
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faculties. The strain of constantly having to make such decisions based on a variety of 
factors (e.g., to take medication or not, judge the level of pain, which medication to take, 
how it will affect other activities, amount of prescribed opioids left, etc.) may lead to a 
hands-off approach in which SCD patients use their as-needed medication on a regular, 
timed schedule in avoidance of continued decision-making. As an additional note, this is 
a misuse of medication and form of non-adherence to doctors’ instructions. 
Decisions of this type may also be clouded by desperation to lessen pain, due to the 
unique nature of SCD pain (i.e., excruciating pain over an extended period of time 
without break). Such pain may cloud judgment when making decisions, and create 
situations in which the patient may become unreliable or careless when determining 
which medication to use, or whether or not to use opioids. Furthermore, use of opioids 
may itself cause judgment impairment through its possible side effects (feelings of 
euphoria, vomiting, etc.) that positively or negatively affect personal bias towards using 
prescribed opioids for pain. Other effects of opioids and excruciating pain may cause 
patient to forget when they took the last dose.  If patient cannot remember when they 
took the last dose and they are still in unbearable pain, they may take a dose earlier than 
prescribed. I must also consider the fact that some patients may be using illicit drugs to 
control pain or other reasons which play a role in inhibit the appropriate thinking process. 
 
 Wanted vs. Unwanted Euphoria  X.
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Surprisingly, I found a contrast within my sample in which some participants desired the 
euphoria that sometimes accompanies opioid use, while others disliked it and found this 
euphoria as an annoyance or hindrance that negatively affected their norms of living. This 
may be attributed to the various forms in which different people experience euphoria. (177) 
Unsurprisingly, because some patients enjoy their feelings of euphoria, they may be 
either diverging their opioid use or at risk of diverging. Although euphoria is a well-
known signal used in assessing aberrant behavior, patients may begin unintentionally 
associating feelings of euphoria and painlessness and create a behavior in which habitual 
pain management is linked to a habitual high. Patients may also perceive that they 
deserve the painlessness that is common among people who do not experience SCD pain. 
Furthermore, because there is variation in descriptions and desire of euphoria, use of 
euphoria in assessing aberrancy is questionable as a determinant signal. 
 
 Routinization of Taking Medicine Y.
 
Many of the interviewed participants reported routinization (i.e., linking use of 
medication with a specific habitual time, environment activities of taking their medicines. 
For instance, some participants would take long-acting medicine upon waking, getting 
home from work, while watching television, before going to bed, or taking the long-
acting medicine concurrently with short-acting medication. Routinizations were 
generated by different situational prompts: time-specific (e.g., in the morning), context-
specific (e.g., when in more pain than usual, while watching television), or situational-
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time-specific, a mix of the two (e.g., in the evening after work or at the end of the day 
with few responsibilities). Interestingly, short-acting medicine received much of the same 
treatment; the same type of routinization took place based on time, context, or a mix of 
the two: taking medicine upon waking, getting home from work, while watching 
television, before going to bed, while taking long-acting medicine. Routinization of both 
medicines (long-acting and short-acting) may imply habituation of taking prescribed 
opioids as a perceived means to remind and guarantee proper opioid taking 
behavior/adherence and decreased need for frequent pain judgment that would result in 
mental fatigue. Routinization of long-acting opioids will eventually reduce the use of 
short-acting medication. 
 
 Prompts for Taking Medications Z.
 
Some patients may not routinize the medication-taking behavior, but they may 
unintentionally link spontaneous or habitual events to medication. Overtime, they 
condition themselves to associate particular circumstances with taking medication, 
similar to Pavlov's experiments regarding reflexes and conditioning (Pavlov's dog). For 
instance, many of my participants would link medication to waking the morning. 
Likewise, awakening in the middle of the night would trigger one participant from my 
study to take a dosage of medication whether or not the wakefulness was due to pain. 
This may be linked to past experiences when they did not take their meds after 
awakening in the middle of the night but later suffered a crisis. As for taking upon 
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awakening, it is possible that some patients may feel as though they been without it all 
night and need to get it into their system to feel normal to prevent feelings of withdrawal. 
 Behavioral and Physical-Chemical Experimental Non-adherence AA.
 
Participants described different ways of modifying/altering their medication-taking 
regimen; I have classified these methods under two main groups: physical-chemical non-
adherence and behavioral non-adherence. Physical-chemical non-adherence refers to 
altering the physical and/or chemical characteristics of the dispensed dosage form of the 
prescribed opioid. This can be further sub-classified into the context of the alteration: pre-
, post-, or during administration. Participants reported crushing long-acting tablets before 
swallowing the tablets (pre-administration), applying heat to skin after putting on 
Fentanyl patches (post-administration), or swallowing tablets with alcohol or any other 
solution that may change its physical-chemical properties (during administration). 
Behavioral non-adherence refers to the deviant patterns of taking medication as 
prescribed. For example, participants would report taking more or less pills per dose or 
changing their frequency of taking medicine from what was prescribed. It is possible that 
some patients express the need to “boost” the effects of their opioids.  Whether this 
phenomena is physical or behavioral remains to be determined.  It may be different for 
each patient.  It may also be some combination of physical-chemical and behavioral.  
“Boosting” the opioid may be an indicator of addiction or ineffective pain management. 
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 Types of Behavior BB.
 
Qualitative thematic analysis uncovered several patterns of opioid-taking behavior 
and several related biopsychosocial-spiritual phenomena, some hypothesized and 
some not. The main three phenomena are 1) SCD patients exhibited various opioid-
taking behavior patterns including adherence, overuse, underuse, and erratic use 2) A 
wide variety of biopsychosocial-spiritual factors hindered or motivated opioid use: 
pain intensity; side effects; fear of addiction; perceived stigma or judgment by others; 
senses of responsibility, productivity, hopelessness, or obligation; stress; social role 
pressure; social desirability; bullying; and anticipatory fear of adverse outcomes; and 
3) Behaviors varied based on the time of day, week, month, or year, and based on 
context at times of doses.   
 
My results raise the hypothesis that, for opioid use in SCD, either of these behaviors 
(overuse or underuse), and presumably all six categories of behavior, including erratic 
use, overuse, underuse, adherence, erratic, arbitrary, and complete withdrawal, may 
be intentional or unintentional.  But I found few if any references describing 
unintentional and intentional use in all six behaviors I discovered in my qualitative 
study.  For example, aberrancy has been defined as “Taking medication in a manner 
that is not prescribed, which may be because of addiction, pseudoaddiction, chemical 
coping, or diversion” (51) and also has been defined as “A behavior outside the 
boundaries of the agreed-on treatment plan which is established as early as possible in 
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the doctor- patient relationship. (52, 179) While non-adherence has been defined as 
“Any use of a medication by the individual to whom it was prescribed where the 
medication was not taken in accordance with prescription directions or where any 
additional specified conditions of treatment were not met”. (52) Most of  the adherence 
literature focuses on underuse while most of studies of opioid use focus on overuse. 
Further, medication-taking behaviors may be intentional or unintentional.  Most of 
the adherence literature focuses on unintentional underuse while most of the addiction 
literature focuses on intentional overuse.  
 
Another explanation for this finding could be that patients reported themselves to be 
more or less adherences than they actually were. Patients may have had a tendency to 
consciously and/or unconsciously want to show their treating physicians that they are 
adherent. This dissertation research probed for whether these six behaviors can be 
classified as intentional or unintentional, but the instrument I intend to develop will 
not itself be designed to determine unintentional vs. intentional behavior (See Figure 
15).  
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Figure 15: Taxonomy of Opioid Taking Behavior in SCD 
 
 
 
 
 Forms/Ways of Behavioral Non-adherence CC.
 
Patients reported several ways of noncomformity when using their prescribed opioids. 
Their forms of noncomformity may be grouped in terms of (See Figure 16): 
1) Amount per dose: increasing or decreasing number of tablets per dose 
2) Duration of therapy: overall time period over which the medication is supposed to 
be taken 
Ex: Taking long-acting prescribed opioids for 2 days a week 
3) Frequency: number of times per day medication is taken 
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Ex: Taking long-acting medication 4 times a day instead of every 12 hours or taking the 
short-acting opioid 12 times a day instead of 6 times a day as needed 
4) Time interval between doses 
Ex: Participant would shorten wait-time before next dose of short-acting opioid (waits 1-
2 hours instead of the recommended 3-4 hours) 
Ex: Participant would lengthen wait-time until feeling excruciating, unbearable pain 
before taking medication (extreme time interval between doses) 
5) Maximum allowable dose per day 
Ex: Instead of maintaining a maximum of 12 tablets per day of Percocet or Tylenol III, 
participants will sometimes take 16 tablets, which exceeds the 12-tablet maximum 
allowable dose 
6) Regularity: Changing the pattern or periodicity of fixed-schedule medication to 
use it as needed for excruciating pain, or using as-needed medication on a fixed 
schedule regardless of pain intensity 
Ex: Establishing a fixed-schedule for short-acting (as-needed) medication; e.g., taking 
Dilaudid every 4 hours a day 
Ex: Using long-acting opioids as-needed 
7) Substituting: replacing a more efficacious medication for another 
1. Changing the type of prescribed opioid agent 
Ex: Taking Dilaudid for any pain anticipation or mild pain instead of reserving Dilaudid 
for strong pain 
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Ex: Insisting on taking Tylenol III for excruciating, unbearable pain and refusing to 
receive stronger oral or IV opioids 
2. Changing the class of pain medicine: There are different classes of pain 
medicine such as opioids, NSAIDs, and other classes of pain medicine 
Ex: Using 400mg ibuprofen for severe, excruciating pain instead of using any type of 
opioid 
3. Changing to a non-pain medicine: Changing from any class of pain medicine 
to other non-pain classes (e.g., adjunctive medicine) of medication to manage 
pain 
Ex: Using antidepressants, anticonvulsants, muscle relaxants, alpha-2-adrenergic 
agonists, anesthetics, and/or steroids for excruciating, unbearable pain instead of opioids 
8) Taking inappropriate, other prescribed, or OTC medications concomitantly with 
opioids 
1. Two opioid agents concomitantly 
Ex: Taking Dilaudid and Percocent concomitantly 
2. One opioid agent and one non-opioid pain medicine concomitantly 
Ex: Taking prescribed ibuprofen concomitantly with prescribed opioids 
3. One opioid agent and one non-pain medicine concomitantly 
a) Adjunctive pain medicine (e.g., prescribed gabapentin, carbamazepine 
Ex: Taking tricyclic antidepressants (e.g., amitriptyline) concomitantly with prescribed 
opioids 
b) Non-adjunctive pain medicine 
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Practitioner may want to keep in mind that SCD patients may have other ailments being 
treated by other practitioners.  Therefore other meds used to treat other ailments may be 
in their profiles. It should not be assumed to be aberrant behavior.  Practitioner should 
have a clear history of their drug history including meds written by other practitioners. 
 
Ex: Taking cyclobenzaprine (Flexeril) concomitantly with prescribed opioids 
4. Using herbal remedies, dietary supplements, and non-pain OTC medications 
concomitantly with opioids 
Ex: Taking Capsaicin concomitantly with prescribed opioids 
9) Off-prescription use 
Ex: Valium or sleep-aid medication  
10) Type of pain medicine prescribed 
1. Various opioid agents with variable potencies,  
2. Use of ER for pain management 
3. OTC or non-prescribed non-opioid pain medicine [ex: Motrin, Advil]  
  
  
 
193 
Figure 16: Ways/ Forms Medication- Taking Behaviors 
Some of the above forms of non-adherence may be due to factors previously discussed.  
e.g. pain and use of opioid may impair patients ability to make decisions. I found that 
adhering to all aspects of opioid prescription is problematic, with waiting interval period 
between doses being the most difficult to follow.  
 
 Medication Adherence and Forgetfulness DD.
 
Most patients reported different variety of situations of forgetfulness with regards to 
taking their medications. Sometimes they would forget to carry their pain medication on 
  
 
194 
outings, to fill the prescription, where they placed their medication, or to follow the 
fixed-schedule for their long-acting opioids.  
 
1. Frequency of Forgetting 
 
When I asked participants how frequently they forgot to take their medicines, I heard a 
variety of responses. Some of them said that forgetting is something they would never do, 
some said that forgetting was something that happened more often than not, and then 
some would say that forgetting was an occasional or rare occurrence. 
 
2. Reasons/Context for Forgetting 
  
Participants dealt with two main types of reasons for forgetting: activities-oriented and 
stress-oriented. Activities-oriented refers to forgetfulness that comes with rushing in 
anticipation of work or home duties, planned or unplanned business (e.g., appointments, 
meetings), or temporary situations of increased activities in which medication-taking 
habits are disturbed. Stress-oriented reasons dealt with extremes of stress. Any stressor 
(e.g., financial) would trigger forgetfulness; in contrast, extreme relaxation and merry or 
distracted (e.g., family gatherings, church) would also cause forgetfulness. 
  
Another context of forgetting, some individuals not only forget to take their medicine, but 
rather they forget to have their medication on hand at all. These individuals may go for 
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days or weeks without filling their prescription. SCD patients must balance self-duties 
and self-satisfaction, but they may create an imbalance in which they push their personal 
needs to the side. An example of this is setting familial priorities (e.g., babysitting, 
driving relatives, or working) over self-care priorities (e.g., scheduling an appointment or 
driving to a faraway pharmacy ahead of time to fill his/her prescription). Such 
procrastination may lead to exhaustive pain, consequently leading to ER visits or 
hospitalization. This may also be due to patients being out of habitual contexts (e.g., on 
vacation) that would remind them of their medicine, or an untroubled behavior as result 
of negligence, carelessness, or absentmindedness. Thirdly, patients sometimes 
underestimate the amount of medication they need or overestimate the amount of time, 
prescriber availability/flexibility, and market availability of medications they have, 
leading to poor planning and medication management. 
 
c. Most Common Time of Day 
Participants repeatedly reported that morning time (i.e., getting ready for the day) and 
evening time (i.e., upon returning from work) were the most common times of day during 
which forgetfulness occurred.  
 
d.   Most Common Situation/Context 
I found a common thread among situations of forgetfulness: Rushing. Throughout the 
day, sickle patients said that when they were rushing to appointments/meetings/work or 
having unplanned activities, they would forget to either use/utilize or carry their 
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medications. Patient may forget to take pain meds when they are not having pain.  The 
pain could be a reminder to take opioids. 
 
3. Strategies after Forgetting to take a dose 
 
After forgetting to take a dose of prescribed opioids, participants exhibited four strategies 
with four subsets each. The four strategies are as listed: 
1) Overcompensating: Increased dosage to “catch-up” 
2) Undercompensating: Decreased dosage to ease medication back to steady levels of 
opioid amounts within the circulatory system 
3) Taking no medication: Taking no dosage for an extended period of time 
4) Maintaining same dosage: No change in dosage amount. 
 
Each strategy varies with time of realization of the missed dose and time of the 
subsequent dose, creating four subsets. For instance, a patient may overcompensate upon 
realizing a missed dose, then either overcompensate, undercompensate, maintain, or 
altogether reject the subsequent dose. Additionally, patients who use the fourth strategy, 
maintaining the same dosage, may take two paths upon not taking the next dose: either 
wait until the succeeding dose to take the same dosage, or shift their entire fixed 
medication schedule to maintain time intervals between doses. 
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 Psychological and Emotional Aftereffects of Missing a Dose EE.
 
Though missing a dose of medication may be a careless behavior, SCD patients in my 
sample often reported various feelings upon missing a dose: indifference, feeling “bad” 
(possibly guilt), and stress (fear and anxiety of the consequences).  
 
 Effect of Anxiety, Fear, and Aura on Medication-taking Behavior FF.
 
1. Classification and Differentiation  
 
It is common knowledge that an “aura” sometimes precedes a migraine or epileptic 
seizure after a prodrome (early symptom or stage indicative of a disease before the 
disease actually occurs). Prodromes typically include feelings of being “off”: for 
example, cravings, fatigue, happiness/sadness, upset GI symptoms. Auras for migraines 
or seizures are changes in perception: visual, auditory, motor-related, some emotional 
disturbance (e.g., fear), or an unexplainable feeling. For migraines and epilepsy, an aura 
follows the prodromal phase just before the actual migraine or seizure. However, such 
distinct phases with unique signs and symptoms for SCD may not be as exclusive as 
those for other diseases. Though any prodromal states and auras before crises have not 
been explicitly described or surveyed among adult SCD patients, participants in my study 
included an occasionally heightened signal when describing the timeline of a pain crisis. 
Despite a lack of visual and auditory “aural” symptoms among my participants, distinct 
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feelings of fatigue, weakness, nausea, mild pain, anxiety, or “still before the storm,” an 
unexplicable “feeling,” were described as signals before pain onset, mirroring auras of 
migraines and seizures. Prodromal symptoms and signs do exist: yellow eyes, pallor, 
enlarged spleen, sweating, fatigue, etc.  Some signs may be those easily recognized by 
patients and their close support network, and some may be more recognized by their 
providers before the crisis. Furthermore, I could not classify some participants’ 
descriptions as prodromal or aural (e.g., fatigue lasting for weeks before a crisis or within 
the half-hour before a crisis).  
 
Like described prodromal auras for migraines and seizures, not all auras progress to 
crises and not all crises are preceded by auras. I will differentiate between those that do 
not progress as independent auras (as in the literature) and “true” auras that progress to 
pain crisis.  
 
As with some other non-cancer (or pain-related diseases), fear is a central component to 
patients. My SCD participants reported fear of medicine, fear of opioids, fear of pain 
before, during, and/or after taking part in activities, fear of pain in general, fear of having 
a crisis, fear of consequences including fear of death, and fear of recurring pain.  
Fear, as described above, may also be part of a patient's aura.  
SCD patients sometimes panic based on the quality of pain due to anxiety and 
anticipation of severe pain. Some patients may also have a fear of opioids' side effects: 
one patient attributed the onset of a crisis and acute chest syndrome to taking prescribed 
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opioid medication. This may, however, also be linked to opioid-induced hyperalgesia, in 
which patients may experience heightened pain sensation and may imprint false feelings 
of impending pain.  
 
In my sample, many participants described feeling anticipation, which is the expectation 
of pain based on the following: pain intensity, planned activities, type of activities, level 
of exhaustion, previous experience, unplanned activities (during the activity), and auras. 
Constant levels of anticipation are also common due to the recurring, chronic nature of 
SCD pain. However, while fear and anticipation do not necessarily go hand in hand and 
may be experienced singly, anticipation may stem from fear or unnecessary, exaggerated 
fear.  
 
2. Effects on SCD patient behavior 
 
i. Instantaneous pain vs. planning 
 
Anticipation may be used by SCD patients to plan their day if they know they can trigger 
pain (e.g., doing yard work may cause physical exertion, and, consequently, pain) and 
treat accordingly, or may negatively affect SCD patients by scaring them into taking 
excessive opioids out of fear of crisis and/or nonproductively or, in contrast, into taking 
less or no opioids out of fear of addiction, abuse, medicines, or side effects, as well as 
productivity.  
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ii. Adherence vs. non-adherence 
 
Opioid-taking behavior may be influenced strongly by auras, fear, panic and anticipation 
as patients may reason a holistic balance for themselves based on the different aspects of 
their lives. Fear and panic impact how a patient perceives medications, allowing one to 
rate a prescribed opioid as good or bad and act accordingly. Auras and anticipation may 
then alter how a patient plans ahead. Accordingly, the degree of alteration to prescribed 
opioid instructions may vary based on a feeling of what may come and what needs to be 
done to manage one’s pain with regards to momentary and projected biopsychosocial 
circumstances. This ultimately results in adherence or different non-adherence behaviors, 
such as overuse and underuse. 
 
Despite the influence of social desirability on reported adherence with regards to their 
provider (good doctor-patient relationship), reasons for adherence may also be strongly 
influenced by fears. Fear of termination from the clinic, fear of change, fear of addiction, 
fear of side effects, etc. may work in conjunction to steer individuals to strictly adhere to 
their given prescription whether or not the techniques of self-adjustment of  pain using 
prescribed opioids is optimal (i.e., individuals resist the notion of dosage self-adjustment 
with regards to prescribed opioids).  
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 Impact of Insurance 'prior authorization' on Patient Care: GG.
 
Some participants express inability to adhere to prescribed pain medication regimen 
because insurance refuse to approve the type and amount of medication necessary for 
treatment. 
 
Prior authorization is a cost driven program that may apply to any type of prescription 
medications. Prescription medications subject to the prior authorization program require 
insurance approval before the insurance company will pay for the medicine. 
Review and pre-approval Prior authorization programs are supposed to help encourage 
the appropriate use of medications and supposed to reduce the chances of unnecessary 
drug treatment and help contain overall healthcare costs. In addition, some insurance 
companies claim that by reducing the amount of pills approved per month they lessen the 
risk of overdose (intentional or accidental), misuse, abuse, diversion and addiction. The 
process of authorization delays the appropriate treatment for the patients. Continuation of 
current treatment is disrupted. Also, initiation of new treatment may be aborted. Both of 
these may result in visit to the ED and/or hospitalization.  
 
Patients, who have an intolerance to multiple medications, even when they are from 
different classes of drugs, are more likely to be sensitive to a new medicine.  The 
question remains: Why should a patient be forced to try a different pain medication just 
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because it is on the insurance company’s formulary or available at a certain tier level so 
patient has a lower co-payment? 
A change in the usual prescription for the patient’s pain medications (including a change 
in the drug, the type of medication, the dose, or the quantity allowed for the month) may 
lead to an increase in the number of ED visits, hospitalizations, and misuse of their 
medicines.  It also may lead to the development of drug-seeking behavior and a need to 
experiment with illegal substances in order to control their pain.  
 
VII. Reasons for Momentary Change in Opioid-Taking Behavior 
(Reasons for Self-Dose Adjustment) 
 
For those participants who took less or no prescribed opioids continuously or 
episodically, reasons from refraining from opioid use are listed in Tabel.1. 
Here I found that SCD patients self-adjust opioid dose to control pain and attain a higher 
quality of life. Self-dose adjustments include medication adherence, taking more, taking 
less or a combination of both (overuse and underuse), or refraining or stopping taking 
medication. Patients’ attentiveness in controlling their medication behavior and 
adherence to their medication regimen as well as consequences of non-adherence and 
opioid effects, that was clear in themes related to concern for personal safety, and change 
in lifestyle issues when using opioid. An explanation for my results is that patients 
receive adequate counseling about prescribed opioid. I believe this is the case in local 
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practices. Most providers spend adequate time discussing opioid adherence and physical 
side effects. They also discuss other psychosocial-spiritual and safety issues related to 
SCD pain. 
 
 Biological A.
 
1. Pain Severity  
 
Escalating pain severity from any level to an unbearable state often led to increased 
medicine use. This was done through increased frequency (shorter time intervals 
than typical medicine use) or through increased quantity (number of pills or number 
of medications). 
 
Less pain than that on a typical day often led to neglecting long-acting and short-
acting medication. Participants were often more willing to bear with the pain than to 
use medication in order to avoid future pain. 
 
Pain projection also played a role in judging medication-taking behavior. Individuals 
would often vary their medication behavior over the day, based on either 
anticipation of future pain escalation based on prior experience(s), or based on the 
experienced pain progression up to when a medication judgment was made. 
Additionally, changes in weather or environment also played a role in determining 
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how individuals decided to take their medicine. Though many did not realize that 
these changes would affect their medicine-taking behavior, interviews revealed that 
several participants avoided changes in weather, took prescribed opioids in 
conjunction with changing weather/environmental patterns, or noted a previous 
experience where they should have taken pain medicine in response to a temperature 
change but did not. 
 
A marked "warning pain" that signaled incoming severe pain was also indicated to 
be a notable factor when judging pain and its future course. Similar to the aura 
experienced by migraine patients, individuals who experienced and categorized this 
milder pain as a signal would often make a special effort to take short-acting 
medicine in anticipation and to ward off possible crisis-level pain. 
 
Pain persistence marked by a long duration and no overall change either led to 
increase in medicine-taking behavior (greater amount, frequency, or shorter 
intervals), or to a state where individuals might simply endure the pain in hopes that 
it would go away rather than visiting a healthcare provider for an opinion after a 
couple of days. Extended duration of pain also sometimes led to disbelief in potency 
of the medicine --individuals experienced that their medication was no longer 
working or that they had acquired a tolerance for their prescribed opioid medicine. 
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Seeking comfort from pain was a primary driver when study participants tried 
different pain treatments. For those more willing to experiment, intentional non-
adherence sometimes occurred when individuals tried physically altering their 
medication (ex: crushing), or taking multiple short-acting medicines simultaneously. 
These present a problem from a pharmaceutical point of view -patients either 
increase the rate of uptake of strong medicine into their body or unnecessarily use 
medicines that, instead of working synergistically, work in competition and reduce 
the efficiency of medicines used. Additionally, many participants were more willing 
to use increased amounts of over-the-counter medicines like Tylenol and Motrin 
rather than increase any dosage their opioid medicines in circumventing 
biopsychosocial effects of opioids, using the OTC medicines synergistically with 
prescribed opioids, or minimizing overall prescribed opioid use. 
 
Most patients tried many methods of home remedies, including heat (ex: showers, 
hot water bottle, heat rubs), herbal remedies (ex: capsaicin), and rest, as an attempt 
at decreasing pain before resorting to prescribed opioids or in combination with 
prescribed opioids. This often occurs at the onset of pain, if circumstances allow, so 
that individuals may "nip the pain in the bud." 
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2. Effectiveness 
Throughout the interviews conducted, participants exhibited various levels of satisfaction 
concerning the efficacy of their prescribed opioid regimens. Most individuals felt 
satisfied with their daily regimen with exception to times of excruciating pain, while a 
few were partially dissatisfied and suggested changes to their prescribed opioid regimen. 
Perception of "working" prescribed opioids also depended largely on biological effects of 
the medication. Participants reported an opioid not working if great side effects occurred 
with little pain relief, while most participants agreed that a short-acting medicine was 
easily felt when working (through pain relief and side effects like euphoria, 
disorientation). Long-acting medications were reported by most patients as probably 
working, but not easily felt. This often led to decreased use of long-acting medication, or 
non-adherent use of short-acting medicine instead of long-acting medicine. 
 
3. Side Effects  
 
Side effects played a great role in participant’s willingness to use their medications at all. 
Most side effects experienced are fairly severe (ranging from euphoria to vomiting), and 
led to most participants' hesitancy but eventual use towards using medication. 
Uncertainty towards how a medication might change a participant's physical and mental 
faculties also led to decreased use as many individuals stressed over the possibility of 
tolerance, dependence, and/or addiction with continued prescribed opioid use. Overall, 
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however, participants regarded prescribed opioids as a necessary means of pain relief 
despite its drawbacks. 
 
4. Drug-drug and Food-drug Interactions  
 
Most individuals were at least somewhat aware of proper prescribed opioid use and 
possible drug-drug or food-drug interactions. Decreased possibility of dependence and 
higher levels of comfort with OTC medicines led to many participants preferring to use 
OTC or prescribed non-opioid medicines before beginning use of short-acting prescribed 
opioids. In addition, use of OTC medicines in conjunction with prescribed opioids was 
often used as a more comprehensive approach to pain relief, as they pain medicines work 
on different receptors. Many individuals who were comfortable with some amount of 
leniency in their prescribed opioid regimens were more likely to use combinations of 
OTC medicine, non-opioid pain medicine, and prescribed opioids to combat different 
levels of pain. This sometimes led to aberrant behavior, though typically combinations of 
pain medicine were used with prudence. 
 
Most participants also reported taking prescribed opioid medicines with water only, while 
a few individuals occasionally took prescribed opioids with alcohol or herbal teas. 
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5. Other ailments  
 
Some participants described taking prescribed opioids to combat pains from other 
symptoms (ex: arthritis pain), stress, and other symptoms, as they did with sickle cell 
pain. Other study participants described saving opioid medicine for sickle cell pain only, 
using other prescribed pain medicines, OTC medications, and home remedies to deal with 
more bearable pains. 
 
 Social B.
 
1. Accomplish school, work or household tasks 
 
Accomplishing necessary tasks for school, work, and/or a household were often a high 
priority for study participants. This often led to decreased opioid use, as many individuals 
felt drowsy, sick, or euphoric as well as less focused after their short-acting medications 
took effect. This was a momentary judgment, however, as participants would sometimes 
take short-acting in order to focus on tasks at hand should they not be able to manage 
pain using sheer will, home remedies, or non-drowsy OTC medicines. 
 
2. Maintain responsibilities/obligations - schedule/time management 
 
Increased or adherent use of opioids was used to maintain ability to do necessary 
responsibilities and obligations such as babysitting or driving others. Many participants 
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would schedule initial or later doses with flexibility within their prescribed regimen to 
maintain work or schools schedules, or routinize their medication taking-behavior such 
that they described aberrant behavior without realizing it. For many participants, 
routinization of long-acting opioids was typical, while routinization of short-acting 
opioids was common among many, and often triggered by things like getting to work on 
time or upon arrival back home after work. 
 
3. Rushing, Spontaneous Events  
Many participants reported forgetting to take prescribed opioids with them when rushing 
to a social event or activity. Others reported that having to often rush to events or work 
led to keeping a stash of prescribed opioids with them at all times, or keeping them with 
others who would typically go to similar events (ex: mother). In addition, spontaneous 
events were also a cause for forgetfulness or this rushing sensation, leading to decreased 
opioid use (choosing to instead bear the pain) or keeping a separate stash of prescribed 
opioids at all times common to many individuals. 
4. Social Gathering Dynamics and Judgment 
 
While at a social event, changing group dynamics and possibility of judgment of 
character often led to changes in time interval of opioid taking behavior, or staunch 
opposition to any person who would suggest changes in opioid taking behavior. Many 
participants talked about taking opioids before a social event to prevent the possibility of 
pain or to avoid judgment by friends or workers who might see them. A few other 
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individuals strongly defended their apathy towards what others thought and defended 
their stance on taking medication wherever they went, so long as they adhered to proper 
opioid taking behavior as prescribed or as necessary for the pain. 
 
i. Influence of others and resistance to lifestyle changes  
 
In this study, I noted that many SCD individuals tried to present a more "normal" lifestyle 
to society, using OTC medicines like others, or by maintaining a lifestyle they see others 
doing (ex: taking no note of weather, doing heavy manual labor, etc.). This led to 
resistance in overall lifestyle changes for SCD (for some), or decreased or erratic use of 
long-acting medication due to feeling little to no difference. Many individuals were prone 
to comparing their medicine use to non-SCD family members or friends and using that as 
a key in judgment on whether or not to take medicine. Additionally, a few participants 
reported being reprimanded by family members on taking or not taking prescribed 
opioids as prescribed, leading participants to either rebel against suggestions or take them 
regardless of how the opioids impacted them or as prescribed. This, in turn, led to 
divergent increased or decreased opioid use. 
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ii. Response to life events 
 
Noted earlier, prescribed opioids were used by very few participants to deal with stressful 
life events or emotions. For those participants who indulged in use of prescribed opioids 
in response to life events, increased use was momentary until normal schedules were 
reintroduced. 
 
 Psychological C.
1. Fear of future negative consequences (medical, side effects/behavior), future 
pain, or going to ER 
 
Based on my qualitative study, participants exhibited attitudes towards two facets of 
taking opioids: (1) general associations with medicines, and (2) specific associations with 
opioid medicines. An ambivalent to negative attitude was prevalent among general 
associations with medicines, as participants would describe wanting to limit the amount 
of (harmful/unnatural) chemicals going into the body. This attitude was extended towards 
physical aspects, such as difficulty in swallowing the large opioid tablets, or social 
aspects, such as public and self-perception of dependency on a drug. On the other hand, 
specific associations with opioid medicines imparted much stronger positive or negative 
outcome attitudes. Experiences with biopsychosocial effects, for example, drowsiness 
  
 
212 
and possibility of addiction, daily functioning, and social stigma, often polarized 
participants' attitudes. 
 
Many participants, females in particular, seemed to describe much more fear or worries 
regarding future negative consequences of opioid medication potency, side effects, odd 
behaviors, and negative stigma that could be imparted to their person or to their families. 
A few mentioned strange or behaviors or others taking advantage of them, and these 
patients ultimately less pain medicine/chose longer time interval between doses. 
 
2. Mental Fatigue  
 
Frequent decision-making may result in mental fatigue in SCD patients. Due to the 
constant necessity of revising pain and pain relief plans daily, many SCD patients 
reported routinizing their prescribed opioid taking behaviors. This is an increased use of 
short-acting, as-needed opioids and possibly builds unnecessary tolerance within 
individuals to their medications. Mental fatigue may also cloud judgment in patients, as 
many already expressed dislike towards having to deal with taking their strong, short-
acting medication and were less inclined to make careful, cautious decisions regarding 
prescribed opioid use when in pain. 
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3. Perception of physician disbelief/misunderstanding  
 
Many participants who distrusted physicians' opinions or felt that physicians were not 
listening to their points of view were more prone to experimenting with their regimens 
and taking more or less medication. These individuals tended to have a heightened sense 
of themselves (or felt they had a better understanding of their bodies) and often 
conducted independent research, typically on the internet, to better understand why their 
physicians prescribed certain medications and any possible adverse effects. 
 
4. Need for strict adherence  
 
For those participants who were more wary of overuse and possibility of addiction, and 
feared so, many reported strictly adhering to doctors' order. However, these mentalities 
also often led to increased use of prescribed opioids through routinization, or through 
underuse in thinking that "as-needed" was for only the most severe pain. 
 
5. Availability, transportation, cost ($), insurance, or ER cost  
Availability was a huge factor in participants deciding to hoard, use medication 
differently than prescribed, or take little to none of their prescribed opioid medication. 
Difficulties in transportation, affording prescribed opioids, lack of insurance, and the fear 
of an ER visit/cost often led to participants increasing use in effort to avoid an ER visit at 
any cost. Other patients would take less medication or cut tablets in half in order to make 
their medications last longer, often hoarding medication when close to running out (5-10 
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tablets from empty) or if having trouble reaching a medical provider or pharmacy. 
Notably, several patients did as directed by their prescribers and went to the ER if their 
medication did not work within 2-3 consecutive doses without improvement in pain level 
(adhered to their drug regimen). 
 
6. Flexibility  
For patients who were willing to experiment or were comfortable adjusting their 
medications as prescribed by healthcare providers, "common sense" was used in judging 
whether to take or not take prescribed opioids. This common sense varied among 
participants, leading some to take more in prevention of increasing pain (overuse), while 
leading others to only take pain medicine as a last resort (underuse). These patients also 
often consulted the internet or family members for judging pain medicine use and for 
more knowledge about pain medicine, rather than their physicians. For very few patients, 
extreme comfort with drugs and prescribed opioids led to accidental overuse incidents in 
which unbearable pain led to exaggerated use of opioids prior to an ER visit. 
 
7. Forgetfulness 
When I asked participants how frequently they forgot to take their medicines, I heard a 
variety of responses. Some of them said that forgetting is something they would never do, 
some said that forgetting was something that happened more often than not, and then 
some would say that forgetting was an occasional or rare occurrence. Depending on how 
individuals felt towards their memory and how to cope with rare (or uncommon) cases of 
  
 
215 
forgetfulness led to divergent responses. For those that routinized medications, memory 
was out of the question as they used external cues to judge whether or not to take pain 
medicine. For those that did not routinize their short-acting opioids, level of pain upon 
remembering was often the factor used to take or not take a dose of pain medicine. 
Finally, for those very relaxed about prescribed opioids and strong medications, some 
might take the medication in warding off possible future pain. Long-acting prescribed 
opioids, for those that had them, were reported as almost never missed, as most 
participants would take their long-acting medications upon waking or prior to work or 
school. 
 
8. Feelings of security with provider, safety or comfort 
 
Needing a feeling of security from pain often led to participants holding pain medicine 
with them at all times, though not necessarily overusing their medication. A sign of 
aberrant use, holding multiple medicines together, was sometimes noted, but participants 
often made a point to remember to take medication with them. Should medication be 
forgotten, participants recalled either dealing with pain, or remembering for the next time. 
Additionally, some participants did take extra medication prior to social events or 
obligations so that they might not forget during the event (if they had routinized 
medication-taking behavior). This extra dose of prescribed opioid was used as a safety 
net in preventing future pain. 
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Some study participants described taking underusing medication to maintain open and 
comfortable connections with their healthcare providers. Most participants were wary of 
the necessity of being addiction- or dependence-free to maintain good standing to 
maintain use of prescribed opioids and would underuse to maintain a facet of being able 
to handle pain without pain medicine. Underuse of prescribed opioids was also reported 
in order to pacify the negative stigmas towards SCD patients that they perceive from their 
healthcare providers. 
 
9. Morality of strong pain medicine - overall opinion of medicine over time 
 
Many participants were morally against putting foreign chemicals in their bodies, instead 
opting for home remedies or no medication, or underusing their prescribed opioids. Some 
participants described opioids as a necessary tool for pain relief in making typical life 
obligations, as comparable to non-SCD individuals, possible, and tended to underuse 
prescribed opioids, or withdraw completely for more independence. 
 
10. Stress  
 
As mentioned before, stress was a factor among a few of the interviewed participants 
when deciding to take a dosage of prescribed opioids. For the few individuals that would 
use prescribed opioids to combat stress, intentional non-adherence was noted through 
overuse (using prescribed opioids not as indicated by a physician). 
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11. Boredom, depression, fearlessness 
 
Boredom, depression, and fearlessness were factors that influenced more open-minded 
study participants to take larger doses of prescribed opioids by physically altering or 
changing other use aspects (frequency, interval, and amount). Very few individuals 
reported intentionally experimenting for the sake of seeing how their medicines affected 
their bodies. Very few participants also reported taking their prescribed opioids for 
depression instead of for sickle cell pain. 
 
12. Judgment  
 
Some interviewed sickle cell patients did alter their medicine-taking behavior in response 
to judgment from others. Whether for fear of their "strange" actions under the influence 
of strong opioids or for respect to relatives' experience, many participants would 
underuse their prescribed opioids on their own. For some participants, urging of their 
family members led them to take more prescribed opioids, to appease these members as 
well as to avoid pity from others. Social comparison led many participants to learn from 
prior experience as well as observed experiences of others in taking less medication. 
Additionally, many participants that experienced others telling them about strange actions 
were prone to underusing their medications in attempt to preserve how they wanted other 
to see them. 
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i. Independence   
 
Many participants experienced much comparison to non-SCD individuals and felt that 
taking such strong medication on a daily basis was abnormal. This led to increased 
feelings of a need for independence from chemicals, and thus led to decreased opioid 
usage. 
 
ii. Beliefs towards opioids  
 
Many participants disliked having to constantly use opioids for pain control but felt that, 
over time, opioids preserved a certain mode of life with which they were comfortable. 
Changes in behavior were not often noted unless different experiences were felt by 
individuals leading to increased or decreased opioid use based on positive or negative 
experiences, respectfully. 
 
iii. Perception of disease & sick role 
 
When interviewed, some participants sought use of prescribed opioids to take a rest from 
daily activities (e.g. work). Depending on their perceptions of sick roles of SCD patients, 
some participants reported underusing prescribed opioids to maintain outward perception 
of being like "everyone else", underusing prescribed opioids because their sickle cell 
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anemia was "more mild than others", overusing because strong medicine is part of the 
identity as a sickle cell patient, or overusing to gain pity from others. Most participants, 
however, disliked feeling any sense of pity from non-SCD relatives or friends. 
 
 Spiritual D.
 
i) Religious reasons/morality obligations & duties -  
Many participants in this study reported religious reasons for preemptive use of 
prescribed opioids in order to fulfill church obligations. This led to unintentional overuse 
of prescribed opioids in prevention of pain during a religious obligation or duty. 
 
1. Religious events  
 
When interviewed, many participants denied changing prescribed opioid use for 
typical social events and gatherings. However, church or other religious events and 
obligations were often a priority for participants, especially with family involved, 
and many reported preemptively taking medication before or during church 
activities. This sometimes led to mild non-adherence in that individuals did not take 
short-acting medication as needed, but as planned for working around a religious 
event. 
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VIII. Conceptual Framework 
 
Strength of framework varies from person to person. However, I built a conceptual 
framework of opioid taking behavior based on my qualitative findings and the prior 
related literature to inform current and future search strategy. Most of the determinant 
and barriers of prescribed opioid adherence explored in this study fit into the categories 
created in the conceptual model. See Figure 17 for a conceptual framework of factors of 
overtime (overall) opioid taking behavior. See Figure 18 for a conceptual framework of 
factors of momentary opioid taking behavior. 
 
Figure 17: A conceptual framework of factors of overtime (overall) opioid taking 
behavior. 
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Figure 18: a conceptual framework of factors of momentary opioid taking behavior. 
 
 
IX. AOTBA Scale  
 
Various disease-specific and general (Morisky et al.) scales have been developed to 
assess medication adherence. However, I found no sickle cell disease (SCD)-specific 
measures of opioid taking behavior and adherence, especially for as-needed medication. 
The objective of my study therefore was to develop a disease-specific research instrument 
describing prescribed opioid adherence and opioid taking behavior in patients with SCD. 
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As part of a multiphase, mixed-method study, I used an adaptation of several published 
methods to construct 20 sequential, chronological steps for developing a new scale. I then 
customized these steps for relevant SCD opioid taking domains. I report here on steps 1-
6, which included wide-ranging quantitative and semi-structured, qualitative interviews 
of 11 male and 10 female African-American adults with SCD (average age = 36 years). I 
used a grounded theory approach to analyze the qualitative data. Next, I used a priori 
procedures for domain specification and survey item delineation, specifically a linguistic-
transformation approach (53, 54). I used a posteriori procedures to conduct a preliminary 
appraisal of translational (content and face) validity.  
Almost all the items have I-CAV equal 1.00. Also, the S-CVI index was 0.989 for 
relevancy and 0.971 for clarity. Both these readings (findings) are very acceptable for 
content validity and indicate that AOTBA scale has exceptional high content validity.  
 
The development of the Assessment of  Opioid Taking Behavior Adherence (AOTBA) 
scale led to the inclusion of a new concept: momentary medication taking behavior, 
which is not previously described in the literature. The scale was also able to capture 
concrete patterns of adherence for as-needed medication in addition to scheduled 
medication regimens.  Lastly, it has given expression to a number of conceptual domains 
that explain observed opioid taking behavior. These domains can be categorized under a 
biopsychosocial-spiritual schema. Domains include (but are not limited to): forgetfulness, 
carelessness, social stigma, fear of addiction, side effects, cost of medication, 
excruciating pain, maintaining functionality at work/ school, meeting life obligations. 
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The emerging draft scale demonstrates that adherence and opioid taking behavior in SCD 
is not characterized by chaos, but rather appears too driven by underlying discernible 
behavior patterns. Additionally, the scale reflects new concepts of medication adherence. 
These concepts challenge current theories and models of medication taking behavior and 
adherence.  
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X. Strengths of the study 
 
There are several unique strengths to this study. There was only one refusal for this study. 
In addition, these patients did not differ on demographic variables suggesting that the 
participants were highly representative of the population. In addition, this study involved 
a diverse sample with male and female participants from urban and suburban areas and 
various socioeconomic backgrounds.  
This study allowed for evaluation multiple aspects of adherence and many different 
reasons of non-adherence behaviors. This study also allowed for the identification of 
many important factors that may not have been included in a study with a more narrow 
focus. Instead of asking participants whether they were adherent, various domains of 
adherence were explored. Participants were asked a number of questions regarding opioid 
use and possible overuse and underuse and other questions designed to assess adherence 
to other aspects of specific opioid recommendations.  
 
In previous adherence studies, many researchers have relied upon dichotomous ratings 
when evaluating adherence and have not attempted to assess multiple domains of 
adherence separately. In addition, this study obtained a heterogeneous distribution and 
range of adherence ratings, particularly for the adherence to other behaviors. This 
allowed for better holistic description of adherence. 
 
To my knowledge, this is the first study attempt to describe adherence to prescribed 
opioid and factors of adherence in SCD. No published studies describe pattern of opioid 
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use to prescribed opioid in SCD patients nor do any explore the possible relationship of 
adherence to biopyschscoical-spiritual factors. It is also the first study that attempted to 
develop a scale for assessing adherence to prescribed opioid in non-cancer pain including 
SCD. Self-report measures of adherence are more likely to be accessible for researchers 
because they are very convenient choice for certain study designs. 
 
 In addition, the adherence measures in my survey and interview questions in this study 
are capturing and differentiating between patients' level of adherence with the use of 
regularly scheduled versus as needed opioids which usually ignored in assessing 
adherence to opioid use in cancer patients. Also, analyzing the data with multiple 
investigators prevented the data from being subjected to subjective analysis of one 
person. Lastly, in this study, I used mixed method (qualitative and quantitative) design, 
which gave me deep insight and understanding of adherence, patterns of opioid use and 
their reasons in SCD. 
 
XI. Limitations of the findings 
 
It is important to point out the limitations of my study. There were several limitations to 
this study. First, the primary limitation of the research is the small sample size, sampled 
using non-random sampling, from a single clinical site at one geographic location 
limiting generalizability of findings and the statistical power to detect significant 
relationships. The selected site was a major academic medical center and may have 
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reflected a high standard on pain education and management that reduced variation. 
Additional interviews with SCD patients conducted at other sites with larger sample size 
may give different results than my findings. My investigation did not assess adherence 
and pattern of opioid use over time. The study design was cross-sectional, so causal 
relations between factors cannot be determined. Participation was restricted to SCD 
patients who had been prescribed opioids and did not address the experience of patients 
who do not report pain or who refuse opioids. Further, the research was on individuals. It 
is acknowledged that other influences people with SCD pain in their surroundings. Both 
family members and providers influence patients' analgesic use. However, in this 
beginning research project the focus was on intra-subject factors.  
 
 This study relied on self-report assessment of adherence and outcome. Self-report has 
been shown to have limitations and problems. Based on previous research, self-report 
assessment of adherence are subject to measurement bias such as social desirability, 
recall bias and response bias.  
 
It is unclear how valid and reliable self-report is. For example, patients may overestimate 
adherence in an attempt to present themselves in favorable light to their healthcare 
practitioner. It is possible that participants in this study wanted to please the investigator 
with reports of minimize the bias of patient report utilizing suggestions to obtain an 
adherence-oriented history and to assure patients that their responses will remain 
anonymous and confidential.  Actually, I ensured the confidentiality of disclosed 
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information by participants, which may encourage honesty. Although self-report may 
have caused the patients to be reluctant to respond in an open and honest manner, I 
believed that this was minimized through careful explanation that participants' comments 
would not be communicated directly to their physician and the importance of their 
honesty to the final results of the study.  
 
I have also explained that their treatment would not be altered in any way by their 
participation; the only potential benefit of participation was to help advance research in 
this area. Thus, participants may have motivation to be honest in their reporting. 
Furthermore, care was taken to question participants in non-threatening manner designed 
to elicit honest responding. 
 
 For example, it was always made clear up front that the investigator was not a medical 
healthcare professional, but was a student reviewing the pain management program and 
its efficacy. This made it easier to avoid direct questions regarding opioid adherence. In 
order to determine if a patient was overusing medication or using medication 
inappropriately, I might approach questioning in a curious manner and say something 
like, “I am not sure as familiar with the opioid that you are taking.  How often can you 
take that opioid?" Participants seemed to respond well to this type of questioning and 
often did not seem aware of the contraindications to using the opioid in the manner they 
subsequently described.  
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The complicated nature of this study coupled with the limited resources of the 
investigator necessitated the use of self- report. In addition, it was believed that more 
patients would agree to participate in this study because it was perceived as involving 
very minimal work.  
 
This study could have been improved by the inclusion of at least one objective measure 
of adherence such as pill counts, the use of pharmacy records, or both. Returned pill 
counting has been traditional used as an objective measure of adherence. However, recent 
evidence indicates that this method is inadequate for adherence assessment. Utilizing a 
system such as the Medication Event Monitoring System to record each time a pill bottle 
is opened or closed would have been an ideal way of assessing medication adherence, 
particularly for symptomatic medication. However, the problem with such measurement 
is the cost associated with it.  Additionally, such as a method would prove more difficult 
if used to assess abortive medication use. 
  
I made every effort to make the study a positive experience for the patients by being 
accommodating regarding the timing of the call as well as being extremely polite and 
friendly. It was believed that this approach would elicit more honest and open responding 
and greater cooperation with the study.  
 
In addition, the findings of this study are limited by the fact that the results are based on a 
sample of patients who received three prescription of opioid in the last 12 month and 
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reported more than 29 % pain days in the last month.  These patients likely experienced 
more frequent and severe pain than what may be found in a more general sample of SCD 
suffers. This has important implications for the results of the present study.  
 
In addition, this study was exploratory in nature; with no previous hypotheses. 
Quantification and validation of the significant findings in another larger sample of the 
SCD population is necessary to demonstrate of statistical the relationships. I believe that 
if these results do replicate, then this research has several research and clinical 
implications. 
 
Although one limitation of this method is its participant bias, instrument specificity, 
sensitivity, validity, and reliability, the ease of administration and reduced resource 
burden are worthwhile considerations. This is particularly true when compared with other 
approaches such as electronic monitoring, pill counts, pharmacy record surveillance, or 
biological assays. Finally, finding of this study must be interpreted in light of the 
limitations of this research project. 
  
  
CHAPTER 6: CONCLUSION 
 
I. Overall Conclusion 
 
I carried out a mixed method multiphase study that explored opioid taking behavior in 
patients with SCD. The project demonstrated that each day, a variety of situations might 
change opioid taking behavior in these patients. The evidence from this study suggests 
that biopsychosocial-spiritual and other factors may be reasons for overall and 
momentary non-adherence. More research needs to be carried out to help clarify the 
issues that this study raises.  
 
I found that pain in SCD has significant biopsychosocial-spiritual consequences. 
Prescription opioids may minimize theses consequence by providing pain control which 
in its turn may create new consequence. Non-adherence to prescribed opioid regimens 
may be one of many reasons for pharmacotherapy plan failure. In light of the 
consequences that I have explored here, it is very important to appropriately understand 
and assess patients’ medication adherence. It is difficult for researchers and clinicians to 
readily identify patients who are non-adherent to opioid regimens. When broken down, 
the act of adhering to opioids is a complex process, influenced by societal, provider, and 
patient issues. The complexity of assessing adherence to prescription opioids suggests the 
  
need for more innovative and convenient self-reported measurements of adherence. 
Additionally, the multifaceted nature of the momentary construct makes defining 
adherence to opioids a complex task. Therefore, to learn more about this facet of opiate 
taking behavior, it was important first to develop new instruments that not only measure 
adherence and opioid taking behavior, but also identify predictors of these behaviors. It 
was then important to develop a scale covering several multifaceted constructs dependent 
on a range of physical, social, economic, and psychological considerations. Also, it was 
important to consider the interplay of these factors in assessing opioid taking behavior. I 
developed a scale to assess adherence to prescription opioids within a context of overall 
and momentary adherence, autonomous dose adjustment, and chemical coping. I 
generated many items incorporating multidimensional biopsychosocial-spiritual 
determinants of opioid taking behaviors as important constructs in the scale. I hope by 
following this approach to yield meaningful results of the scale in the future.  
 
One important finding of this study is that patients with SCD have several healthy and 
unhealthy lifestyle changes to cope with their pain and opioid effects. This study 
highlights that other non-pain factors should not be ignored. Regular discussions with 
patients could include coping with dependency, stigma, inadequate sleep, and stress. In 
my sample of patients with SCD, I found that opioid-taking behaviors should be an area 
of emphasis during patient interactions.  
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My results raise the hypothesis that, for opioid use in SCD, all six categories of behavior, 
including erratic use, overuse, underuse, adherence, arbitrary, and complete withdrawal, 
may be intentional or unintentional.  But I found few if any references describing 
unintentional and intentional use in all six behaviors I discovered in my qualitative study.   
 
This dissertation research probed for whether these six behaviors can be classified as 
intentional or unintentional, but the instrument I plan to develop will not itself be 
designed to determine unintentional vs. intentional behavior.  
 
Together, my results suggest that the accepted terminology, which is based on current 
models and theories of medication adherence, does not accurately describe all medication 
taking behaviors. I found that contextual factors may drastically affect opioid taking 
behavior. Further, these newly described phenomena raise new hypotheses that may 
challenge current theories and models of medication taking behaviors and methods of 
assessing adherence. These hypotheses call for a new round of research on opioid taking 
behavior, and should be rigorously tested in future research.  
 
II. New concepts with expanded framework 
Like all of human behavior, opioid-taking behavior is an intriguing and complex 
phenomenon. Existing concepts, terminology, and measures of medication taking 
behavior seem inadequate to actually improve behavior when improvement is warranted.  
This dissertation introduces a new framework containing concepts of medication taking 
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behavior that, integrated with traditional ones, may inform theory and practice. The 
framework emphasizes patient-oriented terminology, which better acknowledges that 
medication taking requires patients’ cooperation and insight.  The framework also 
emphasizes not only longer-term but also momentary adherence assessment. Applying 
the new, combined framework may uncover previously ignored or unmeasured aspects of 
adherence, may answer many old questions about how to improve adherence, and may 
reveal contextually rich, more accurate information and substantive insights regarding 
medication-taking behavior. My research groups are currently working to develop 
formulas and methods of measurement for each of the concept I have described in my 
new framework. I was also exploring whether current theories about behavioral 
determinants of medication adherence fully explains and is completely consistent when 
tested using my newly framework 
 
Based on the findings of this project, my research group will continue working to develop 
formulas and methods of measurement for each of the concept I have described in my 
new framework. I was exploring whether current theories about behavioral determinants 
of medication adherence fully explains and is completely consistent when tested using 
my new framework 
 
Accordingly, emerging methods of assessment may allow this new framework to be 
better applied to medication taking behavior data. Meanwhile, this framework underlines 
the challenges and opportunities currently associated with obtaining and using current 
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medication taking behavior data. It is my hope that the scientific, practice, and policy 
community can adopt and apply this framework, moving this field ahead. 
The findings of this project elucidate the importance of finding new measures of 
adherence. It proposes a new framework containing more inclusive concepts and more 
standardized terminology that not only describes adherence in more detail, as well as 
more specific measures of various sub-categories of adherence, but also describes all 
medication taking behavior. It argues for the integration of and measurement of behavior 
associated with specific medication types or dose schedules. Last, it describes promising 
research enabled by the new framework that, if implemented, might lead to improved 
adherence. They suggested that improving concepts and methods of adherence 
assessment is key to improving adherence outcomes. 
 
III. AOTBA Scale 
 
The objective of my multiphase, mixed-method studies was to develop a disease-specific 
patient-reported outcomes (PROs) scale for prescribed opioid taking in patients with 
SCD. The newly developed scale is completely built on patient-reported experience. I 
started by collecting all experiences qualitatively, in the patients’ voice. I then continued 
to involve patients in successive (total of 3) phases of scale development. The resulting 
draft scale is aimed to capture patient values, patient-centered decision making, patient 
characteristics, patient preferences, and practical considerations related to prescribed 
opioids, rather than physician-judged outcomes or outcomes of biomedical assays related 
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to prescribed opioids. It is focused on symptoms, function, satisfaction, and quality of 
life. This patient-centered approach challenges current theories and models. For example, 
models and measures of medication-taking behavior and adherence have generally not 
focused on patient judgments or perspectives. This research relied on PROs to uncover a 
new general concept of medication adherence—momentary medication-taking 
behavior—not previously described in the literature.  This concept captures concrete 
patterns of adherence for as-needed medications as well as for scheduled medications.  
 
Patients reported positive and negative effects of prescribed opioids on biopsychosocial-
spiritual outcomes in SCD. To my knowledge, this is the first hypothesis-generating 
research that can inform the debate about the appropriateness of the use of opioids in 
SCD, and form the basis for evidence-based practice. My resulting draft scale reflects 
underlying discernible behavior patterns of adherence and behavior in opioid taking for 
SCD, rather than chaos. Third, the scale documents and measures newly uncovered 
general concepts of medication adherence.  
 
I believe that application and wide use of this scale may predict and improve all the 
above high-impact PROs, not just capture them. The mechanism of improvement of 
PROs should be through improved physician-patient communication and improved 
prescribing, as well as provision of a more concrete basis for behavioral and self-
management interventions in patients.  
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IV. Implications for clinical practice  
 
Although the implications of this study for clinical practice are preliminary because of 
the small sample size and single-site design, Findings from this study may have the 
several important clinical implications. However, because some findings were consistent 
with previous research in pain, cautionary recommendations can be made. Health care 
providers can recommend that patients keep a diary of their opioid use, particularly if 
new opioids are prescribed or in adequate pain relief is reported.    
 
Given the problems with adherence noted qualitatively during this study, 
recommendations for improving SCD patient adherence to opioid prescriptions can be 
offered. First, I recommended that the biopsychosocial-spiritual factors identified as 
reasons of adherence in the present study be routinely assessed within the context of a 
multidisciplinary setting in order to determine which patients need specialized attention 
to maximize adherence. It is possible that healthcare practitioners may increase adherence 
rates among their patients if they routinely screen for a history of different situations, 
negative effects, and non-adherence attributions and make specific treatment 
recommendations as a result.  
 
Second, patient education may be a useful intervention for those patients with 
excruciating pain. I recommend that SCD specialty clinics routinely follow up with their 
patients by telephone approximately 1 month after their visit. Numerous patients 
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communicated difficulty understanding of their opioid regimen or other treatment 
recommendations that could have been easily clarified over the telephone.  For example, 
one patient stated that he had to take long-acting only when he is pain. This patient 
believed that he had been prescribed long-acting opioid for as-needed basis. (Perhaps you 
do not need to cite any specific examples since this is the conclusion?) In addition, many 
patients often communicated little awareness of how to take their medication despite 
being provided this information in writing from the physician. A follow-up telephone call 
could provide patients with the opportunity to ask questions and clarify any 
misunderstandings that may have occurred during the practitioner-patient interaction.  
 
Patients with a history of opioid overuse may require more patient education from either 
the physician or another healthcare practitioner. Such patients may benefit from a follow-
up telephone call two weeks after their clinic appointment to monitor their opioid use and 
determine if any changes can be made to their prescribed opioid regimen to enhance their 
medication adherence, such as changing the type of short-acting opioid to reduce a 
particularly bothersome side effect. 
 
Patients endorsing biopsychosocial-spiritual attributions for their non-adherence should 
be given special attention as well. It is recommended that these patients be allotted 
additional time with the healthcare practitioner during their routine visit.  A careful 
adherence history should be taken with such patients to determine the possible 
associations between their history and non-adherence. It may be the case that the reasons 
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represent a defensive or hopeless state that warrants further consideration. Patient 
education regarding appropriate opioid use may be helpful with these patients, 
particularly if specific causes for previous non-adherence are discovered.  
 
Further research should be conducted to identify improved measures of both adherence 
behavior and its underlying causes. Such variables may account for larger portions of the 
variance of adherence. The results of exploratory analyses provided in this study can 
provide useful information to guide the researcher.  For example, future studies may seek 
corroborating information on adherence behaviors from family or friends. Other self-
report measures might provide stronger and more consistent relationships as well.  
 
Patient satisfaction with treatment and the doctor-patient relationship is another variable 
that might be interesting to examine in future studies. A longitudinal study would be 
particularly helpful, so that the course of this critical relationship could be understood 
more clearly. 
 
Furthermore, assessing adherence can help to customize appropriate analgesics regimen 
and clinical interventions. Additionally, investigating adherence in prescription opioid 
use can assist clinicians in designing more effective and better therapeutic pain plans that 
address patient priorities. Activities of daily living, particular situations may require 
adjustments in adherence to the analgesic regimens. Such studies are necessary to 
understand factors that affect adherence in this population and to serve as the foundation 
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for the development of more effective strategies to improve adherence. Hopefully, the 
findings may help clinicians to plan better care for patients who may underuse or overuse 
on the prescribed opioid. Recognizing factors will help to find solutions that may help the 
clinician to identify patients at risk and intervene appropriately. Providers who are able to 
overcome the obstacles to adherence will improve the lives and outcomes of their SCD 
patients.  
 
On a broader level, especially given the magnitude of the epidemic of non-cancer pain, 
improving adherence to pain management has very widespread public health 
implications. The quantitative survey of this study may serve to predict which subjects 
would be adherent to long-acting opioids or short-acting opioids. Finally, a broad 
taxonomy of patterns of opioid use and barriers to adherence can be created for patients 
with SCD and patients with non-cancer pain. This taxonomy can be used to assist 
medical providers in developing interventions designed to optimize patient education and 
problem solving with regard to prescription opioid regimens. The taxonomy may also 
help to develop and evaluate the efficacy of specific analgesic regimens.   
 
Although I learned many things during the course of carrying out this study, two major 
areas worth special attention. First, this study did not directly address physician-patient 
relationship, which could have helped to clarify some important relationships and to help 
understand how patient education could be improved. Clinical observation suggests that 
this is an important area for consideration. More time should be spent with SCD patients 
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to help them understand their role in managing their pain and their responsibility to 
remain adherent to their opioid regimen.  
 
Secondly, this population represents a group of patients that is very difficult to treat 
successfully for a number of reasons, including the significant biopsychosocial-spiritual 
factors discussed here. This is also well known in the literature and in healthcare settings. 
It is believed that the multidisciplinary team approach is the best model for treating these 
patients. Inclusion of a pharmacist as a team member is essential to educate patients 
about their prescribed opioid and ensure their awareness of appropriate use. 
  
V. Future Research directions  
 
There is much work to be done in the area of adherence to prescription opioid regimens 
in SCD and non-cancer pain to better characterize the nature of pain. It is critical to 
determine and understand the underlying causes of adherence or non-adherence. In this 
area, future studies can address the possible relationship of adherence with different 
biopsychosocial-spiritual factors. A prospective longitudinal study describing and 
assessing adherence is the logical next step. For example, using other adherence 
assessment such as an electronic pill monitoring system and electronic E-diary to 
measure adherence, detect patterns of opioid use and to assess reason for use will be very 
practical and useful way of adherence monitoring especially for PRN medications.  
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In addition, ensuring reliability and further validation steps (explained in chapter 3) are 
needed in the future to validate and start using AOTBA scale in research. 
 
There were several ultimate objectives of this line of research, beyond the scope of this 
dissertation research.  These include: 1) completion of the steps of validation of the 
research instrument to describe adherence and opioid taking behaviors in SCD adults, 
both over time and at particular times and their related contextual factors; 2) adaptation of 
the validated SCD opioid taking behavior instrument and completion of a similar 
validation process to describe opioid taking behavior in chronic non-cancer pain, and; 3) 
revision of the instrument(s) so that it (they) is (are) useful to practitioners to enhance 
communication with their chronic non-cancer pain patients. Although we are not sure that 
this instrument would validate in other non-cancer pain populations, we have designed 
the instrument to be adaptable to other non-cancer pain populations. 
 
For future work, the quantitative survey was shaped based on the findings of Phase I.  For 
example, several hypotheses could expand to comparative hypotheses; depending on 
whether both multiple opioid taking behaviors and multiple contexts related to those 
medications behaviors.   
 
There is a need for further research to determine how, when, and where in the course of 
SCD do patients need to be educated on all aspects of their disease to improve adherence 
to their prescribed opioid regimens. The physician’s role in adherence should be 
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thoroughly investigated to establish strategies that improve adherence. The data from 
such a study can be transformed into a measure of the most common and frequently 
occurring pattern of opioid use and the problems associated with it (i.e., categories of 
problematic situations in such population). Data about time and context specific-
adherence can be used to develop a more accurate and useful measure of adherence to 
opioids especially for PRN short-acting opioids. This measure can serve to provide 
outcome data for interventions to improve adherence not only in SCD patients but also 
for patients with non-cancer pain. Prospective studies or predictive models can also 
determine which factors are significantly related to adherence to opioid of use and 
whether patients’ outcomes differ based on the patterns of opioid use. Improving 
measurement of PRN medication adherence should allow the adherence researcher to get 
on the development and evaluation of adherence-improving interventions with tested 
adherence measures. 
 
 Computing a Total Score E.
 
Currently, I do not have a clear idea about calculating a score for adherence using this 
new scale. I will consider the calculations for scoring adherence using this scale. I will try 
to preserve the ability to calculate an overall adherence score. I will calculate a total score 
for each respondent, by summing the values of all items. Suppose respondent X will have 
the following response pattern for 5 items. The total score computed for respondent X 
would be: 
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4 + 4 (Negative item) + 5 + 3 + 4 (Negative item) = 20/25 
 
The score report (indicate) that the level of non-adherence reported by the participants. 
The item was worded so that “always” indicated an unfavorable behavior (more of non-
adherence). For ease of comparison with other items, scores will be made so that higher 
values indicate more unfavorable responses (higher level of non-adherence).  I will 
calculate the mean subscore for the items in each Assessment of opioid-taking behavior 
and Adherence (AOTBA) dimension.  
 
For statements indicating perfect adherence, the scoring is reversed so that ‘always’ 
would be scored as ‘1’, and so on, with ‘Never’ being scored as ‘5’.  
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VI. Other Types of Reliability and Validity  
 
For the next phase of instrument development and validation, several steps should be 
used in the assessment of this new instrument, future research should add to the other 
assessments of translational validity (content validity and face validity), construct 
validity, reliability testing (internal consistency, and test-retest), and criterion validity. 
Although these steps of validations needed large sample size, and therefore it beyond the 
scope of this dissertation project, however, I will report preliminary psychometric results 
related to construct, criterion validity and internal reliability. I do not consider these 
results as completion of validation steps 11-20. 
 
 Criterion Validity A.
 
For criterion validity, I need an external gold standard assessment of medication 
adherence or another measure generally accepted as a more accurate or criterion variable 
that correlates with my proposed new measure. However, in the field of medication 
adherence measurement, it is rarely if ever that a perfect ‘gold-standard’ measure exists 
against which to test the validity of new adherence measure. Perhaps the only untarnished 
gold standard is recorded observation of each prescribed dose of therapy. However, this 
method is not feasible and practical. Instead, a number of more indirect approaches are 
recommended to judge instruments’ validity of adherence measure. Many treat these 
approaches as a practical and feasible gold standard, even though they each have 
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limitations. Thus, with all these limitation, selecting an appropriate and meaningful 
criterion measure can be a challenge for medication adherence.  
 
I also realized that monitoring prescribed opioid therapy could be done by 
pharmacokinetic measures (e.g. predicting oral or IV morphine doses using serum or 
urine morphine concentration. (157)  Other methods of monitoring pain and prescribed 
opioid are functional magnetic resonance imaging (158) and vascular inflammatory 
markers. (159) Likewise, these measurements are costly and often impractical. 
 
For validating a new self-report measure of medication adherence with concurrent 
measurement most would suggest using a MEMS cap. However, because MEMS 
technology is expensive, a less costly measure, such as pill count or refill records, 
therefore, I will instead use pill count and the validated Morisky adherence scale (160) to 
provide evidence of criterion validity. 
 
 Construct Validity B.
 
Construct validity refers to the degree to which the items on an instrument relate to the 
relevant theoretical construct. (135, 136) It refers to the degree to which the intended 
independent variable (construct) relates to the proxy independent variable (indicator). (135, 
136) For example, in the AOTBA, dose-self-adjustment (chemical coping), pain intensity, 
and pain relief from prescribed dose will be used as proxy indicators of non-adherence. 
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When an indicator consists of multiple items, factor analysis is used to determine 
construct validity. 
 
Future construct validity studies can measure whether the adherence measures tap the 
constructs I intend, by measuring correlation with related concepts.  Opioid use is well 
known to be correlated with pain intensity in SCD. (4) Thus I expect that overusers should 
have more pain than erratic users, since they in general should have more opioid use.  
Similarly, erratic users should have more pain than underusers, since they should have 
more opioid use.   Besides pain, I expect that pain relief should be correlated with opioid 
use, i.e. patients with more use (overusers) should have more pain relief than erratic users 
or underusers.  Similar relationships should exist for use and emergency department 
utilization and hospital utilization.   
 
Satisfaction with provider in term of drug regimen may have a complex relationship. 
Given the unclear standards about appropriate prescribing (quantity of opioids), “stingy” 
prescribers may be alternately seen as satisfactory or not depending on patients’ attitudes 
about opioids and tendency toward overuse or underuse.  However, it is possible to 
measure agreement (satisfaction or dissatisfaction) of patients with prescribed doses.  I 
expect that underusers may be quite satisfied, whereas overusers may be quite 
dissatisfied, distinct from whether the satisfaction is appropriate.  
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I will use the commonly statistical method known as Factor Analysis in order to cluster 
items into common factors, interpret each factor according to the items having a high 
loading (measure of association between an item and a factor on it), and summarize the 
items into a small number of factors. (135, 136, 161, 162) I define a factor as a list of items that 
belong together. Related items define the part of the construct that can be grouped 
together. Unrelated items, those that do not belong together, do not define the construct 
and should be deleted. (135, 136, 161, 162) 
 
I will use the commonly statistical method known as exploratory factor analysis (EFA) 
to: a) explore the hypothesized dimensions; b) examine the relationships among 
variables; and c) helps us define the construct based on the theoretical framework, which 
indicates the direction of the measure (135, 136) and identifies the greatest variance in scores 
with the smallest number of factors. (135, 136, 161, 162) All items will be loaded as predicted 
on the hypothesized dimensions. To further purify the measure, a Confirmatory Factor 
Analysis on the final numbers of items will be performed in order to assess the 
psychometric properties of the scale developed in this study. (135, 136, 161, 162) 
 
 Reliability C.
 
Once the preliminary validity procedures are completed, the final draft version of the 
AOTBA will be examined to assess its reliability. Reliability refers to the ability of a 
questionnaire to consistently measure an attribute and how well the items fit together, 
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conceptually. (135, 136) Two estimators of reliability are commonly used: internal 
consistency reliability and test-retest reliability: both will be used to examine the 
reliability of the AOTBA. 
 
Internal consistency examines the inter-item correlations within an instrument and 
indicates how well the items fit together conceptually. (135, 136, 161, 162) In addition, a total 
score of all the items will be computed to estimate the consistency of the whole 
questionnaire. Internal consistency is measured in two ways: Split-Half reliability and 
Cronbach’s alpha correlation coefficient.  (135, 136, 161, 162) 
 
Cronbach’s alpha is the most frequently used reliability statistic to establish internal 
consistency reliability, (135, 136, 161, 162) therefore, I will compute the Cronbach’s alpha to 
examine the internal consistency of the AOTBA, where the average correlations of all 
items that measure the same construct are computed. If an instrument contains more than 
one subscale, Cronbach’s alpha will be computed for each subscale as well as the entire 
scale. A measure of internal consistency or composite reliability is a composite alpha 
value. For reliability analyses of several factors from this instrument, Cronbach’s alpha 
will be calculated (in order to determine whether any items need to be recoded and/or 
deleted to make a stronger subscale). I will create scale scores for each of the factors and 
compute the bivariate correlations among the scales. Finally, I will create confidence 
intervals around the estimates of reliability. Construct reliabilities, average variances 
extracted, means, standard deviations, and correlations for all latent variables will be are 
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identified. Construct reliability coefficients should all exceed the .70 (lower limit), to 
conclude good reliability. (135, 136, 161, 162) 
 
Future reliability studies can measure test-retest reliability, which is estimated by 
administering the same tool to the same sample on two different occasions on the 
assumption there will be no substantial change in the construct under study between the 
two sampling time points. (135, 136, 161, 162) I believe opioid taking behavior is stable 
characteristics over two weeks that a high correlation between the scores at the two time 
points (15 days of administration). The duration of time between the two tests is critical. 
The shorter the interval the higher the correlation between the two test. (135, 136) Longer 
interval than two weeks can affect the results because of changes in participants or their 
environment. Currently, there is no definite evidence about the best time interval to allow 
between the test and the retest for medication adherence. To make an appropriate 
decision about the time interval between tests, I need to consider factors such as the 
effects of time on health status such as deterioration or improvement in health. I hope to 
see no significant differences between the two tests (test and retest in two weeks). 
  
 Additional Survey Tools D.
 
In addition to the above draft survey, I will co-administer several other items and pre-
validated surveys, scales, and instruments, to enrich my understanding of the draft 
survey’s construct and criterion validity.  These include the Morisky Adherence Scale, 
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(160) BPI Pain Scale, (48) the McGill Pain Scale, (48) PiCES Pain Diary, (4) and baseline 
assessment of psychosocial variables inclusive of the Coping Strategies Questionnaire 
(163, 164) to assess coping skills, and the Pain Medication Attitude Questionnaire (PMAQ) 
(156) attitudes about opioid use.  
 
 Pilot Testing the Draft Survey E.
 
I plan to identify problems with items or responses by pilot testing my draft survey with 
colleagues and a few SCD patients. These pilot tests will help identify redundant or poor 
questions and provide an early indication of the reproducibility of the responses. For 
example, I may rewrite or drop an item if it confuses several respondents. I plan at least 
two pretests, and with each revision, the will likely become shorter. 
 
 
 
 
 
 
 
 
 
 
  
 
251 
 
 
 
 
 
 
 
 
  
  
 
252 
List of References 
 
1. Serjeant GR, Serjeant BE. Management of sickle cell disease; lessons from the 
Jamaican Cohort Study. Blood Rev. 1993; 7:137-45.  
 
2. Serjeant GR. Sickle-cell disease. Lancet. 1997; 350:725-30.  
 
3. Hassell KL.Population estimates of SCD in the U.S. Am J Prev Med. 2010 
Apr;38(4 Suppl):S512-21. 
 
4. Gallaway S.et al. Sickle cell anemia-a review. J Emerg Med. 1988;6:213- 226. 
5. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults 
with sickle cell disease. Ann Intern Med. 2008; 148:94 –101. 
 
6.  Dampier C, Ely E, Brodecki D, O’Neal P. Home management of pain in sickle 
cell disease: a daily diary study in children and adolescents. J Pediatr Hematol 
Oncol. 2002 Nov; 24(8):643– 647. 
 
7.  Dampier C, Ely B, Brodecki D, O’Neal P. Characteristics of pain managed at 
home in children and adolescents with sickle cell disease by using diary self-
reports. J Pain. 2002 Dec;3(6): 461–470. 
 
8.   J.D. Loeser, Economic implications of pain management, Acta Anaesthesiol 
Scand 43 (1999), pp. 957–959.  
 
9.  Laurence B, George D, Woods D. Association between elevated depressive 
symptoms and clinical disease severity in African-American adults with sickle 
cell disease. J Natl Med Assoc. 2006; 98:365–369. 
 
10.  Levenson JL, McClish DK, Dahman BA, et al. Depression and anxiety in adults 
with sickle cell disease: the PiSCES Project. Psychosom Med. 2008;70:192–196. 
 
11.  Jensen MP. A neuropsychological model of pain: research and clinical 
implications. J Pain. 2010 Jan;11(1):2–12. 
 
12.  Brandow AM, Brousseau DC, Pajewski NM, Panepinto JA. Vaso-occlusive 
painful events in sickle cell disease: impact on child well-being. Pediatr Blood 
Cancer. 2010 Jan;54(1): 92–97. 
 
13.  McClish DK, Penberthy LT, Bovbjerg VE, et al. Health related quality of life in 
sickle cell patients: the PiSCES project. Health Qual Life Outcomes. 2005;3:50. 
 
  
 
253 
14.  Johnson MC, Kirkham FJ, Redline S, et al. Left ventricular hypertrophy and 
diastolic dysfunction in children with sickle cell disease are related to asleep and 
waking oxygen desaturation. Blood. 2010 Jul 8;116(1):16 –21. 
 
15.  Palermo TM, Kiska R. Subjective sleep disturbances in adolescents with chronic 
pain: relationship to daily functioning and quality of life. J Pain. 2005 
Mar;6(3):201–207. 
 
16.  Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle 
cell painful crisis. Blood. 1992;79:2154– 2163. 
 
17.  Brandow AM, Brousseau DC, Panepinto JA. Postdischarge pain, functional 
limitations and impact on caregivers of children with sickle cell disease treated for 
painful events. Br J Haematol. 2009 Mar;144(5):782–788. 
 
18. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily pain in sickle cell disease. 
Ann Intern Med. 2008;148(2):94-101. 
 
19. Smith WR, Bovbjerg VE, Penberthy LT, et al. Understanding pain and improving 
management of sickle cell disease: the PiSCES study. J Natl Med Assoc. 
2005;97(2):183-193. 
 
20. McClish DK, Penberthy LT, Bovbjerg VE, et al. Health related quality of life in 
sickle cell patients: the PiSCES project. Health Qual Life Outcomes. 2005;3:50. 
 
21.  McClish DK, Levenson JL, Penberthy LT, et al. Gender differences in pain and 
health care utilization for adult sickle cell patients: the PiSCES Project. J Womens 
Health (Larchmt). 2006;15(2):146-154. 
 
22. Levenson JL, McClish DK, Dahman BA, et al. Alcohol abuse in sickle cell 
disease: the PiSCES project. Am J Addict. 2007;16(5):383-388. 
 
23. Citero VA, Levenson JL, McClish DK, et al. The role of catastrophizing in sickle 
cell disease--the PiSCES project. Pain. 2007;133(1-3):39-46.  
 
24.  Aisiku IP, Penberthy LT, Smith WR, et al. Patient satisfaction in specialized 
versus nonspecialized adult sickle cell care centers: the PiSCES study. J Natl Med 
Assoc. 2007;99(8):886-890. 
25. Levenson JL, McClish DK, Dahman BA, et al. Depression and anxiety in adults 
with sickle cell disease: the PiSCES project. Psychosom Med. 2008;70(2):192-
196. 
 
  
 
254 
26. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful 
episodes: frequency, etiology, and prognostic significance. Am J Hematol. 
2005;79:17–25. 
 
27. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. 
Mortality in sickle cell disease. Life expectancy and risk factors for early death. N 
Engl J Med 1994;330:1639–44 
 
28. J.C. Ballantyne and J. Mao, Opioid therapy for chronic pain, N Engl J Med 349 
(2003), pp. 1943–1953. 5.  Kalso E, Allen N, Dellemijn PL, Faura CC, Ilias WK, 
Jensen TS, Perrot S, Plaghki LH, Zena M: Recommendations for using opioids in 
chronic non-cancer pain. Eur J Pain 2003, 7:381-386. 
 
29.  A. Van Zee, The promotion and marketing of oxycontin: commercial triumph, 
public health tragedy, Am J Public Health 99 (2009), pp. 221–227 
 
30. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003 Nov 
13;349(20):1943-53. 
 
31. Adams LL, Gatchel RJ, Robinson RC, Polatin P, Gajraj N, Deschner M, Noe 
C.Development of a self-report screening instrument for assessing potential 
opioid medication misuse in chronic pain patients. J Pain Symptom Manage. 2004 
May;27(5):440-59. 
 
32. Compton P, Darakjian J, Miotto K. Screening for addiction in patients with 
chronic pain and "problematic" substance use: evaluation of a pilot assessment 
tool. J Pain Symptom Manage. 1998 Dec;16(6):355-63. 
 
33. Chabal C, Erjavec MK, Jacobson L, Mariano A, Chaney E. Prescription opioid 
abuse in chronic pain patients: clinical criteria, incidence, and predictors. Clin J 
Pain. 1997 Jun;13(2):150-5. 
 
34. Sullivan MD, Edlund MJ, Steffick D, Unützer J. Regular use of prescribed 
opioids: association with common psychiatric disorders. Pain. 2005 Dec 
15;119(1-3):95-103. 
 
35. Jensen MK, Thomsen AB, Højsted J. 10-year follow-up of chronic non-malignant 
pain patients: opioid use, health related quality of life and health care utilization. 
Eur J Pain. 2006 Jul;10(5):423-33. 
 
36. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in 
cancer pain. A review of published literature. Ann Oncol 2008; 19(12):1985–91.  
 
  
 
255 
37. Passik SD, Kirsh KL. The interface between pain and drug abuse and the 
evolution of strategies to optimize pain management while minimizing drug 
abuse. Exp Clin Psychopharmacol 2008; 16(5):400–4.  
 
38. U.S. Department of Justice. Drug Enforcement Administration, Office of 
Diversion Control. Retail drug summary, 1997–2007 
 
39. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic 
prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain. Jun 2004; 
109(3): 514-519. 
 
40. Hudson TJ, Edlund MJ, Steffick DE, et al. Epidemiology of regular prescribed 
opioid use: Results from a national, population-based survey. J Pain Symptom 
Manage 2008; 36(3):280–8.  
 
41.  Starck P, Sherwood GD, Adams-McNeill J, Thomas EJ. Identifying and 
addressing medical errors in pain mismanagement. Jt Comm J Qual Improv 
2001;27(4):191–9.  
 
42. Manchikanti L, Singh A. Therapeutic opioids: A ten-year perspective on the 
complexities and complications of the escalating use, abuse, and nonmedical use 
of opioids. Pain Physician 2008; 11(suppl 2):S63–88.  
 
43. Kuehn BM. Opioid prescriptions soar: Increase in legitimate use as well as abuse. 
JAMA 2007; 297(3):249–51.  
 
44. Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain 
patients: A systematic review and literature synthesis. Clin J Pain 2008; 
24(6):497–508.  
 
45. Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: 
Prediction and identification of aberrant drug-related behaviors: A review of the 
evidence for an American Pain Society and American Academy of Pain Medicine 
clinical practice guideline. J Pain 2009; 10(2):131–46.  
46. Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Medication 
adherence in patients with chronic non-malignant pain: Is there a problem? Eur J 
Pain 2009;13(2):115–23.  
 
47.  Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 
353(5):487–97.  
 
48. Sabate E, ed. Adherence to long-term therapies:evidence for action. Geneva, 
World Health Organization 2003 
  
 
256 
 
49. Fishman S, Wilsey B, Yang J, et al. Adherence monitoring and drug surveillance 
in chronic opioid therapy. J Pain Symptom Manage 2000; 20(4):293–307. 
  
50. Gunnarsdottir S, Donovan HS, Serlin RC, Voge C, Ward S. Patient-related 
barriers to pain management: The Barriers Questionnaire II (BQ-II). Pain 2002; 
99(3):385–96.  
 
51. Taylor LE, Stotts NA, Humphreys J, Treadwell MJ, Miaskowski C. A review of 
the literature on the multiple dimensions of chronic pain in adults with sickle cell 
disease. J Pain Symptom Manage. 2010 Sep; 40 (3):416-35.  
 
52. Labbé E, Herbert D, Haynes J. Physicians' attitude and practices in sickle cell 
disease pain management. J Palliat Care. 2005 Winter; 21 (4):246-51.  
 
53. Pack-Mabien A, Labbe E, Herbert D, et al. Nurses' attitudes and practices in 
sickle cell pain management. Appl Nurs Res. 2001; 14:187–192.  
 
54. Zempsky WT. Treatment of sickle cell pain: fostering trust and justice. JAMA. 
2009 Dec 9; 302 (22):2479-80.  
 
55. Shapiro BS, Benjamin LJ, Payne R, et al. Sickle cell-related pain: perceptions of 
medical practitioners. J Pain Symptom Manage. 1997; 14:168–174.   
 
56. Waldrop RD, Mandry C. Health professionals' perceptions of opioid dependence 
among patients with pain. Am J Emerg Med. 1995; 13:529–531.  
 
57. Becker WC, Starrels JL, Heo M, Li X, Weiner MG, Turner BJ. Racial differences 
in primary care opioid risk reduction strategies. Ann Fam Med. 2011 May-Jun; 9 
(3):219-25.  
 
58. Lusher J, Elander J, Bevan D, Telfer P, Burton B. Analgesic addiction and 
pseudoaddiction in painful chronic illness. Clin J Pain. 2006 Mar-Apr; 22 (3):316-
24.  
 
59. Elander J, Lusher J, Bevan D, Telfer P, Burton B. Understanding the causes of 
problematic pain management in sickle cell disease: evidence that 
pseudoaddiction plays a more important role than genuine analgesic dependence. 
J Pain Symptom Manage. 2004 Feb; 27 (2):156-69.  
 
60. Brozovic M, Davies SC, Yardumian A, et al. Pain relief in sickle cell crises. 
Lancet. 1986; 2:624–625.  
 
  
 
257 
61. Payne R. Pain management in sickle cell disease: rationale and techniques. Ann 
NY Acad Sci. 1989; 565:189–206.  
 
62. Wilkie DJ, Molokie R, Boyd-Seal D, Suarez ML, Kim YO, Zong S, Wittert H, 
Zhao Z, Saunthararajah Y, Wang ZJ. Patient-reported outcomes: descriptors of 
nociceptive and neuropathic pain and barriers to effective pain management in 
adult outpatients with sickle cell disease. J Natl Med Assoc. 2010 Jan; 102 (1):18-
27. 
 
63. Dampier C, LeBeau P, Rhee S, Lieff S, Kesler K, Ballas S, Rogers Z, Wang W, 
Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC) Site 
Investigators. Health-related quality of life in adults with sickle cell disease 
(SCD): a report from the comprehensive sickle cell centers clinical trial 
consortium. Am J Hematol. 2011 Feb; 86 (2):203-5.  
 
64. Ballas SK, Bauserman RL, McCarthy WF, Castro OL, Smith WR, Waclawiw 
MA, Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell 
Anemia. Utilization of analgesics in the multicenter study of hydroxyurea in 
sickle cell anemia: effect of sex, age, and geographical location. Am J Hematol. 
2010 Aug; 85 (8):613-6. 
 
65. Elander J et al Understanding the causes of problematic pain management in 
sickle cell disease: Evidence that pseudoaddiction plays a more important role 
than genuine analgesic dependence. Journal of pain and symptom 2004; vol 27 
 
66. Brozovic, M et al Pain relief in sickle cell crises Lancet 1986;624-625 
 
67. Waldrop, RD et al Health Professional perceptions of opioid dependence among 
patients with pain American journal of emergency medicine 1995; vol 13 
 
68. Elander J et al Pain management and symptoms of substance dependence among 
patients with sickle cell disease Social science and medicine 2003;1683-166 
 
69. National Council on Patient Information and Education. Enhancing Prescription 
Medication Adherence: A National Action Plan. Available at: 
http://www.talkaboutrx.org/documents/enhancing_prescription_medicine_adhere
nce.pdf. Accessed Sep 15, 2012. 
 
70. Stewart RB, Cluff LE. A review of medication errors and compliance in ambulant 
patients. Clin Pharmacol Ther 1972; 13: 463–8.  
 
71. Rand CS, Weeks K. Measuring adherence with medication regimens in clinical 
care and research. In Shumaker SA,  Schron EB, Ockene JK, McBee WL, editors, 
  
 
258 
The handbook of health behavior change, 2nd edition. New York7 Springer; 
 1998. p. 114–32.  
 
72. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication 
compliance: a healthcare problem. Ann  Pharmacother 1993; 27:S1–24.  
 
73. Schaub AF, Steiner A, Vetter W. Compliance to treatment. Clin Exp Hypertens. 
1993;15:1121–30.  
 
74. Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereik SM, Doswell WM. 
Adherence in chronic disease. Annu Rev  Nurs Res 2000;18:49–90.  
 
75. Watters RE. Regulating: the social control process registered nurses use to teach 
psychiatric patients about their medications. Issues Ment Health Nurs. 2000 Jun; 
21(4): 411-31. 
 
76. Saxena S. Pharmacotherapy of compulsive hoarding. J Clin Psychol. 2011 May; 
67(5): 477-84. doi: 10.1002/jclp.20792. Epub 2011 Mar 14. Review.  
 
77. Chue P, Prinzo RS, Binder CE. Do formulation switches exacerbate existing 
medical illness? Results of an open-label transition to orally disintegrating 
risperidone tablets. Hum Psychopharmacol. 2007 Jul; 22(5): 307-14.  
 
78. Morin AK. Possible intranasal quetiapine misuse. Am J Health Syst Pharm. 2007 
Apr 1;64(7):723-5. 
 
79. Sokol MC, McGuigan KA, Verbrugge, Epstein RS. Impact of medication 
adherence on hospitalization risk and healthcare cost. Med Care. 2005; 43:521-30. 
 
80. Take as Directed: A Prescription Not Followed. Research conducted by The 
Polling Company. National Community Pharmacists Association December 16, 
2006. 
 
81. Shaner A, Eckman T, Roberts LJ, Fuller T. Feasibility of a skills training 
approach to reduce substance dependence among individuals with schizophrenia. 
Psychiatr Serv. 2003 Sep; 54(9): 1287-9.  
 
82. Phillips CO, Wright S, Kern DE, et al. Comprehensive discharge planning with 
post discharge support for older patients with congestive heart failure: a meta-
analysis. JAMA. 2004; 291:1358-1367. 
 
83. DiMatteo MR. Variations in patients' adherence to medical recommendations: a 
quantitative review of 50 years of research. Med Care. 2004 Mar; 42(3):200-9.  
  
 
259 
 
84. Shrank WH, Porter ME, Jain SH, Choudhry NK. A Blueprint for Pharmacy 
Benefit Managers to Increase Value. American Journal of Managed Care, 
February 2009. 
 
85. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to 
treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 
2001 Oct;26(5):331-42. Review.  
 
86. LaFleur J, Nelson RE, Sauer BC, Nebeker JR. Overestimation of the effects of 
adherence on outcomes: a case study in healthy user bias and hypertension. Heart. 
2011 Nov; 97(22): 1862-9.  
 
87. Horne R. Compliance, adherence, and concordance: implications for asthma 
treatment. Chest. 2006 Jul; 130(1 Suppl): 65S-72S. Review. 
 
88. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: 
terminology and definitions. Value Health. 2008 Jan-Feb; 11(1):44-7. Review. 
 
89. Krousel-Wood MA, Muntner P, Islam T, Morisky DE, Webber LS. Barriers to 
and determinants of medication adherence in hypertension management: 
perspective of the cohort study of medication adherence among older adults. Med 
Clin North Am. 2009 May; 93(3): 753-69. Review. 
 
90. Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to 
medication adherence in the elderly: looking beyond cost and regimen 
complexity. Am J Geriatr Pharmacother. 2011 Feb; 9(1): 11-23. Review. 
 
91. García-Ribera C, Bulbena A. Determinants of medicine-taking in psychiatric 
patients. Curr Clin Pharmacol. 2011 May; 6(2): 100-7. Review 
 
92. World health organization. Adherence to long-therapies: Evidence for action. 
geneva.(2003).  
 
93. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 Aug 4; 
353(5):487-97. Review.  
 
94. Farmer KC. Methods for measuring and monitoring medication regimen 
adherence in clinical trials and clinical practice. Clin Ther. 1999 Jun; 21(6): 1074-
90; discussion 1073. Review.  
 
  
 
260 
95. Spilker B. Methods of assessing and improving compliance in clinical trials. In 
Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical 
trials. New York, Raven Press, 1991:37-56 25.  
 
96. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral 
therapy for human immunodeficiency virus/acquired immune deficiency 
syndrome among drug users: a systematic review. Addiction. 2008 Aug; 103(8): 
1242-57. Review.  
 
97. DiMatteo MR. Variations in patients' adherence to medical recommendations: a 
quantitative review of 50 years of research. Med Care. 2004 Mar; 42(3): 200-9. 
  
98. Hess LM, Saboda K, Malone DC, Salasche S, Warneke J, Alberts DS. Adherence 
assessment using medication weight in a phase IIb clinical trial of 
difluoromethylornithine for the chemoprevention of skin cancer. Cancer 
Epidemiol Biomarkers Prev. 2005; 14(11 pt 1): 2579 -83 27.  
 
99. Hill MN, Miller NH, Degeest S, et al. Adherence and persistence with taking 
medication to control high blood pressure. J Am Soc Hypertens. 2011 Jan-Feb; 
5(1): 56-63. 
 
100. Krigsman K, Nilsson JL, Ring L. Adherence to multiple drug therapies: 
refill adherence to concomitant use of diabetes and asthma/COPD medication. 
Pharmacoepidemiol Drug Saf 2007; 16:1120–1128. 
 
101. Gilberg K, Laouri M, Wade S, Isonaka S. Analysis of medication use 
patterns: apparent overuse of antibiotics and underuse of prescription drugs for 
asthma, depression, and CHF. J Manag Care Pharm. 2003 May-Jun;9(3):232-7 
 
102. Dolce JJ, Crisp C, Manzella B, Richards JM, Hardin JM, Bailey WC. 
Medication adherence patterns in chronic obstructive pulmonary disease. Chest. 
1991 Apr; 99(4): 837-41. 
 
103. Fishman SM, Wilsey B, Yang J, Reisfield GM, Bandman TB, Borsook D. 
Adherence monitoring and drug surveillance in chronic opioid therapy. J Pain 
Symptom Manage. 2000 Oct; 20(4): 293-307. Review. 
 
104. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk 
of death and near death from asthma. N Engl J Med. 1992 Feb 20; 326(8): 501-6. 
 
105. Dekker FW, Dieleman FE, Kaptein AA, Mulder JD. Compliance with 
pulmonary medication in general practice. Eur Respir J. 1993 Jun; 6(6): 886-90. 
  
  
 
261 
106. Ryan GW, Wagner GJ. Pill taking 'routinization': a critical factor to 
understanding episodic medication adherence. AIDS Care. 2003; Dec; 15(6): 795-
806.  
 
107. Rudd P, Byyny RL, Zachary V, LoVerde ME, Mitchell WD, Titus C, 
Marshall G. Pill count measures of compliance in a drug trial: variability and 
suitability. Am J Hypertens. 1988 Jul;1(3 Pt 1):309-12.  
 
108. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the 
tablets? Clin Pharmacol Ther.1989; 46:163-168 31.  
 
109. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between 
clinic visits. Arch Intern Med. 1990 Jul; 150(7): 1509-10. 
 
110. Zolnierek KB, Dimatteo MR. Physician communication and patient 
adherence to treatment: a meta-analysis. Med Care. 2009 Aug; 47(8): 826-34. 
 
111. Thompson C, Pledger L. Doctor-patient communication: is patient 
knowledge of medical terminology improving? Health Commun 1993;5:89-97. 
 
112. Ben-Arye E, Bar-Sela G, Frenkel M, Kuten A, Hermoni D. Is a 
biopsychosocial-spiritual approach relevant to cancer treatment? A study of 
patients and oncology staff members on issues of complementary medicine and 
spirituality. Support Care Cancer. 2006 Feb; 14(2):147-52. 
 
113. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The 
Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol. 2007 
Jul 3;7:30. 
 
114. Nieuwkerk PT, de Boer-van der Kolk IM, Prins JM, Locadia M, Sprangers 
MA. Self-reported adherence is more predictive of virological treatment response 
among patients with a lower tendency towards socially desirable responding. 
Antivir Ther. 2010; 15(6): 913-6. 
 
115. King MF, Bruner GC. Social desirability bias: A neglected aspect of 
validity testing. Psychology & Marketing. 2000; 17 (2), 79-103. 
 
116. Kravitz RL, Bell RA, Franz CE, et al. Characterizing patient requests and 
physician responses in office practice. Health Serv Res. 2002 Feb; 37(1): 217-38.  
 
117. van de Mortel TF. Faking it: social desirability bias in self-report research. 
Aus J Adv Nurs. 2008; 25(4): 40-48.  
 
  
 
262 
118. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease 
inhibitors, HIV-1 viral load, and development of drug resistance in an indigent 
population. AIDS. 2000 Mar 10;14(4):357-66.  
 
119. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial 
comparing combinations of nevirapine, didanosine, and zidovudine for HIV-
infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia 
Study. JAMA. 1998 Mar 25;279(12):930-7.  
 
120. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor 
therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 Jul 4; 
133(1):21-30. Erratum in: Ann Intern Med 2002 Feb 5; 136(3): 253.  
 
121. Greaves CJ, Hyland ME, Halpin DM, Blake S, Seamark D. Patterns of 
corticosteroid medication use: non-adherence can be effective in milder asthma. 
Prim Care Respir J. 2005 Apr;14(2):99-105. Epub 2005 Jan 21.   
 
122. Carlquist JF, Anderson JL. Pharmacogenetic mechanisms underlying 
unanticipated drug responses. Discov Med. 2011 May;11(60):469-78. Review. 
 
123. Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for 
measuring medication adherence. J Am Pharm Assoc (2003). 2011;51:90–94. 
 
124. Shi L, Liu J, Fonseca V, Walker P, Kalsekar A, Pawaskar M. Correlation 
between adherence rates measured by MEMS and self-reported questionnaires: a 
meta-analysis. Health Qual Life Outcomes. 2010;8:99. doi: 10.1186/1477-7525-8-
99. http://www.hqlo.com/content/8//99.1477-7525-8-99 
 
125. Rolley JX, Davidson PM, Dennison CR, Ong A, Everett B, Salamonson 
Y. Medication adherence self-reported instruments: implications for practice and 
research. J Cardiovasc Nurs. 2008;23:497–505. 
 
126. Cameron J, Worrall-Carter L, Driscoll A, Stewart S. Measuring self-care 
in chronic heart failure: are view of the psychometric properties of clinical 
instruments. J Cardiovasc Nursing in press; Accepted July 2009. 
 
127. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity 
of a self-reported measure of medication adherence.  Med Care.  1986;24:67–74 
  
128. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a 
medication adherence measure in an outpatient setting.  J Clin 
Hypertens.  2008;10:348–54 
 
  
 
263 
129. Risser J, Jacobson TA, Kripalani S. Development and psychometric 
evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in 
low-literacy patients with chronic disease.  J Nurs Meas.  2007;15:203–19 
 
130. Svarstad BL, Chewing BA, Sleath BL, Claesson C. The Brief Medication 
Questionnaire: a tool for screening patient adherence and barriers to 
adherence.  Patient Educ Couns.  1999;37;113–24.  
 
131. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the 
Hill-Bone Compliance to High Blood Pressure Therapy Scale.  Prog Cardiovasc 
Nurs.  2000;15:90–6 
 
132. Krousel-Wood M, Muntner P, Jannu A, et al. Reliability of medication 
adherence measure in an outpatient setting.  Am J Med Sci.  2005;330:128–33 
 
133. hompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new 
Medication Adherence Rating Scale (MARS) for the psychoses.  Schizophr 
Res.  2000;42:241–7 
  
134. Fialko L, Garety PA, Kuipers E, et al. A large-scale validation study of the 
Medication Adherence Rating Scale (MARS).  Schizophr Res.  2008;100:53–9 
 
135. DeVellis, Robert F (2003). Scale Development: Theory and Applications 
(2nd ed.). London: Sage Publications.  
 
 
136. DeVon, H. A., Block, M. E., Moyle-Wright, P., Ernst, D. M., Hayden, S. 
J., Lazzara, D. J. et al. (2007). A psychometric Toolbox for testing Validity and 
Reliability. Journal of Nursing scholarship, 39 (2), 155-164. 
 
137. Patrick DL, Burke LB, Gwaltney CJ, et al.  Content validity - Establishing 
and reporting the evidence in newly-developed patient-reported outcomes (PRO) 
instruments for medical product evaluation: ISPOR PRO good research practices 
task force report: Part 1 - Eliciting concepts for a new PRO instrument.  Value 
Health 2011;14; 967-977.  
 
138. Passmore C, Dobbie AE, Parchman M, Tysinger J. Guidelines for 
constructing a survey. Fam Med. 2002 Apr;34(4):281-6. 
 
139. Prior ME, Hamzah JC, Francis JJ, Ramsay CR, Castillo MM, Campbell 
SE, Azuara-Blanco A, Burr JM. Pre-validation methods for developing a patient 
reported outcome instrument. BMC Med Res Methodol. 2011 Aug 9;11:112. 
 
  
 
264 
140. Creswell, J. W. (2003). Research design: Qualitative, quantitative, and 
mixed method approaches. Thousand Oaks, CA: Sage Publications. 
 
141. Strauss, A., & Corbin, J. (1990). Basics of qualitative research: Grounded 
theory procedures and techniques. Newbury Park, CA: Sage Publications, Inc. 
 
142. Strauss, A., & Corbin, J. (1998). Basics of qualitative research: 
Techniques and procedures for developing grounded theory. Thousand Oaks, CA: 
Sage Publications, Inc. 
 
143. Merrick, E. (1999). An exploration of quality in qualitative research. In M. 
Kopala, & L. A. Suzuki (Eds.), Using qualitative methods in psychology (pp. 25-
36). Thousand Oaks, CA: Sage Publications, Inc. 
 
144. Lincoln, Y. S., & Guba, E. G. (1985). Naturalistic inquiry. Beverly Hills, 
CA: Sage Publications, Inc. 
 
145. Fontana, A., & Frey, J. H. (2000). The interview: From structured 
questions to negotiated text. In N. K. Denzin, & Y. S. Lincoln (Eds.), Handbook 
of qualitative research (pp. 645-672). Thousand Oaks, CA: Sage Publications, Inc. 
 
146. Denzin, & Y. S. Lincoln (Eds.), Handbook of qualitative research (pp. 
509-535). 
 
147. Patton, M. Q. (2002). Qualitative research and evaluation methods (3rd 
ed.). Thousand Oaks, CA: Sage Publications, Inc.  
148. Morse, J.M., & Field, P.A. (1995). Qualitative research methods for health 
professionals. Thousand Oaks, CA: Sage.  
 
149. Cleeland CS, Ryan KM. Pain assessment: Global use of the Brief Pain 
Inventory. Ann Acad Med Singapore 1994; 23:129–38. 
 
150. Melzack R. The short-for m McGill Pain Questionnaire.  Pain. 1987; 
30(2):191-197. 
 
151. Spector S. Noncompliance with asthma therapy--are there solutions?. J 
Asthma. 2000 Aug; 37 (5) :381-8.  
 
152. Weaver M,Schnoll S. Addiction issues in prescribing opioids for chronic 
nonmalignant pain. J Addict Med. 2007;1(1):2-10.  
 
153. Larance B, Degenhardt L, Lintzeris N, Winstock A, Mattick R. 
Definitions related to the use of pharmaceutical opioids: Extramedical use, 
  
 
265 
diversion, non-adherence and aberrant medication-related behaviours. Drug 
Alcohol Rev 2011;30: 236–45.  
 
154. Beck, C.T., & Gable, R.K. (2001). Ensuring content validity: An 
illustration of the process. Journal of Nursing Measurement, 9(2), 201–215. 
 
155. Guttman, L. (1969). Integration of test design and analysis. In Proceedings 
of the 1969 invitational conference on testing problems (pp. 15–18).  
 
156. Lynn, M.R. (1996). Determination and quantification of content validity. 
Nursing Research, 35, 382-385. 
 
157. Polit DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of 
content validity? Appraisal and recommendations. Research in Nursing & Health. 
2007;30:459–467.  
 
158. McCracken LM, Hoskins J, Eccleston C. Concerns about medication and 
medication use in chronic pain. J Pain. 2006 Oct;7(10):726-34.  
 
159. Oscar A Linares and Annemarie L Linares.Computational Opioid 
Prescribing: A Novel Application of Clinical Pharmacokinetics. J Pain Palliat 
Care Pharmacother. 2011 June; 25(2): 125–135.  
 
160. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic 
resonance imaging evidence of augmented pain processing in fibromyalgia. 
Arthritis Rheum. 2002;46:1333–1343. 
 
161. Smith WR, Scherer M. Sickle-cell pain: advances in epidemiology and 
etiology. Hematology Am Soc Hematol Educ Program. 2010;2010:409- 415. 
 
162. Morisky De, Green LW, Levine DM. Concurrent and pre- dictive validity 
of a self reported measure of medication adherence. Med Care . 1986;24:67–74. 
  
163. Rust, J., & Golombok, S. (2009). Modern psychometrics: The science of 
psychological assessment (3rd ed.). London, England: Routledge. 
 
164. Osburn, H.G. (1968). Item sampling for achievement testing. Educational 
and Psychological Measurement, 28, 95–107.  
 
165. Hadjistavropoulos HD, MacLeod FK, Asmundson GJG.  Validation of the 
Chronic Pain Coping Inventory.  Pain 1999; 80: 471-81. 
 
  
 
266 
166. Gil KM, Carson JW, Sedway JA, Porter LS, Schaeffer JJW, Orringer E.  
Follow-up of coping skills training in adults with sickle cell disease: Analysis of 
daily pain and coping practice diaries.  Health Psychol 2000; 19: 85-90.  
 
167. Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: 
Prediction and identification of aberrant drug-related behaviors: A review of the 
evidence for an American Pain Society and American Academy of Pain Medicine 
clinical practice guideline. J Pain 2009;10(2):131–46.  
 
168. Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. 
Medication adherence in patients with chronic non-malignant pain: Is there a 
problem? Eur J Pain 2009; 13(2):115–23.  
 
169. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 
353(5):487–97. 
 
170. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a 
comprehensive review. J Am Geriatr Soc. 1992 Sep; 40 (9) :922-35. 
 
171. Miaskowski C, Dodd MJ, West C, et al: Lack of adherence with the 
analgesic regimen: A significant barrier to effective cancer pain management. J 
Clin Oncol 19: 4275-4279, 2001 
 
172. Morgan AE, Lindley CM, and Berry JI. Assessment of pain and patterns 
of analgesic use in hospice patients. Am J Hosp Palliat Care 94;11(1):13-9, 22-5. 
 
173. Schug, S.A., Zech, D., Grond, S., Jung, It., Meuser, T. and Stobbe, B., A 
long-term survey of morphine in cancer pain patients, J. Pain Sympt. Manag., 7 
(1992b) 259-2662,' 
 
174. Ferrell, B.R., Juarez, G., & Borneman, T. (1999). Use of routine and 
breakthrough analgesia in home care. Oncology Nursing Forum, 26, 1655–1661. 
 
 
175. Ward S, Gatwood J. Concerns about reporting pain and using analgesics. 
A comparison of persons with and without cancer. Cancer Nurs 1994;17(3):200–
206. 
 
176. Wells N, Johnson RL, Wujcik D. Development of a short version of the 
Barriers Questionnaire. J Pain Symptom Manage 1998;15:294–298. 
 
177. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side 
effects. Pain Physician. 2008;11(2 Suppl):S105-S120. 
  
 
267 
178. Seltzer, A., Roncari, I., and Garfinkel, P. “Effect of Patient Education on 
Medication Compliance.” Canadian Journal of Psychiatry, 1980,25, 638-645. 
 
179. Weaver, K. E., Llabre, M. M., Durán, R. E., Antoni, M. H., Ironson, G., 
Penedo, F. J., & Schneiderman, N. (2005). A Stress and Coping Model of 
Medication Adherence and Viral Load in HIV-Positive Men and Women on 
Highly Active Antiretroviral Therapy (HAART). Health Psychology, 24(4), 385-
392. 
 
180. Kerse N, Buetow S, Mainous AG 3rd, Young G, Coster G, Arroll B. 
Physician – patient relationship and medication compliance: a primary care 
investigation. Ann Fam Med. 2004;2:455–461. 
 
181. Tremblay J, Hamet P. Genetics of pain, opioids, and opioid 
responsiveness. Metabolism. 2010;59(Suppl. 1):S5–S8 
 
182. Holford NH, Holford NH. Chapter 3. Pharmacokinetics & 
Pharmacodynamics: Rational Dosing & the Time Course of Drug Action. In: 
Katzung BG, Masters SB, Trevor AJ, eds. Basic & Clinical Pharmacology. 12nd 
ed. New York: McGraw-Hill; 2012. 
http://www.accesspharmacy.com/content.aspx?aID=55820341. Accessed April 
25, 2013. 
 
183. Wills, T. A. (1981). Downward comparison principles in social 
psychology. Psychological Bulletin, 90, 245–271. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
268 
APPENDICIES 
 
Appendix A 
 
Pre-Screening Form 
Pre-Screening Eligibility Criteria through Chart Review  
 
• Is patient’s age between 18-64? 
Ø If less than 18 or more than 64, exclude 
• What is the race/ethnicity of the patient?  
Caucasian      African-American     Asian Hispanic     Other 
Ø If not African-American, exclude 
• Did the patient receive three outpatient prescriptions for at least one 
(Schedule II or Schedule III) opioid medications from Virginia 
Commonwealth University Health Care System (VCUHS) within the 
previous 12 months?  YES NO  
Ø if No, exclude 
• Does the chart show evidence of patient dependence on any psychoactive 
substance or history of drug use problem   YES  NO 
Ø If yes, exclude  
• Serious psychiatric diagnosis (by chart review and electronic medical record 
(EMR) system). YES  NO 
§ If yes, exclude 
 
  
 
269 
 
 
Appendix B 
 
Recruitment Form and Script 
 
 “Hello, my name is Abdulkhaliq Alsalman and I am a PhD student working under the 
supervision of Dr. Wally Smith from the sickle cell anemia research team in the 
Department of Internal Medicine at Virginia Commonwealth University. The reason I'm 
talking to/contacting you is that I am currently conducting research on pain medicine use 
in sickle anemia. As part of my dissertation research; I am conducting interviews with 
sickle cell anemia patients to discover their ways of using prescribed opioid and their 
perspectives on why they use their pain medicines in that ways. I am recruiting 
participants for that reason.  This research will hopefully lead to a better understanding of 
how physicians should prescribe opioid and eventually be used to guide and teach sickle 
cell anemia patients to use their pain medicine in more effective and safe ways especially 
when they have special circumstances and situations. I am contacting you because you 
are scheduled to have an outpatient medical appointment in sickle cell anemia clinic. We 
are currently seeking volunteers from the adult sickle cell anemia clinic patients as 
participants in this study and I wondered if you would be interested in hearing more 
about it. Is this a convenient time to give you further information about the interviews? 
[IF YES] provide some more information regarding the interviews that will be conducted 
(Continue on page 2) 
OR No, could you talk back later (agree on a more convenient time to contact person 
back). With your permission, I would like to email/mail/fax you an information letter 
which has all of these details along with contact names and numbers on it to help assist 
you in making a decision about your participation in this study and If you are not 
interested in the study, then I will destroy the personal information you give me. 
May I call you in 2 or 3 days to see if you are interested in participating study?  
Yes (get contact information from potential participant i.e., phone/mailing address/fax 
number). 
[IF NO] Thank you for your time. Have a good day. Good-bye. 
“Participation in this study involves coming into a private room and having interview. If 
you volunteer as a participant in this study, you will be asked during the interview to talk 
about your pain, how and why you use your pain medicine, filling out a questionnaire 
about your pain, saying words and personal memories out loud. Participation in this study 
would take approximately 1.5 hours of your time and would be arranged for a time 
convenient to your schedule. Involvement in this interview is entirely voluntary and there 
are no known or anticipated risks to participation in this study. You may decline to 
answer any of the interview questions you do not wish to answer and may terminate the 
interview at any time. With your permission, the interview will be tape-recorded to 
facilitate collection of information, and later transcribed for analysis. All information you 
provide will be considered confidential. The data collected will be kept in a secure 
location. If you have any questions regarding this study, or would like additional 
  
 
270 
information to assist you in reaching a decision about participation, please feel free to 
contact Dr. Wally Smith at 804-828-6938. After all of the data have been analyzed, you 
will receive an executive summary of the research results. In appreciation of your time 
commitment, you will receive $45. I would like to assure you that this study has been 
reviewed and approved by the VCU Office of Research IRB. 
However, the final decision about participation is yours. 
Would you be interested in participating?” 
[If NO] Thank you for your time. Good-bye. 
[IF YES] Thank you; we appreciate your interest in my research! If you are interested in 
participating, please fill out one of the individual confidential recruitment cards* and I 
will be in touch with you.  Alternatively, you can come to Ambulatory Clinic building, 
4th floor and see me.  Thank you. (Schedule a mutually agreeable time to come to the 
interview room.) “ 
Now, let me give you some important information about the study. Have you got a pen 
and piece of paper? The name of the study is Understanding Adherence to Prescribed 
Opioids in Sickle Cell Disease, and my name is Abdulkhaliq Alsalman.  “The study is 
being conducted in the Clinical Research Service Unit (CRSU) in the 8th floor of the 
North Hospital building on the MCV campus at Virginia Commonwealth University. On 
the day of your appointment, please meet me in the Ambulatory Clinic Parking lot. We 
will provide you with a parking pass or cover any needed parking costs. Please plan to 
arrive in the waiting area on the 1st floor of the Ambulatory Clinic building five minutes 
before the time of your appointment. Also, if you wear glasses or contact lenses to correct 
your vision, or if you use a hearing aid, please bring them with you to the session.” “The 
day before your session, I will phone you to make sure that you are still able to make it. If 
you have to cancel your appointment, you can call the research team at (804) 728-9803 to 
contact me or leave a message on the answering machine. I look forward to meeting you 
on [day and time of appointment]. Thank you very much for helping us with my 
research!” Once again, if you have any questions or concerns, please do not hesitate to 
contact me at my research office number 804-728-9803. Thank you very much for your 
time.  
* Individual Confidential recruitment cards: please request the following information to 
be completed by potential participants: 
 Name  
Email 
Fax number  
Phone number  
Best Days and Times to call you 
 Best Days and Times to interview you (if agree to participate) 
* If you are not interested in the study at anytime, then I will destroy the personal 
information you give me. 
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Appendix C 
 
Screening for Eligibility 
 
MINI-MENTAL STATE EXAM 
Participant study number: ___________________ 
 Date of Exam:            
 The Mini-Mental Status Examination offers a quick and simple way to quantify cognitive function 
and screen for cognitive loss. It tests the individual’s orientation, attention, calculation, recall, 
language and motor skills.  
Each section of the test involves a related series of questions or commands. The 
individual receives one point for each correct answer.  
To give the examination, seat the individual in a quiet, well-lit room. Ask him/her to 
listen carefully and to answer each question as accurately as he/she can.  
To score, add the number of correct responses. The individual can receive a maximum 
score of 30 points. 
Right / Wrong?  - 30 questions for 30 points  
ORIENTATION – 10 points 
Ask the following questions: 
1. What is today's date? 
2. What is the month? 
3. What is the year? 
4. What day of the week is it today? 
5. What season is it?                                              
6. What is the name of this clinic (place)? 
7. What floor are we on? 
8. What city are we in?  
9. What county are we in? 
10. What country are we in?                          Orientation subtotal =    /10 
IMMEDIATE RECALL – 3 points 
Ask the subject if you may test his/her memory. Then say "ball", "flag", "tree" clearly and 
slowly, about 1 second for each. After you have said all 3 words, ask him/her to repeat 
them - the first repetition determines the score (0-3):  
11. BALL 
12. FLAG 
13. TREE                                                   Recall subtotal =     /3 
ATTENTION – 5 points 
NB PERFORM SERIAL 7S OR ‘WORLD’ BACKWARDS BUT NOT BOTH! 
 
A) Ask the subject to begin with 100 and count backwards by 7. Stop after 5 subtractions. 
Score the correct subtractions. 
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14. "93" 
15. "86" 
16. "79" 
17. "72" 
18. "65"                                               
B) Ask the subject to spell the word "WORLD" backwards. The score is the number of 
letters in correct position. For example, "DLROW" is 5, "DLORW" is 3, "LROWD" is 0. 
"D" 
"L" 
"R" 
 "O" 
"W"                                             "DLROW" or Serial 7s subtotal =         /5     
DELAYED VERBAL RECALL – 3 points 
Ask the subject to recall the 3 words you previously asked him/her to remember.  
19. BALL? 
20. FLAG? 
21. TREE?                                  Delayed verbal recall subtotal =          /3 
NAMING –2 points  
Show the subject a wrist watch and ask him/her what it is. Repeat for pencil.  
22. WATCH 
23. PENCIL 
REPETITION – 1 point 
Ask the subject to repeat the following :"No ifs, ands, or buts"  
25. REPETITION 
3-STAGE COMMAND - 3 points 
Give the subject a plain piece of paper and say, "Take the paper in your hand, fold it in 
half, and put it on the floor."  
25. TAKES 
26. FOLDS 
27. PUTS 
READING – 1 point 
Hold up the card reading, "Close your eyes", so the subject can see it clearly. Ask 
him/her to read it and do what it says. Score correctly only if the subject actually closes 
his/her eyes. 
28. CLOSES EYES 
WRITING 1 point 
Give subject a piece of paper and ask him/her to write a sentence. It is to be written 
spontaneously. It must contain a subject and verb and be sensible. Correct grammar and 
punctuation are not necessary.  
29. SENTENCE 
                                              Language subtotal = /8             
COPYING – 1 point 
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Give subject a piece of paper and ask him/he to copy a design of two intersecting shapes. 
One point is awarded for correctly copying it. All angles on both figures must be present, 
and the figures must have one overlapping angle.  
Example:  
 
30. PENTAGONS                                    Pentagon subtotal  =           /1 
 
 TOTAL MMSE =            /30 
(MMSE maximum score = 30) 
• What is the MMSE score at screening? (See  below for MMSE exam) 
Ø Is patient incapable of being interviewed (e.g., dementia, mental retardation, 
illiteracy)?  YES    NO  If yes and MMSE less than 23,  exclude 
 
• How much pain are you experiencing today?  If 0 is ‘‘no pain’’ and 10 is the ‘‘worst pain 
imaginable’’     
Ø If more than >7, exclude 
• In the last month, how many days did you feel pain? 
o Circle one: 
§ ≤ 8 days (≤ 30% of days), exclude 
§ 9-14 days (> 30-50% of days) 
§ > 14 days (> 50% of days)   
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Appendix D 
Baseline Information 
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Appendix G 
 
Semi-Structure Interview Guide 
 
Project Title: Understanding Adherence to Prescribed Opioids in Sickle Cell Disease 
Arrival  
Welcoming patient and having some informal chat in order to put them in their ease and 
make them feel comfortable. Opening Questions: How are you today? How is [school] 
[Work]? “Please tell us your first and last name.” 
The following statement is to be read to the participants before each interview.   
“Thank you so much for agreeing to participate in this study.  What we would like to do 
today is talk about issues connected with sickle cell disease pain. We will be discussing 
how you manage your pain, drawing on your experiences.   We want to learn from you to 
help other people in the future. We have a number of areas we would like to cover, 
including how patients use their medicine and other ways of pain control. At any time if 
you think of any comments or experiences, we would very much like to hear them, even 
if that’s not what we are talking about right then.  We want to understand the different 
ways people cope with their pain.” 
Introduction 
Medication adherence: “As I mentioned before, the first thing we will ask you is a 
series of questions about your experience with pain and how it made you feel.   Then we 
will ask you a series of questions about how patients take their prescribed pain medicines. 
I am interested in things that people do that affect their ways of taking their pain 
medicines. The purpose of the study is not to judge whether your ways of taking pain 
medicine are good or bad. The purposes of the study are to just learn exactly how pain 
affects you and what you do about it.  That includes what medicines you take, and how 
you take them, regardless of how they are prescribed. Please try and answer each 
question with as much detail as possible.”  
1) Beginning the interview: I'd like to start out this interview by hearing a little bit 
about your experiences with Sickle Cell Disease.  Can you tell me how you usually 
experience your disease?  
Probe: 
a) How has your sickle cell disease pain affected your personal life? Think about 
when you are in pain–during that time, how are your family, life style, daily 
activities affected? 
2) Please tell me all the medical problems that cause you pain.  
Explore:  
a) Follow-up questions (f/u): Of all the problems you have that are causing you 
pain, which one is the worst? 
Sickle Cell Anemia and Pain (generally) 
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3) What medicines are you currently taking for your pain?  (Please tell me all you can 
remember, regular or occasional, prescription or over the counter). 
Explore:  
a. (f/u): How well do these medicines work for you? 
 
In the following questions, I would like to know about how you use your strong pain 
medicine like Morphine, MS Contin, Tramadol, Tylenol III, Codeine, Darvocet, 
propoxyphene, Percocet, OxyContin, oxycodone, Vicodin, Lortab, hydrocodone, 
Dilaudid, hydromorphone, or Pain patches (Fentantl), prescribed by a doctors. But 
from now on I will just say pain medicine for strong pain medicine. Let’s talk now 
about that.  
 
Adherence to Prescribed Opioid: To Identify Actual Behavior of Use 
4) It sounds like you are taking (select appropriate phrase according to above) [both] 
[short-acting] [and] [long-acting] to manage your pain.  Thinking back over the last 
30 days, how did you use your pain medicine?  
Probes: 
a. Do you usually use as needed and/or scheduled pain medicine every day? 
b. How often do you take them? How many pills do you take each time? How 
many times are you supposed to take pills each day?  
Explore: 
a. Typically, how long do you wait to take your next dose of pain 
medication?  What factors influence your decision? 
b. How long does it take you to get comfortable after taking your 
medication? 
c. Do you ever take your medicine in a different order or dosage than 
prescribed by your doctor?  Why?  What factors influence your decision? 
d. Have you ever stopped using your medicine for any reason?  Can you tell 
me a little bit about that? 
 
 
5) The following questions below depend on answer to this question # 4) [For Adherent 
what was it that made you want to keep taking your pain medicine as prescribed?] 
[For Non-adherent: Why did you decide that you wanted to quit using your pain 
medicine?] [For Erratic User: You mention that you sometimes use more and 
sometime use less of your pain medications that your doctor than prescribed of your 
strong pain medicines; what is the reason? What made you use it that way?]  
 Reasons for Underuse, Overuse, Erratic, and Quitting 
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6) I know that many doctors prefer to treat sickle cell pain with a combination of as-
needed and scheduled pain medicine or a number of different medicines at the same 
time. How do you know which kinds of medicine to use? How did you decide to take 
them?  
7) Besides using your pain medicine to help with pain, what other methods do you use, 
such as home remedies?  
Explore: 
a. (f/u) If you use more than one method, how do you choose which one to use 
when? How do you combine methods? 
8) Thinking about a typical day (with pain or without pain),  tell me how you usually 
take your prescriptions during that 24 hour period.    
Probes:  
a. When do you usually take your pills? 
b. Are there any times of day (or night) when you take more or less of your 
medications?Why?  
c. How would your medication usage vary on an atypical (unusual) day?  What 
does an atypical day look like for you?  Why would you change the way you 
use your medicine? 
9) Do you agree with the amount of pain medicine your doctor prescribes for your sickle 
cell pain?   
Probes:  
a. Do you think that your doctor has you on the right medicines?  
b. What changes would you make to your drug regimen if it were up to you? 
 
10) Regimen Complexity Do you take your pain medication the way that your doctor 
originally prescribed it?  Have you ever had any problems understanding how to take 
your medications?  (If so) Tell more me about it.  
 
General Factors Affect Adherence (Motivations and Difficulties) Over the Time or 
Episodically 
Transition: Next, I would like to ask you some questions about your experiences with 
pain medicine 
11) Motivations or Factors for Use: What factor influence, encourage, or motivate you to 
use your pain medicine (scheduled pain medicine or as-needed pain medicine)? 
12) Barriers, Challenges or Difficulties of Adherence to Pain Medicine at Home: 
Sometimes SCD adults find it difficult to take medicines as the doctor has ordered. 
What are some things that make it difficult to continue taking your pain medicines as 
prescribed? Why?  
Explore: 
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a. (f/u) Describe a time when you experienced difficulty taking your scheduled or 
as-needed pain medicine.  How did these challenges affect your ways of using 
pain medicine?  
13) Family or Friends Concern of Opioid Use: Think of your environment.  By 
environment I mean the physical and social world around you. How does your 
environment affect the way you take your medicine?  
Probe:  
a. How do your family and friends affect how you take (or don’t take) your pain 
medicine? Share with us about how people in your life play a role in taking 
your medicine?  
b. (f/u) How does society affect how you take your pain medicine?  Do you feel 
you must be “responsible” to yourself or to others?  
c. How does the weather affect how you take your pain medicine? If you can, 
share with us what kinds of weather change the way you take your pain 
medicine. 
14) Reasons for Underuse: There are many reasons why SCD patients use less pain 
medicine than prescribed, don’t use pain medicine for a time, or choose not to use it. 
Thinking about the last three months, please tell me a story of a time when you took 
less of your medicine than you usually take or took less than you thought you 
needed?  
Explore: 
a. (f/u) What were the reasons for each of the times that you needed/wanted to 
use pain medicine, but didn’t use? Describe those reasons in detail.  
15) Reasons for Overuse: There are many reasons why SCD patients use more pain 
medicine than prescribed or there are times when they don’t need or want to use pain 
medicine, but they choose to use it anyway. Thinking about the last three months, 
please tell me a story of a time when you took more of your medicine than you 
usually take or took more than you thought you needed? 
Explore: 
a. (f/u) What were the reasons for each of the times that you didn’t need/want to 
use pain medicine, but used more or used it anyway? Describe those reasons 
in detail. 
Using Opioid for Symptoms/Reasons Other than Pain 
16) Some SCD patients may use pain medicine for reasons other than pain. Thinking 
about the last three months, please tell me a story of a time you used your pain 
medicine for reasons or symptoms other than pain. How would you describe these 
reasons?  
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17) Forget or Missing Doses: People have a lot of different feelings about how medicines 
work and what the results are if they miss a dose.  Thinking about the last three 
months, please tell me a story of a time you missed a dose or several doses of pain 
medicine.  
Explore: 
a. (f/u) How did you feel you when you missed a pill or several pills?  
b. (f/u) How important is it to you to take your medicines as prescribed? Please 
explain. 
c. (f/u) What do you do when you realize you miss/forget to take a dose of your 
prescribed medicines?  Take more, take less? Describe. 
   
Reasons for Episodic and Temporary Change in Adherence 
Using Opioid while in Pain when Feeling Worse than Usual 
18) Think back to when you were feeling worse pain than usual or when you having 
crises. What, if anything, did you do differently to get rid of your pain? 
Explore: 
a. Why do you think you chose to use your pain medicine in this way, in this 
situation? 
b. (f/u) What did you do when the pain was not relieved (you were still feeling 
pain) after you took your pain medicines? Did you use your pain medicine 
differently then? Did you use more or less than prescribed?  
c. (f/u) What made you decide to use the medicine in such a way?  
d. (f/u) Did the location of pain affect your way of using pain medicine? 
Using Opioid while in Pain when Feeling Good 
19) When you are feeling good, how do you use your medicine?  
20) Think back when you are/were feeling better after you took your pain medicines, how 
did you use your medicine then?  
Probes: 
a. Did you ever stop taking your scheduled or as-needed medicines when you 
were feeling good? If so, tell more about that.   
21) Describe a time for me when you were having no/little SCD pain (or you felt better) 
but still chose to take more pain medicine?   
Explore: 
a. (f/u) Why do you think you chose to use your pain medicine in this way, in the 
situation you explained to me?  
Psychosocial Factors 
Using Opioid while in Pain and Having Social Activities, Special Events, Circumstances, 
or Situation  
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22) How do you use your pain medicine before, after, or during some special social event, 
activity or special situation?  
Explore: 
a. (f/u) To what extent are you able to use your medicine as prescribed during 
this time?  Do you change your routine?  
Using Opioid while in Pain and Having Stress or Other Psychological Components 
23) How does stress in your life relate to your pain?  Which usually comes first, the stress 
or the pain?   
Explore: 
a. (f/u) How do you cope with the stress when you are in pain?  
b. (f/u) Do you change your routine (I mean the way in which you take your 
medicine) when you are in stress and in pain?  
c. (f/u) Do you change how you use your pain medicine when you are under 
stress? 
 
   
Ending the Interview 
24) Recommendations: Based on your experience, what information do you think is 
important for other patients and healthcare providers to know about pain medicine?  
Probes: 
a. What advice would you give a person who is considering maintaining his/ her 
pain medicine as prescribed or improving his /her way of taking pain 
medicine?  
To wrap up: We have come to the end of the interview. You explained before how 
you use your pain medicine and the reasons for using them. In light of what we have 
just been discussing (medicine use and reasons for use), I’d like to ask you if you 
have any additional, final comments, or anything that you think we should have 
talked about but didn’t? This concludes ends the interview. As we conclude, I would 
like to thank you for your assistance with this research project. You have been most 
helpful in responding to the questions. Thank you for taking part in this interview and 
for responding to the questions so thoroughly. I appreciate your time, interest, and 
openness.  How do you feel about the interview we have just had? May I call you if I 
need to clarify or add to any information you have provided?  Is there anything that 
you would like to ask me? I am happy to answer any questions that you may have.  
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Appendix H 
 
Phase 1: Preliminary Survey (to be administered after the 
interview) 
 
 
1) In general, how did you take your pain medicine during the last seven days?” 
a) Regularly took all pain medications.  
b) Regularly took some prescribed pain medications. 
c) Took all prescribed pain medications after an increase in pain 
d) Took some medications after an increase in pain.  
e) Did not take prescribed pain medication most of the time.  
                                                                                                                                                                                                                                                                  
2) Which of the following statements best describes the way that you take your as-
needed (short-acting) pain medicine?  
a) Over the last month, I usually took my medication as prescribed.   
b) Over the last month, I usually took LESS medicine than prescribed.   
c) Over the last month, I usually took MORE medicine than prescribed 
d) Over the last month, I sometimes took MORE medicine than prescribed and 
sometimes LESS medicine than prescribed.   
e) Over the last month, I usually took my medicine more than prescribed when I had 
little pain and less than prescribed when I had more pain.   
f) Over the last month, I stopped taking my medicine without consulting my health 
care provider.  
 
3) Which of the following statements best describes the way that you take your as-
needed (short-acting) pain medicine?  
a) Over the last month, I usually used my medication according to the directions on 
the bottle. 
b) Over the last month, I usually took LESS medication than the directions on the 
bottle said I should take. 
c) Over the last month, I usually took MORE medication than the directions on the 
bottle said I should take. 
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d) Over the last month, I used both MORE and LESS medication than the directions 
on the bottle said I should take. 
 
4) If you are taking long-acting medicine, which of the following statements best 
describes how you take your scheduled (long-acting) pain medicine?  
a) Over the last month, I usually took my medication as prescribed.   
b) Over the last month, I usually took LESS medicine than prescribed.   
c) Over the last month, I usually took MORE medicine than prescribed.   
d) Over the last month, I sometimes took MORE medicine than prescribed and 
sometimes LESS medicine than prescribed.   
e) Over the last month, I usually took my medicine more than prescribed when I had 
little pain and less than prescribed when I had more pain.   
f) Over the last month, I stopped taking my medicine without consulting my health 
care provider.  
 
5) If you are taking long-acting medicine, which of the following statements bests 
describes how you take your scheduled (long-acting) pain medicine?  
a) Over the last month, I usually used my medication according to the directions on 
the bottle. 
b) Over the last month, I usually took LESS medication than the directions on the 
bottle said I should take. 
c) Over the last month, I usually took MORE medication than the directions on the 
bottle said I should take. 
d) Over the last month, I used both MORE and LESS medication than the directions 
on the bottle said I should take. 
e) Over the last month, I usually took my medicine more than prescribed when I had 
little pain and less than prescribed when I had more pain.   
f) Over the last month, I stopped taking my medicine without consulting my health 
care provider.  
 
6) Some SCD patients may take medicines because they worry about having more pain 
and other complications in the future. How frequently do you take your medicine 
because you have this feeling? 
a) Never 
b) Rarely 
c) Sometimes 
d) Often 
e) Always 
  
 
290 
 
7) While in pain, some SCD patients may want to continue moving and doing their daily 
activities, such as work, social activities, housework, or attending school, but the fear 
of movement or injury keeps them from doing such things. How frequently do you 
take your medicine because you have this feeling? 
a) Never 
b) Rarely 
c) Sometimes 
d) Often 
e) Always 
  
8) Some SCD patients may use more pain medication when they are dealing with 
difficult situations, like family, relationship, or financial problems, or other kinds of 
stressors. How frequently do you take your medicine to escape of avoid these kinds of 
feelings? 
a) Never 
b) Rarely 
c) Sometimes 
d) Often 
e) Always 
 
9) Some SCD patients may change the way they take their medication to deal with 
temporary situations, like taking exams, finishing assignments, or dealing with 
specific work duties. How frequently do you INCREASE your medicine when you 
are in this situation? 
a) Never 
b) Rarely 
c) Sometimes 
d) Often 
e) Always 
 
10) Some SCD patients may change the way they take their medication to deal with 
temporary situations, like taking exams, finishing assignments, or dealing with 
specific work duties. How frequently do you REDUCE your medicine when you are 
in this situation? 
a) Never 
b) Rarely 
c) Sometimes 
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d) Often 
e) Always 
 
11) SCD patients told me that because they were rushing off to appointment/ meeting or 
having unplanned activities, they chose to take less or more of pain medicine or they 
forgot to take their medicine. How frequently you take LESS pain medicine because 
you have this situation? 
a) Never 
b) Rarely 
c) Sometimes 
d) Often 
e) Always 
Background Information Form 
Lastly, I would like to gather some demographic information about you. Fill in 
the blank or check the response that best fits you as an individual  
Partnership status (Are you married, single, or in a relationship? 
___Married    
___Widowed      
___Separated     
___Divorced  
___Single  
___Unknown 
___Others: Partnered 
 Living arrangement: 
___ live alone 
___ live with partner/spouse 
___ live with roommate (how many ____) 
___ live with parents 
___ other (explain___________________________________) 
Education:  What is the highest level of education that you have obtained? 
___Less than High School 
___High School Graduate  
___Some College  
___College Graduate   
What is your yearly household income? 
___ No income 
___ $1 - $25,000 
___ $25,001- $50,000 
___ $ 50,001 - $75,000 
___ $75,001 - $100,000 
___$ 100,001+ 
What are your sources of income?  What is your current employment status? 
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Do you have health insurance? ___Yes   ___No If so, what kind?___________ 
How much do you spend on your medicine (per prescription)? 
$3 to $5.00 per pain prescription 
$6 to $29 per pain prescription  
$30.00 to $50.00 per pain prescription  
More than $ 100 per pain prescription 
Do you drink alcohol? ___Yes   ___No   
When you do, how much do you drink per day? ________________________ 
Do you smoke cigarettes? ___Yes ___No 
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Appendix J 
 
Assessment of Opioid Taking Behaviors and Adherence Scale (AOTBA) 
 
"Hello. My name is Abdul. I'm a graduate student working with Dr. Smith. 
I’d like to ask you some questions about your pain medicine(s) As you may 
know, you are participating in a research study designed to learn more 
about pain medicine(s)and how it works in order to help health care 
providers to better prescribe for their Sickle Cell Disease (SCD) patients. I 
also want to remind you that the information you give me will be 
completely confidential. It will be used only for my research, and we will 
not share it with anyone outside my research project. Some of these things 
you may know about and some you may not. Just give me the best 
information you can, and let me know if you're not clear of what I'm 
asking. Do you have any questions before we begin?"   
Part 1: Background Information 
 
First, I would like to gather some demographic information about you. Fill 
in the blank or check the response that best fits you as an individual  
 
4. How would you describe your racial or ethnic (origin) background? 
 
 American Indian/Alaskan Native 
 Hispanic 
 Asian/Pacific Islander 
 White (non-Hispanic) Caucasian 
 Black African American (non-Hispanic) 
 Other____________ (Please specify.) 
 
5. Are you: 
 
 Female 
 Male 
 
6. How old are you? ____________ years old 
 
 
7. Relationship status (Are you married, single, or in a relationship? 
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 Married    
 Widowed/ Widower      
 Separated     
 Divorced  
 Single  
 Unknown 
 Partnered  
 Others: 
 
8.  Living arrangements (mark best answer): 
 
 House 
 Apartment 
 Other 
 
With whom: (mark all that apply)  
 
 I live alone 
 I live with my partner/spouse 
 I live with roommate(s) (if so, how many? ____) 
 I live with my parent(s) 
 I live with my children 
 I live with parent, partner/spouse and/or children 
 other (explain___________________________________) 
 
9. County of residence: ____________ Zip Code: ____________ 
 
10. How long have you lived in this county? 
 Less than one year 
 One to two years 
 Two to five years 
 Five to 10 years 
 Ten years or longer 
 
11. What is the highest level of education that you have completed? 
 
 Grade school 
 Some high school 
 High School Graduate  
 Some College  
 Associate degree 
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 College Graduate (Bachelor’s degree) 
 Professional degree 
 
12. If you have children, how many children do you have? 
....................... Child (ren) 
 
13. If you have children, how old are they?  (Mark all that apply.) 
 I do not have any children  
 0-4 years 
 5-9 years 
 10-14 years 
 15-17 years 
 18-21 years 
 Over 21 years 
14. What is your total household income from all sources, before taxes? 
 
 ___ No income 
 $10,000 or less 
 $10,001 to $20,000 
 $20,001 to $30,000 
 $30,001 to $40,000 
 $40,001 to $50,000 
 $ 50,001 - $75,000 
 $75,001 - $100,000 
 $ 100,001+ 
 
15. What are your sources of income? 
______________________________________ 
__________________________________________________________________
_____ 
 
16. What is your current employment status? 
_______________________________ 
 
17. Do you have health insurance?  
 
___Yes   ___No  
 
If so, what kind? ___________ 
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18. How much do you spend on your pain medicine(s)(per 
prescription)? 
 
 $3 to $5.00 per prescription 
 $6 to $29 per prescription  
 $30.00 to $50.00 per prescription  
 $51.00-100.00 per prescription 
 More than $ 100 per prescription 
 
19. Do you drink alcohol? ___Yes   ___No   
20. When you do, how much do you drink per day? ________________ 
21. Do you smoke cigarettes? ___Yes ___No 
22. Do you use illicit (illegal) drugs? ___Yes ___No 
 
23. Place of permanent residence: 
 In-state 
 USA, out of state 
 Other country
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Part 2  
 
19. At what age did you first take prescribed pain medicine?  (Mark an 
X in the appropriate columns and fill the blank) 
 As-needed Short acting 
pain medicine 
Scheduled long-acting 
pain medicine 
 I have never 
used 
prescribed pain 
medicine 
¨  ¨  
I have started 
taking 
prescribed pain 
medicine(s)at 
age 
………………………………………………………………........ ………………………………………………………………… 
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Type of Pain Medicine(s) 
20. Health care provider(s) prescribe the following strong pain 
medicine(s) Which of the following medicine(s)do you take?  Mark 
an X in one box for each type of prescribed pain medicine(s)that 
you take. 
 I currently 
take this 
medicine(s) 
I’ve tried it a 
few times (at 
least once) 
I’ve cut 
down my 
use  
 
I have 
regularly 
used this pain 
medicine(s) 
in the past 
but no 
longer.  
I have never 
used this 
medicine(s) 
at all. 
 
Why?  
(E.g. if 
stopped, 
Why 
Stopped?) 
Morphine IR 
(short-acting) 
¨  ¨  ¨  ¨  ¨   
MS Contin 
(long-acting 
Morphine)  
¨  ¨  ¨  ¨  ¨   
Ultram 
(Tramadol) 
¨  ¨  ¨  ¨  ¨   
Any Tylenol 1-4 
(acetaminophe
n/codeine).  
¨  ¨  ¨  ¨  ¨   
Codeine ¨  ¨  ¨  ¨  ¨   
Darvocet 
(propoxyphene
) 
¨  ¨  ¨  ¨  ¨   
Methadone ¨  ¨  ¨  ¨  ¨   
Oxycodone IR 
(short-acting) 
¨  ¨  ¨  ¨  ¨   
OxyContin 
(long-acting 
Oxycodone) 
¨  ¨  ¨  ¨  ¨   
Percocet ¨  ¨  ¨  ¨  ¨   
Lortab  OR 
Vicodin  
¨  ¨  ¨  ¨  ¨   
Dilaudid 
(hydromorphon
e) 
¨  ¨  ¨  ¨  ¨   
Opana (short 
acting 
oxymorphone) 
¨  ¨  ¨  ¨  ¨   
Opana ER 
(Long acting 
oxymorphone) 
¨  ¨  ¨  ¨  ¨   
Pain patches 
(Fentanyl) 
¨  ¨  ¨  ¨  ¨   
Demerol ¨  ¨  ¨  ¨  ¨   
Other strong 
prescribed pain 
medicine(s) Not 
listed……………
¨  ¨  ¨  ¨  ¨   
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Frequency of Use within the Last Year 
21. To the best of your knowledge, in the past 12 months, how often 
have you used your strong prescribed pain medicine? Mark one 
column for each medicine(s)you currently take.  
 Never Once/year Every other 
month  
Every month Other 
Morphine IR ¨  ¨  ¨  ¨  ……………. 
MS Contin 
LA  
¨  ¨  ¨  ¨  ……………. 
Ultram 
(Tramadol)  
¨  ¨  ¨  ¨  ……………. 
Any Tylenol 
1-4 
(acetamino
phen/code
ine) 
¨  ¨  ¨  ¨  ……………. 
Codeine ¨  ¨  ¨  ¨  ……………. 
Methadon
e 
¨  ¨  ¨  ¨  ……………. 
Oxycodone 
IR 
¨  ¨  ¨  ¨  ……………. 
OxyContin  ¨  ¨  ¨  ¨  ……………. 
Percocet ¨  ¨  ¨  ¨  ……………. 
Lortab  OR 
Vicodin  
¨  ¨  ¨  ¨  ……………. 
Dilaudid 
(hydromorp
hone) 
¨  ¨  ¨  ¨  ……………. 
Opana 
(short 
acting 
oxymorpho
ne) 
¨  ¨  ¨  ¨  ……………. 
Opana ER 
(Long 
acting 
oxymorpho
ne) 
¨  ¨  ¨  ¨  ……………. 
Pain 
patches 
(Fentanyl) 
¨  ¨  ¨  ¨  ……………. 
Demerol ¨  ¨  ¨  ¨  ……………. 
Other 
strong 
prescribed 
pain 
medicine(s) 
NOT 
listed………
……. 
¨  ¨  ¨  ¨  ……………. 
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Frequency of use within the last month 
 
22. To the best of your knowledge, during the past 30 days, how many 
days have you used your strong prescribed pain medicine? (Mark one 
for each line)  
 0 
days 
 
1-4 
days 
 
5-9 
days 
 
10-14 
days 
 
About 
14 
days 
 
15-19 
days 
 
20-24 
days  
 
25-29 
days  
 
Every 
day 
Morphine ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
MS Contin LA  ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Tramadol  ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Tylenol III ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Codeine ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Methadone ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Oxycodone ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
OxyContin  ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Percocet ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Lortab  OR 
Vicodin  
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Dilaudid 
(hydromorphone) 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Opana (short 
acting 
oxymorphone) 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Opana ER (Long ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
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acting 
oxymorphone) 
Pain patches 
(Fentanyl) 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Demerol ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
Other strong 
Prescription 
Painkillers Not 
Listed……………. 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨   
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Frequency of use within the last week 
 
23. To the best of your knowledge, during the last week, how many 
days have you used your strong prescribed pain medicine? 
 Non
e last 
wee
k 
One 
day 
last 
week 
Two 
days 
last 
week 
Three 
days last 
week 
Four 
days last 
week 
Five 
days last 
week 
Six days 
last 
week 
Every 
day 
last 
week 
Morphin
e 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
MS 
Contin 
LA  
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Tramad
ol  
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Tylenol III ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Codeine ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Methad
one 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Oxycod
one 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
OxyCon
tin  
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Percoce
t 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Lortab  
OR 
Vicodin  
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Dilaudid 
(hydrom
orphone
) 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Opana 
(short 
acting 
oxymorp
hone) 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Opana 
ER (LA 
oxymorp
hone) 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Pain 
patches 
(Fentan
yl) 
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Demerol ¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
Other 
Painkiller
¨  ¨  ¨  ¨  ¨  ¨  ¨  ¨  
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s Not 
Listed 
________ 
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Frequency of Use within the Last 24 hours  
 
24. To the best of your knowledge, in the past 24 hours, how many 
doses of strong prescribed pain medicine(s) did you take?  
 5 or more 
doses in 24 
hours 
Four doses 
in last 24 
hours 
Three doses 
in last 24 
hours 
Two doses in 
last 24 hours 
One dose in 
last 24 hours 
Morphine ¨ ¨  ¨  ¨  ¨  
MS Contin 
LA  
¨ ¨  ¨  ¨  ¨  
Tramadol  ¨ ¨  ¨  ¨  ¨  
Tylenol III ¨ ¨  ¨  ¨  ¨  
Codeine ¨ ¨  ¨  ¨  ¨  
Methado
ne 
¨ ¨  ¨  ¨  ¨  
Oxycodo
ne 
¨ ¨  ¨  ¨  ¨  
OxyConti
n  
¨ ¨  ¨  ¨  ¨  
Percocet ¨ ¨  ¨  ¨  ¨  
Lortab  
OR 
Vicodin  
¨ ¨  ¨  ¨  ¨  
Dilaudid 
(hydromor
phone) 
¨ ¨  ¨  ¨  ¨  
Opana 
(short 
acting 
oxymorph
one) 
¨ ¨  ¨  ¨  ¨  
Opana ER 
(Long 
acting 
oxymorph
one) 
¨ ¨  ¨  ¨  ¨  
Pain 
patches 
(Fentanyl) 
¨ ¨  ¨  ¨  ¨  
Demerol ¨ ¨  ¨  ¨  ¨  
Other 
Prescriptio
n 
Painkillers 
Not 
¨ ¨  ¨  ¨  ¨  
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Listed………
……. 
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25. To the best of your knowledge, during the last week, how much of 
each type of medicine(s)did you take? What is the average daily use of 
your strong prescribed medicine?  
Name of 
medicine 
Actual use 
 
 Strength of 
pill 
(How many 
milligrams/pill) 
Average 
number 
of pills I 
take at 
a time  
 
Average 
number 
of pills I 
take a 
day  
 
I usually 
wait  ____ 
hours 
between 
doses of 
medicine(s) 
Calculation 
or 
comments 
(to be filled 
in by 
investigators) 
Morphine ………mg Up 
to…..pills 
Up 
to…..pills 
………………  
MS Contin LA  ………mg Up 
to…..pills 
Up 
to…..pills 
………………  
Tramadol  ………mg Up 
to…..pills 
Up 
to…..pills 
……………..  
Tylenol III ………mg Up 
to…..pills 
Up 
to…..pills 
………………  
Codeine ………mg Up 
to…..pills 
Up 
to…..pills 
………………  
Methadone ………mg Up 
to…..pills 
Up 
to…..pills 
………………  
Oxycodone ………mg Up 
to…..pills 
Up 
to…..pills 
………………  
OxyContin  ………mg Up 
to…..pills 
Up 
to…..pills 
……………...  
Percocet ………mg Up 
to…..pills 
Up 
to…..pills 
………………  
Lortab  OR 
Vicodin  
………mg Up 
to…..pills 
Up 
to…..pills 
……………..  
Dilaudid 
(hydromorphone) 
………mg Up 
to…..pills 
Up 
to…..pills 
………………  
Opana (short 
acting 
oxymorphone) 
………mg Up 
to…..pills 
Up 
to…..pills 
……………  
Opana ER (Long 
acting 
oxymorphone) 
………mg Up 
to…..pills 
Up 
to…..pills 
………………  
Pain patches 
(Fentanyl) 
………mg Up 
to…..pills 
Up 
to…..pills 
……………..  
Demerol ………mg Up 
to…..pills 
Up 
to…..pills 
…………..  
Other Prescription 
Painkillers Not 
Listed……………. 
………mg Up 
to…..pills 
Up 
to…..pills 
……………..  
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Physician Instructions  
26. To the best of your knowledge, what are the instructions on the 
label of the bottle of your strong prescribed pain medicine?  
Name of 
medicine 
 
 Strength of 
pill 
(How many 
milligrams/pill) 
Minimum 
and 
Maximum 
number of 
pills to take 
at a time 
Maximum 
Number of 
pills to be 
taken a 
day (if 
stated) 
 
I usually 
wait ___ 
hours 
between 
doses of 
medicine 
Comments (to 
be filled in by 
investigators) 
Morphine ………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
MS Contin LA  ………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Tramadol  ………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Tylenol III ………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Codeine ………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Methadone ………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Oxycodone ………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
OxyContin  ………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Percocet ………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Lortab  OR 
Vicodin  
………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Dilaudid 
(hydromorphone) 
………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Opana (short 
acting 
oxymorphone) 
………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Opana ER (Long 
acting 
oxymorphone) 
………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Pain patches 
(Fentanyl) 
………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
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Demerol ………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
Other Prescription 
Painkillers Not 
Listed……………. 
………mg ___ to ___ 
pills. 
Up 
to…..pills 
……..hour  
 
27. How many days out of the last 30 did you take any pain medicine? 
……………..days 
28. In the last 6 months, how many times did you have to call the doctor 
for pain medicine(s) before they were due, but you had no more 
medicine(s)to take, and to get more?  
…………………..times 
29. Why did you call early? 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
……………………………………………………………………………………… 
30. In the last 30 days, how many days were you in severe pain but you 
did not have your as-needed pain medicine? 
…………….. days 
31. Which of the following statements best describes the way that you 
take your as-needed (short-acting) pain medicine(s)over the last 
month? (Please choose one) 
h. I usually took my medicine(s)as prescribed  
i. I usually took LESS medicine(s)than prescribed  
j. Over the last month, I usually took MORE medicine(s)than 
prescribed 
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k. Over the last month, I sometimes took MORE medicine(s)than 
prescribed and sometimes LESS medicine(s)than prescribed.   
l. Over the last month, I usually took my medicine(s)more than 
prescribed when I had little pain and less than prescribed when I 
had (great) pain.   
m. Over the last month, I stopped taking my medicine(s) 
n. Other…………………………………………………………………… 
32. I receive pills to last a certain amount of time, at the end of the time 
normally	  (OR	  At	  the	  end	  of	  most	  (every)	  month) I had  
a. For as-needed short-acting strong pain medicine(s)(Please choose 
one) 
 All or most the pills left 
 Few pills left 
 Taken all the pills in the bottle 
 Finished all the pills before the 30 days  
b. For scheduled long-acting strong pain medicine(s)(Please choose 
one) 
 All or most the pills left 
 Few pills left 
 Taken all the pills in the bottle 
 Finished all the pills before the 30 days  
33. For as-needed short-acting strong pain medicine, if my next prescription is 
due to start the first week of the month, 
a. I normally try to get the medicine:  
 Two weeks or more before due 
 One week before due 
 The week due 
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 One week late (after due)  
 Two weeks or more before due 
b. I normally begin taking it (Please choose one) 
 First week of the month   
 Second week of the month 
 Third week of the month 
 Fourth week of the month 
c. When do you normally finish taking it? (Please choose one) 
 First week of the month   
 Second week of the month 
 Third week of the month 
 Fourth week of the month 
 Beginning of next month 
 
28. My as-needed short-acting strong pain medicine(s)should last ____ 
days.  They actually last ___ days. 
34. During the last 30 days, what influence your decision to take pain 
medicine(s) other than pain? (Please circle up to 3 of the items) 
1. Life situations (e.g. school/work/household tasks, responsibilities,, social 
gathering ) 
2. Mood (e.g. stress, boredom) 
3. Environmental (e.g. change in weather)  
4. Other people: (e.g. family, friends/peers, health care providers) 
5. Other:……………………………………………………………………………… 
6. Nothing 
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Part 3  
 
Par 3: a. Characterizing Overall Medication Taking Behavior and 
Adherence with Pain Medicines 
35.  Which of the following statements best describes the way that you 
took your pain medicine during the past week? Please mark the 
one statement below that best describes how you took your pain 
medicine in the last seven days. Please mark tables, one for short-
acting and one for long-acting medication. Please note that “as 
prescribed” means according to the directions on the bottle. All the 
statements that list pain medication mean the medication that is 
prescribed. The word “pain medication” refers to the medicine that 
is prescribed for you. 
 
 Short-acting Opioid Long-acting Opioid 
 Nev
er 
  
Rarel
y 
  
 
Sometim
es 
  
 
Ofte
n 
  
 
Alway
s 
  
 
 
Never 
  
Rarel
y 
  
 
Sometim
es 
  
 
Ofte
n 
  
 
Alway
s 
  
 
1. I take LESS 
medicine 
than 
prescribe
d.   
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
2.  I take 
MORE 
medicine 
than 
prescribe
d. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
3.  I take 
both 
MORE 
medicine 
than and 
LESS 
medicine 
than  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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prescribe
d on 
certain 
days 
/occasion
s. 
4. I take LESS 
than 
prescribe
d when I 
have 
severe 
pain.   
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
5. I take 
MORE 
than 
prescribe
d when I 
have mild 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
6. I take 
both 
MORE 
than 
prescribe
d when I 
have mild 
pain and 
less than 
prescribe
d when I 
have 
severe 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
7. My health 
care  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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provider 
gives me 
prescriptio
n for pain 
medicine 
and I fill 
them but 
do not 
take 
them. 
8. My health 
care 
provider 
gives me 
prescriptio
n for pain 
medicines 
but I do 
not fill 
them on 
time 
(when 
they are 
due). 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
9. My health 
care 
provider 
gives me 
prescriptio
n for pain 
medicine 
but I do 
not fill 
them at 
all. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
10. 6. I am 
able to  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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follow 
exactly 
the 
agreeme
nt I made 
with my 
prescriber 
about 
how to 
take my 
pain 
medicine. 
11. I 
accuratel
y describe 
the way I 
take my 
pain 
medicine 
to my 
healthcar
e 
provider.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
12. I consult 
my health 
care 
providers 
before 
making 
any 
change. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
13. I follow 
changes 
recomme
nded by 
my health 
care  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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providers. 
14. I consult 
and 
follow my 
health 
care 
providers 
before 
making 
any 
changes  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
15. I consult 
and 
follow my 
health 
care 
providers 
before 
making 
some 
changes.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
16. I do 
consult 
but may 
NOT 
follow my 
health 
care 
providers 
before 
making 
some 
changes 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
17. I stopped 
taking my 
medicine  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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without 
consulting 
my health 
care 
provider. 
18. I choose 
to NOT 
take my 
pain 
medicine. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
19. I choose 
to NOT 
take my 
pain 
medicine 
because I 
do not like 
it. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
20. I choose 
to NOT 
take my 
pain 
medicine 
because 
it reminds 
me that I 
have 
chronic 
illness. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
21.  I cut 
back or 
stop 
taking my 
pain 
medicine 
because  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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its use will 
be long-
term use 
associate
d and 
long-term 
side 
effect. 
22. I cut back 
or stop 
taking my 
pain 
medicine 
because I 
worry 
about 
addiction 
(depende
nce upon 
the 
medicine)
. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
23. I cut back 
or stop 
taking my 
pain 
medicine 
because I 
do not 
want to 
become 
tolerant 
and have 
to 
increase 
the dose 
for pain  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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relief. 
24. I cut back 
or stop 
taking my 
long-
acting 
pain 
medicine 
because 
it was too 
hard to 
maintain 
a 
schedule. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
25. I cut back 
or stop 
taking my 
pain 
medicine 
because 
it 
interfered 
with 
normal 
every day 
activities. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
26. I have 
trouble 
remembe
ring if I 
have 
already 
taken my 
medicatio
n(s). 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
27. I have 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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difficulty 
remembe
ring to 
take all 
my 
medicine. 
28. I take all 
pain 
medicines 
as 
prescribe
d for me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
29. I took 
some 
prescribe
d pain 
medicine. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
30. I take 
prescribe
d pain 
medicine 
when I 
have mild 
to 
moderate 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
31. I take 
prescribe
d pain 
medicine 
when I 
have 
severe 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
32. I take 
prescribe  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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d pain 
medicatio
ns only 
when I 
have 
severe 
pain. 
33. I am able 
to rely on 
myself 
more 
today 
than I was 
several 
years ago 
to 
manage 
my pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
34.  I rely on 
myself to 
manage 
minor 
everyday 
pain with 
prescribe
d pain 
medicine. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
35. I rely on 
myself to 
manage 
severe 
pain with 
prescribe
d pain 
medicine. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
36. I take 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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responsibil
ity for 
whether 
or not I 
take my 
pain 
medicine 
in the way 
that it is 
prescribe
d. 
37. I take my 
pain 
medicine 
even 
when I 
am not in 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
38. I manage 
non-pain 
symptoms 
with 
changes 
from what 
is written 
on the 
prescriptio
n. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
39. I remove 
my 
medicatio
n from its 
original 
bottle for 
convenie
nce. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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40. I carry 
some 
pain 
medicine 
with me 
for 
emergen
cies. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
41. I rely on 
natural 
means 
rather 
than my 
pain 
medicine 
to relive 
my pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
 
Par 3: b. Momentarily Medication Taking Behavior and Momentarily 
Adherence with Pain Medicines 
How often was each of the following statements true for you during the 
past week (the last 7 days)? (How frequently do you take your medicine 
because you have this feeling?) Mark one number per line. 
  
 Short-acting Opioid Long-acting Opioid 
 Neve
r 
  
Rarel
y 
  
 
Sometim
es 
  
 
Ofte
n 
  
 
Alwa
ys 
  
 
 
Never 
  
 
Rarel
y 
  
 
Sometim
es 
  
 
 
Ofte
n 
  
 
 
Alwa
ys 
  
 
42. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n when I  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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am 
dealing 
with 
difficult 
situations. 
43. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n to deal 
with 
temporary 
situations.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
44. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n when I 
am 
dealing 
with 
financial 
problems. 
¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
45. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n to finish 
school or 
work 
assignmen ¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
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t.   
46. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n when I 
am 
dealing 
with any 
kind of 
stress. 
¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
47. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n to finish 
Household 
chores 
/duties.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
48. I change 
the 
prescribed 
way I take 
my pain 
medicine 
in response 
to my 
responsibili
ties/obliga
tions. 
¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
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49. I change 
the 
prescribed 
way I take 
pain 
medicine 
in response 
to Family 
obligations 
and 
responsibili
ties. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
50. I change 
the 
prescribed 
way I take 
my pain 
medicine 
in response 
to social 
events or 
activities.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
51. I changed 
the 
prescribed 
way I take 
pain 
medicine 
in response 
to a social 
gathering. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
52. I change 
the 
prescribed 
way I take 
my pain 
medicine  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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in response 
to opinions 
of others.  
53. I change 
the 
prescribed 
way I take 
my pain 
medicine 
because 
of the 
influence 
of others. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
54. I change 
the 
prescribed 
way I take 
my pain 
medicine 
in response 
to life 
events. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
55. I change 
the 
prescribed 
way I take 
pain 
medicine 
in response 
spiritual 
needs or 
obligations
. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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56. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n because 
I was 
rushing off 
to 
appointm
ent or 
meeting. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
57. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n because 
of 
unexpecte
d events. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
58. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n because 
of 
unplanned 
activities. 
¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
59. I change 
the 
prescribed 
way I take ¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
Survey: Understanding Adherence to Prescribed Opioids in Sickle Cell Disease 
 
338 
 
pain 
medicine 
in response 
to pain 
severity.  
60. I adjust my 
pain 
medicine 
dosage 
based on 
pain level. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
61. I take my 
pain 
medicines 
at the first 
feeling of 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
62. I take my 
pain 
medicine 
only if I am 
really 
suffering. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
63.  I take my 
pain 
medicine 
whenever I 
have 
severe 
pain.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
64. I change 
the 
prescribed 
way I take 
my pain 
medicine  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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in response 
to amount 
of pain 
relief. 
65. I change 
the 
prescribed 
way I take 
my pain 
medicine 
in response 
to how I 
think my 
pain will 
change 
over the 
day. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
66. I take my 
pain 
medicines 
whenever I 
feel any 
warning 
sign of 
pain 
(before 
the actual 
pain 
begins). 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
67. I change 
the 
prescribed 
way I take 
my pain 
medicine 
because it 
makes me  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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feel better.  
68. I change 
the 
prescribed 
way I take 
my pain 
medicine 
because I 
am bored.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
69. I change 
the 
prescribed 
way I take 
my pain 
medicine 
because I 
have I 
difficulty 
thinking/c
oncentra-
ting with 
the 
prescribed 
dose. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
70. I change 
the 
prescribed 
way I take 
my pain 
medicine 
because I 
experienc
e different 
outcomes. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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71. I change 
the 
prescribed 
way I take 
my pain 
medicine if 
I 
experienc
e any side 
effects. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
72. I change 
the 
prescribed 
way I take 
my pain 
medicine 
in response 
to the 
severity of 
side 
effects. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
73. I change 
the 
prescribed 
way I take 
my pain 
medicine 
in response 
to fear 
worry of 
negative 
conseque
nces. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
74. I take my 
pain 
medicines 
whenever I  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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worry 
about 
having 
more pain 
in the near 
future. 
75. I take my 
pain 
medicines 
when I 
worry 
about 
having 
complicati
ons in the 
near 
future. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
76. I change 
the 
prescribed 
way I take 
my pain 
medicine 
because I 
used other 
prescribed 
medicines. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
77. I change 
the 
prescribed 
way I take 
my pain 
medicine 
because 
my doctor 
do NOT 
believe  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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and 
understan
d my pain. 
78. I take my 
pain 
medicines 
whenever I 
think I 
need 
them. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
79. I manage 
to take my 
pain 
medicine 
in 
whatever 
way works 
for me in 
my current 
situations. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
80. I take my 
pain 
medicine 
as 
prescribed 
in every 
situation. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
81. I take the 
same dose 
of pain 
medicine 
as 
prescribed 
throughout 
the day. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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82. I change 
the 
prescribed 
way I take 
my pain 
medicine 
at different 
times of 
the day.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
83. I take the 
same dose 
of pain 
medicine 
as 
prescribed 
at the 
same time 
throughout 
the day. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
84. I take the 
same dose 
of pain 
medicine 
as 
prescribed 
every day 
of the 
week. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
85. I change 
the 
prescribed 
way of 
taking my 
pain 
medicine 
on the  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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weekend.  
86. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n at 
different 
time of the 
day 
throughout 
the week. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
87. I take the 
same dose 
of my pain 
medicine 
as 
prescribed 
in every 
season of 
the year. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
88. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n in 
different 
season of 
the year. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
89. I change 
the 
prescribed           
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way I take 
my pain 
medicine 
because 
of 
changes in 
the 
weather. 
90. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n in 
different 
geographi
c location. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
91. I change 
the 
prescribed 
way I take 
my pain 
medicatio
n 
whenever I 
am away 
from 
home. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
92. I change 
the 
prescribed 
way I take 
my pain 
medicine 
because I 
keep my  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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medicatio
ns in 
different 
places. 
93. I change 
the 
prescribed 
way I take 
my pain 
medicine 
based 
upon the 
amount of 
pills 
available 
next to 
me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
94. I change 
the 
prescribed 
way I take 
my pain 
medicine 
because I 
did not 
arrange to 
have the 
medicine 
available 
to me.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
95. I change 
the 
prescribed 
way I take 
my pain 
medicine 
because I  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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have no 
transportat
ion to 
bring me 
to my 
clinic visit.  
96. I change 
the 
prescribed 
way I take 
my pain 
medicine 
whenever I 
learn 
about 
other ways 
that may 
work for 
me 
personally.   
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
97. I change 
the 
prescribed 
way I take 
my pain 
medicine 
based 
upon 
informatio
n I have 
read and 
decide 
what works 
best for 
me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
98. I try to find 
the best  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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way to use 
my pain 
medicine 
for pain 
control 
and follow 
it as long 
as it is work 
for me. 
99. I control 
my pain 
with 
changes 
to my daily 
dose of 
pain 
medicine.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
100. I 
control my 
pain with 
changes 
from what 
is written 
on the 
prescriptio
n. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
101. I have 
adjusted 
my pain 
medicine 
in different 
ways at 
different 
times in my 
life. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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102. I 
manage 
more of 
my pain at 
home 
instead of 
consultatio
n with my 
prescriber. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
103. I rely on 
myself to 
adjust the 
way I take 
my pain 
medicine.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
104. I take 
responsibili
ty for how I 
take my 
pain 
medicine 
in different 
situations. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
105. I use 
common 
sense to 
adjust my 
pain 
medicine. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
106. I 
change 
the 
prescribed 
way I take 
my pain 
medicine  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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because I 
have only 
a few pills 
left to last 
for many 
days. 
107. I 
change 
the 
prescribed 
way I take 
my pain 
medicine 
because I 
have no 
more pills 
of one of 
my pain 
medicatio
n. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
108. I 
change 
the 
prescribed 
way I take 
my pain 
medicine 
because I 
have only 
a few pills 
left to last 
for many 
days. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
109. I 
change 
the 
prescribed  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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way I take 
my pain 
medicine 
because 
of the cost 
of the pills. 
110. I 
change 
the 
prescribed 
way I take 
my pain 
medicine 
because 
my 
insurance 
will NOT 
pay for it. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
111. I take 
more of 
my 
prescribed 
pain 
medicine 
to avoid 
the need 
to go the 
Emergenc
y 
Departme
nt. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
112. I forget 
to bring 
along my 
pain 
medicine, 
when I  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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travel or 
leave 
home. 
113. I miss 
taking my 
pain 
medicine 
because I 
do not 
want to 
take it out 
of my 
house with 
me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
114. I miss 
taking my 
pain 
medicine 
because I 
feel unsafe 
carrying it 
with me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
115. I cut 
back or 
stop taking 
my pain 
medicine 
when I feel 
better but 
the pain 
still there. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
116. I cut 
back or 
stop taking 
my pain 
medicine  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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when my 
pain is 
relived 
completel
y.   
117. I cut 
back or 
stop taking 
medicatio
ns when I 
feel worse 
from side 
effects. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
118. I cut 
back or 
stop taking 
my pain 
medicines 
when does 
not work 
and I need 
to try 
something 
for my 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
119. I cut 
back or 
stop taking 
my pain 
medicine 
because I 
do not 
believe it is 
morally 
right for 
me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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120. I cut 
back or 
stop taking 
my 
medicatio
ns 
because I 
feel worse 
and need 
to go the 
Emergenc
y 
Departme
nt.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
121. I forget 
to take my 
medicine 
because I 
have to 
deal with 
a variety 
of life 
situations 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
122. I miss 
taking my 
pain 
medicines 
for reasons 
other than 
forgetfulne
ss.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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Par 3: c. Ways of non-adherence/Ways of Deviation (Aspect of 
Non-adherence) 
 
 Short-Acting Opioid Long-Acting Opioid 
 Never 
  
Rarely 
  
 
Sometimes 
  
 
Often 
  
 
Always 
  
 
Never 
  
 
Rarely          
  
 
Sometimes 
  
 
 
Often                    
  
 
Always
  
 
123. I take 
my pain 
medicine 
at the 
same times 
daily 
regardless 
of pain 
intensity.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
124. I take 
every pain 
medicine 
only when I 
have pain 
or on an 
“as-
needed 
basis” 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
125. I take 
the 
prescribed 
type of 
medicine 
for 
whatever 
level of 
pain 
severity I 
have at  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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the 
moment. 
126. I take 
every pain 
medicine 
prescribed 
for me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
127. I take 
my long-
acting 
pain 
medicine 
only when I 
have 
severe 
pain at the 
moment.   
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
128. I take 
my long-
acting 
pain 
medicine 
only during 
days of 
severe 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
129. I take 
my short-
acting 
pain 
medicine 
to prevent 
any pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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130. I take 
my short-
acting 
pain 
medicine 
to prevent 
severe 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
131. I take 
my short-
acting 
pain 
medicine 
until pain 
severity is 
at 
managea
ble level 
for me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
132. I 
change 
the 
number of 
pills I take 
at a time. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
133. I take a 
different 
number of 
pills at a 
time from 
the 
prescribed 
dose. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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134. I take 
more pills 
at a time 
than the 
prescribed 
dose. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
135. I take 
fewer pills 
at a time 
than the 
prescribed 
dose. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
136. I take 
more pills 
to manage 
symptoms 
other than 
pain.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
137. I 
change 
the 
prescribed 
way I take 
my pain 
medicine 
to manage 
symptoms 
other than 
pain (e.g. 
sleep, 
anxiety, 
etc.) 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
138. I take 
my pain 
medicine 
at different  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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number of 
times per 
day than 
what is 
written on 
my 
prescriptio
n. 
139. I take 
my pain 
medicine 
more often 
than 
prescribed  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
140. I take 
my pain 
medicine 
less often 
than 
prescribed  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
141. I take 
my pain 
medicine 
more often 
than 
prescribed 
to manage 
symptoms 
other than 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
142. I wait to 
take my 
pain 
medicine 
until it is 
time for the  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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next dose. 
143. I wait to 
take my 
pain 
medicine 
until it is 
time for a 
dose 
according 
to the 
prescribed 
schedule.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
144. I wait 
the 
required 
(prescribed
) amount 
of time 
between 
doses. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
145. I take 
my pain 
medicine 
until I 
receive 
relief. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
146. I wait a 
shorter 
amount of 
time 
between 
doses than 
prescribed. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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147. I take 
my pain 
medicine 
more 
frequently 
than 
prescribed. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
148. I take 
my pain 
medicine 
less 
frequently 
than 
prescribed. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
149. I take 
my pain 
medicine 
at the 
prescribed 
time 
interval 
(waiting 
time 
between 
doses) 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
150. I take 
my pain 
medicine 
and wait 
the 
prescribed 
amount of 
time 
between 
doses.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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151. I take 
my pain 
medicine 
in the time 
interval 
(waiting 
time 
between 
doses) that 
works for 
me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
152. I wait to 
take my 
pain 
medicine 
until it is 
time for a 
dose 
according 
to the 
prescribed 
schedule.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
153. I wait 
less than 
the 
prescribed 
amount of 
time 
between 
doses. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
154. I wait 
more than 
the 
prescribed 
amount of 
time 
between  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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doses. 
155. I take 
more than 
the 
maximum 
number of 
pills 
prescribed 
per day. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
156. I take 
more than 
the 
prescribed 
maximum 
daily 
number of 
pills that 
contain 
Tylenol. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
157. I take 
my pain 
medicine 
for the full 
number of 
days 
prescribed. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
158. I take 
my pain 
medicine 
for less 
number of 
days than 
prescribed.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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159. I take 
more than 
one type 
of 
prescribed 
short-
acting 
pain 
medicine 
at the 
same time. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
160. I take 
over the 
counter 
products 
and pain 
medicine 
at the 
same time 
without 
consulting 
my health 
care 
provider. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
161. I take 
herbals 
and pain 
medicine 
at the 
same time 
without 
consulting 
my health 
care 
provider. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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162. I take 
medicine 
prescribed 
for other 
conditions 
at the 
same time 
as pain 
medicine 
without 
consulting 
my health 
care 
provider. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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Appendix K 
Revised AOTBA Instrument 
Part 3  
Part 3a 
36.  Which of the following statements best describes the way that you took 
your pain medicine(s) during the past month? Please mark the one 
statement below that best describes how you took your pain 
medicine(s)in the last seven days. Please mark tables, one for short-
acting and one for long-acting medicine(s)(if applicable). Please note 
that “as prescribed” means according to the directions on the bottle. 
All the statements that list pain medicine(s) mean the medicine(s)that 
is prescribed to you.  
 
 Short-acting Opioid Long-acting Opioid 
 Nev
er 
  
Rarel
y 
  
 
Sometim
es 
  
 
Ofte
n 
  
 
Alway
s 
  
 
 
Neve
r 
  
Rarel
y 
  
 
Sometim
es 
  
 
Ofte
n 
  
 
Alway
s 
  
 
1. I take LESS 
pain 
medicine(s
) than 
prescribed
.   
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
2.  I take 
MORE 
pain 
medicine(s
) than 
prescribed
. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
3. I take LESS 
pain 
medicine 
than 
prescribed 
when I 
have  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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severe 
pain.   
4. I take 
MORE 
pain 
medicine 
than 
prescribed 
when I 
have mild 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
5. I fill the 
pain 
medicine 
prescriptio
ns I 
receive 
from my 
doctor but 
I do not 
take the 
medicine(s
) 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
6. I do not fill 
the pain 
medicine 
prescriptio
ns I 
received 
from my 
doctor on 
time 
(when 
they are 
due). 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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7. I do not fill 
the pain 
medicine 
prescriptio
ns I 
receive 
from my 
doctor.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
8. I am able 
to faithfully 
follow the 
agreemen
t that I 
made with 
my doctor 
regarding 
pain 
medicine(s
) 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
9. I describe 
accurately 
the way I 
take my 
pain 
medicine(s
) to my 
doctor.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
10. I consult 
my doctor 
before I 
make any 
change in 
the way I 
take my 
pain 
medicine(s  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
Survey: Understanding Adherence to Prescribed Opioids in Sickle Cell Disease 
 
371 
 
) 
11. I follow the 
changes 
recomme
nded by 
doctor 
regarding 
pain 
medicine(s
). 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
12. I do 
consult but 
may NOT 
follow my 
doctor’s 
advice 
before 
making 
any 
changes 
to how I 
take my 
pain 
medicine(s
). 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
13. I stopped 
taking my 
pain 
medicine(s
) without 
consulting 
my doctor. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
14. I choose 
NOT to 
take my  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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pain 
medicine 
because I 
do not like 
it. 
15. I choose 
NOT to 
take my 
pain 
medicine(s
) because 
it reminds 
me that I 
have a 
chronic 
illness. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
16.  I cut back 
or stop 
taking my 
pain 
medicine(s
) when I 
feel worse 
from side 
effects. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
17. I cut back 
or stop 
taking my 
pain 
medicine(s
) because 
I worry 
about 
dependen
ce upon 
the  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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medicine. 
18. I cut back 
or stop 
taking my 
long-
acting 
pain 
medicine(s
) because 
it was too 
hard to 
maintain a 
schedule. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
19. I cut back 
or stop 
taking my 
pain 
medicine(s
) because 
it 
interfered 
with 
normal 
every day 
activities. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
20. I have 
trouble 
rememberi
ng if I have 
already 
taken my 
pain 
medicine(s
) 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
21. I have 
difficulty  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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rememberi
ng to take 
all my pain 
medicine(s
) 
22. I take all 
my pain 
medicine(s
) as 
prescribed 
for me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
23. I take my 
pain 
medicine(s
) when I 
have mild 
to 
moderate 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
24. I take my 
pain 
medicine(s
) only 
when I 
have 
severe 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
25.  I rely on 
myself to 
manage 
minor 
everyday 
pain with 
pain 
medicine(s
) 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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26. I rely on 
myself to 
manage 
severe 
pain with 
prescribed 
pain 
medicine(s
) 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
27. I ignore 
the 
doctor’s 
advice 
about how 
I take my 
pain 
medicine 
because I 
know 
better 
what 
works for 
me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
28. I ignore 
the 
directions 
on my 
pain 
medicine 
bottle 
because I 
know 
better 
what 
works for 
me. 
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29. I take my 
pain 
medicine(s
) even 
when I am 
not in 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
30. I change 
the way I 
take my 
pain 
medicine(s
) to 
manage 
non-pain 
symptoms. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
31. I remove 
some pain 
medicine(s
)from the 
original 
bottle for 
convenien
ce/ 
emergenci
es 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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Par 3: b.  
How often was each of the following statements true for you during the 
past week (the last 7 days)? (How frequently do you take your 
medicine(s) because you have this feeling?) Mark one number per line. 
  
 Short-acting Opioid Long-acting Opioid 
 Neve
r 
  
Rarel
y 
  
 
Sometim
es 
  
 
Ofte
n 
  
 
Alwa
ys 
  
 
 
Never 
  
 
Rarel
y 
  
 
Sometim
es 
  
 
 
Ofte
n 
  
 
 
Alwa
ys 
  
 
32. I changed 
the way I 
take my 
pain 
medicine(s
) when I 
was 
dealing 
with 
difficult 
situations. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
33. I changed 
the way I 
take my 
pain 
medicine(s
) from the 
prescribed 
instructions 
when I was 
dealing 
with 
financial 
problems. 
¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
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34. I changed 
the way I 
took my 
pain 
medicine(s
) from the 
prescribed 
instructions 
to finish my 
school or 
work 
assignmen
t.   
¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
35. I changed 
the way I 
took my 
pain 
medicine(s
) when I 
was 
dealing 
with stress. 
¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
36. I changed 
the way I 
took my 
pain 
medicine(s
) to finish 
Household 
chores 
/duties.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
37. I changed 
the way I 
took my 
pain 
medicine(s  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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) in 
response 
to Family 
obligations 
and 
responsibili
ties. 
38. I changed 
the way I 
took my 
pain 
medicine(s
) in 
response 
to social 
events or 
activities.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
39. I took 
more of 
my pain 
medicine(s
) than 
prescribed 
in response 
to opinions 
of others. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
40. I took less 
of my pain 
medicine(s
) than 
prescribed 
in response 
to opinions 
of others. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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41. I changed 
the way I 
took my 
pain 
medicine(s
) in 
response 
to spiritual 
needs or 
obligations
. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
42. I changed 
the way I 
took my 
pain 
medicine(s
) because 
of 
unexpecte
d events.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
43. I took less 
of my pain 
medicine(s
) than 
prescribed 
when my 
pain got 
better.  
¨1 ¨2 o3 ¨4 o5 ¨1 ¨2 o3 ¨4 o5 
44. I took 
more of 
my pain 
medicine(s
) than 
prescribed 
when my 
pain got           
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worse. 
45. I changed 
the way I 
took my 
pain 
medicine(s
) in 
response 
to amount 
of relief. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
46. I changed 
the way I 
took my 
pain 
medicine(s
) in 
response 
to how I 
thought 
my pain 
would 
change 
over the 
day. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
47. I took my 
pain 
medicine(s
) 
whenever I 
felt any 
warning 
sign(s) of 
pain 
(before  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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the actual 
pain 
began). 
48. I changed 
the way I 
took my 
pain 
medicine(s
) because 
it made 
me feel 
better 
emotionall
y. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
49. I changed 
the way I 
take my 
pain 
medicine(s
) because I 
was bored.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
50. I changed 
the 
prescribed 
way I take 
my pain 
medicine(s
) because I 
had 
difficulty 
thinking/c
oncentra-
ting with 
the 
prescribed  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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dose. 
51. I changed 
the way I 
take my 
pain 
medicine(s
) 
whenever I 
experienc
ed 
complicati
ons of 
SCD.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
52. No matter 
how bad 
the side 
effects, I 
kept trying 
to take my 
pain 
medicine(s
). 
          
53. I changed 
the way I 
took my 
pain 
medicine(s
) in 
response 
to fear or 
worry of 
negative 
conseque
nces.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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54. I took my 
pain 
medicine(s
) when I 
worried 
about 
having 
complicati
on in the 
near 
future. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
55. I changed 
the way I 
take my 
pain 
medicines 
because I 
used my 
other 
prescribed 
non-pain 
medicine(s
). 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
56. I changed 
the way I 
took my 
pain 
medicine(s
) because 
my doctor 
does NOT 
believe my 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
57. I changed 
the way I 
took my  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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pain 
medicine(s
) because 
my doctor 
does NOT 
understan
d my pain. 
58. I take my 
pain 
medicine(s
) as 
prescribed 
in every 
situation. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
59. I took the 
same dose 
of pain 
medicine(s
) as 
prescribed 
throughout 
the day. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
60. I changed 
the way I 
took my 
pain 
medicine(s
)at 
different 
times of 
the day.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
61. I took the 
same dose 
of pain 
medicine(s  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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) as 
prescribed 
at the 
same time 
every day 
throughout 
the week. 
62. I took the 
same dose 
of pain 
medicine(s
) as 
prescribed 
every day 
of the 
week. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
63. I changed 
my way of 
taking my 
pain 
medicine(s
) on the 
weekend.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
64. I changed 
the way I 
took my 
pain 
medicine(s
) to 
different 
times of a 
given day 
throughout 
the week. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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65. I took the 
same dose 
of my pain 
medicine(s
) as 
prescribed 
every 
season of 
the year. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
66. I changed 
the way I 
took my 
pain 
medicine(s
) in 
different 
season of 
the year. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
67. I changed 
the way I 
took my 
pain 
medicine(s
) because 
of 
changes in 
the 
weather. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
68. I changed 
the way I 
took my 
pain 
medicine(s
) 
whenever I 
was away  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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from 
home. 
69. I changed 
the way I 
took my 
pain 
medicine(s
) based 
upon the 
amount of 
pills 
available 
to me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
70. I changed 
the way I 
took my 
pain 
medicine(s
) because I 
did not 
arrange to 
have the 
medicine(s
) available 
to me.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
71. I changed 
the way I 
take my 
pain 
medicine(s
) 
whenever I 
learned 
about 
other ways 
that may  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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work 
better for 
me 
personally.   
72. I controlled 
my pain by 
taking my 
pain 
medicine(s
) differently 
from what 
is written 
on the 
bottle. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
73. I managed 
more of 
my pain at 
home 
without 
talking with 
my doctor. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
74. I changed 
the way I 
took my 
pain 
medicine(s
) because I 
only had a 
few pills 
left to last 
for few 
days. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
75. I changed 
the way I 
took my           
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pain 
medicine(s
) because I 
lost my 
pills. 
76. I changed 
the way I 
took my 
pain 
medicine(s
) because I 
did not get 
my 
prescriptio
n on time. 
          
77. I changed 
the way I 
took my 
pain 
medicine 
because I 
ran out of 
one of 
them (pain 
medicines)
. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
78. I changed 
the way I 
take my 
pain 
medicine(s
) because 
of the cost 
of the pills. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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79. I changed 
the way I 
took my 
pain 
medicine(s
) because 
my 
insurance 
would NOT 
pay for it. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
80. I took 
more of 
my 
prescribed 
pain 
medicine(s
) to avoid 
the need 
to go the 
Emergenc
y 
Departme
nt. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
81. I forgot to 
bring 
along my 
pain 
medicine, 
when I 
travelled 
or left 
home. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
82. I missed 
taking my 
pain 
medicine(s  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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) because I 
did not 
want to 
take it out 
of my 
house with 
me. 
83. I missed 
taking my 
pain 
medicine(s
) because I 
felt unsafe 
carrying it 
with me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
84. I cut back 
or stopped 
taking my 
pain 
medicine(s
) when I 
felt better 
even if I still 
had some 
pain.   
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
85. I cut back 
or stopped 
taking my 
pain 
medicine(s
) when my 
pain was 
relieved 
completel
y.   
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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86. I cut back 
or stopped 
taking my 
pain 
medicine(s
) when it 
did not 
work. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
87. I cut back 
or stopped 
taking my 
pain 
medicine(s
) because I 
do not 
believe it is 
morally 
right for 
me. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
88. I cut back 
or stopped 
taking my 
medicine(s
) because I 
feel worse 
and need 
to go the 
Emergenc
y 
Departme
nt.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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Part 3: c.  
 
 Short-Acting Opioid Long-Acting Opioid 
 Never 
  
Rarely 
  
 
Sometimes 
  
 
Often 
  
 
Always 
  
 
Never 
  
 
Rarely          
  
 
Sometimes 
  
 
 
Often                    
  
 
Always
  
 
89. I take my 
pain 
medicine(s
) at the 
same time 
daily 
regardless 
of pain 
intensity.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
90. I take my 
pain 
medicine(s
) only when 
I have 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
91. I change 
which pain 
medicine I 
take  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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according 
to the level 
of pain I 
have at 
the 
moment  
92. I take my 
long-acting 
pain 
medicine(s
) only when 
I have 
severe 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
93. I take my 
long-acting 
pain 
medicine(s
) only 
during days 
of severe 
pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
94. I take my 
short-
acting pain 
medicine(s
) to 
prevent 
any pain. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
95. I take my 
pain 
medicine(s
) to 
prevent 
severe  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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pain. 
96. I take my 
short-
acting pain 
medicine(s
) until my 
pain is 
manageab
le. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
97. I take more 
pills at a 
time than 
the 
prescribed 
dose. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
98. I take 
fewer pills 
at a time 
than the 
prescribed 
dose. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
99. I take my 
pain 
medicine(s
) more 
often than 
prescribed 
to manage 
stress. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
100. I take 
my pain 
medicine(s
) more           
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often than 
prescribed 
to help me 
sleep. 
101. I take 
my pain 
medicine 
at different 
times of 
day than 
what is 
written on 
my bottle. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
102. I take 
my pain 
medicine(s
) more 
often than 
prescribed.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
103. I take 
my pain 
medicine(s
) less often 
than 
prescribed.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
104. I wait to 
take my 
pain 
medicine(s
) until it is 
time for the 
next dose. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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105. I keep 
taking my 
pain 
medicine(s
) until I get 
relief. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
106. I take 
my pain 
medicine(s
) more 
frequently 
than 
prescribed. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
107. I take 
my pain 
medicine(s
) less 
frequently 
than 
prescribed. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
108. I wait a 
shorter 
amount of 
time 
between 
doses than 
prescribed. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
109. I wait 
more than 
the 
prescribed 
amount of 
time 
between  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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doses. 
110. I take 
more than 
the 
maximum 
number of 
pills 
prescribed 
per day. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
111. I take 
more than 
the 
prescribed 
maximum 
daily 
number of 
pills that 
contain 
Tylenol. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
112. I take 
my pain 
medicine(s
) for fewer 
numbers of 
days than 
prescribed.  
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
113. I take 
more than 
one type of 
prescribed 
short-
acting pain 
medicine(s  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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) at the 
same time. 
114. I take 
over-the-
counter 
products 
and pain 
medicine(s
) at the 
same time 
without 
consulting 
my health 
care 
provider. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
115. I take 
herbal 
medicine 
and pain 
medicine(s
) at the 
same time 
without 
consulting 
my health 
care 
provider. 
 ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
116. I take 
medicine(s
) 
prescribed 
for other 
conditions 
at the 
same time 
as pain  ¨1 ¨2 o3 ¨4 o5  ¨1 ¨2 o3 ¨4 o5 
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medicine(s
) without 
consulting 
my doctor. 
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Appendix L 
Table: Summary of all emergent themes in domain 3 (related to opioid taking 
behaviors)  
1.1 A variety of medications are taken for individuals with sickle cell anemia to cope 
with pain. Among these are long-acting and short-acting opioid medicines, such as 
Dilaudid, Percocet, and morphine, used to prevent and lessen pain. Non-opioid over-
the-counter medications, such as Tylenol and Motrin, are also used, sometimes in 
conjunction with home remedies.  
1.2 In choosing what medication to take, many patients weigh the intensity of pain, speed 
of onset of medication, pending responsibilities, availability of medication, and side 
effects. A few patients would use long-acting medication to dull pain but continue 
with responsibilities, while short-acting medication would be dedicated to reducing 
more intense pain when there were few responsibilities. 
1.3 Many SCD patients typically use routines for long-acting opioid medications long-
acting drugs are typically scheduled, and a scale of as-needed, personal judgment for 
short-acting opioid medications while short-acting drugs are taken as needed within 
the limits of a prescribed schedule. Use of short-acting medication is typically 
includes factors such as pain, time of day, and future tasks while maintaining standard 
time intervals of at least 2-4 hours apart per dose. Factors that determine short-acting 
drug use other than pain include time of day, and anticipated tasks. 
1.4 Situation, context, and time of day of the SCD individual is often key to routinization 
of long-acting and short-acting medications. Setting schedules for taking medicine is 
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often done for habit, to avoid forgetfulness, and avoid the mental fatigue of making 
pain judgments every few hours. 
1.5 A typical day with pain involves scheduled long-acting medications with pain 
judgments and extrapolation to decide the course of short-acting medicines. 
1.6 Over a typical day without pain, most participants continued use of schedule long-
acting medication, while decreasing the amount or frequency of the short-acting 
medicine. More typically, a day without pain meant a day with more bearable pain. 
1.7 Reported frequency for taking medications varied from 3-4 times a day to once a day 
depending on the severity of pain and estimated probability of future pain. 
1.8 Unusual intervals between medication doses was more typical with highly severe pain 
and little to no pain. 
1.9 Unusual interval times between doses were usually interpreted by SCD patients to 
mean shorter time intervals. 
1.10 Behaviors towards taking medication varied greatly among study participants. 
Behaviors depended on routines, context specificity, and participant attitude towards 
medicine as a whole. Additionally, participants were keen on either being 
independent of their medicines by taking less than prescribed and using home 
remedies, or by tolerating the need for opioid medicine to maintain daily normalcy. 
1.11 Reported time to comfort after taking medication varied greatly, from less than 20 
minutes to never feeling noticeable comfort. 
1.12 Time to become comfortable after taking short-acting medication was typically 
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after half an hour, but sometimes unnoticed during bouts of severe pain. 
1.13 Time to become comfortable after taking long-acting was typically a subtle effect, 
if noticed.  
1.14 Many participants were aware of the preventative use of long-acting opioid 
medicine and has routinized its use. 
1.15 Participants’ ways of taking medication during a crisis usually included 
decreasing the time interval between doses, increasing the amount of medicine in the 
dose, and combining the opioid medicine with other home and over-the-counter 
medicines. Additionally, number of doses after beginning of the severe pain was 
counted as a measurable way of knowing when to go to the emergency room. 
1.16 Ways of taking medication after a crisis were usually very similar to pre-crisis 
habits; however, participants were likely to feel increased vulnerability to future 
crises and were more likely to slightly increasing their opioid medicine dosage. 
1.17 Some participants used schedules to keep track of and regulate their medications 
and dosages. Familiarity with a dosage schedule allowed participants to be more 
aware of their written instructions while minimizing the possibility of missed doses. 
Additionally, the constancy of having decreased pain led to more productivity and 
relief from fears of dependence on the medicine. 
1.18 A majority of participants entertained the idea of stopping medication due to a 
decreased amount of pain, boredom with medicine, or test of pain-bearing skill. 
However, those that tried stopping either had little consequences or had a stronger 
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wave of pain. 
1.19 Motivation for continuing medicine use was the decrease in pain and decrease in 
complications from pain. 
1.20 Despite the use of at-home pain management, most SCD patients are sensitive to 
the need for emergency room care should the need arise. A gray area of pain and 
decreased medicine efficiency leads to confusion for the transfer of at-home to 
emergency treatment. 
1.21 Others who knew or watched a SCD patient sometimes changed how the SCD 
patient would later act specifically around that individual or around others. 
Encouragement and discouragement often assisted positive or negative opinions 
about the opioid medicine. Family and friends of patients also changed their 
behaviors towards the patient depending on the patients’s pain and medication status. 
However, some patients perceived themselves more distanced from family and/or 
friends, resulting in a distanced, apathetic view towards others’ opinions on the 
patient’s medicine-taking behavior. 
1.22 Many patients agreed that opioid medication did not take the sickle cell pain 
away, instead reducing it to bearable severity. 
1.23 Many of the patients interviewed worried about the risks of under-treating their 
severe pain and were scared of the possible complications that could result. 
1.24 Many SCD patients who were prescribed long-acting medicine often ran out due 
to inability to refill or availability of the medicine. 
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1.25 Some patients who suffered from other pains (e.g., due to arthritis) as well as 
SCD pain often used the “feel” and location of pain to determine how to adjust their 
medication. Ultimately, the nature of the momentary pain led to either taking less 
than prescribed, taking as prescribed, or taking more than prescribed. 
1.26 Participants reported a variety of reasons for running out of medication, including: 
theft, decreased availability, financial hardship, misplacement, and miscalculation of 
remaining amount of medication. 
1.27 Most patients felt that they did not take advantage of their opioid medication like 
“other” SCD patients did. Additionally, they also often felt that “others” had worse 
sickle cell pain than they did. 
1.28 Some patients had the flexibility to choose between different prescribed opioids, 
such as Dilaudid, Percocet, and OxyContin, to most effectively treat varying levels of 
pain. 
1.29 Patients reported preferences for different pains. For severe pain, 1 tablet of 
Dilaudid every 2-4 hours was preferred, while 1 tablet of Percocet every 4 hours or 1 
tablet of OxyContin every 3-4 hours was preferred for moderate pain. Additionally, 2 
tablets of oxycodone every 4 hours was used for regular and mild pain, while Tylenol 
III was used to reduce mild pain. 
1.30 Among most patients, usage of opioid medication varied dependent on crisis 
duration, typically 1-2 weeks per month. 
1.31 Many patients time their medications and wait between doses to fulfill 
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responsibly using their medication and to maintain attention to duties, responsibilities, 
and other tasks at hand. 
1.32 Many SCD patients understand the risk of overdose as too harmful, and many 
patients are under the impression that the initial dose of medication should take effect 
in reducing their pain. Additionally, many patients also felt that taking another dosage 
“too close” to a previous dose would be considered an overdose. 
1.33 The main reason reported for not delaying the next dose of medication was to deal 
with unbearable pain. 
1.34 Factors influencing the decision to take medicine involved the severity of pain, 
difficulty in doing tasks, emotional state, time of the last dose, the location of pain, 
the want for comfort, adherence to a medication schedule, increased activity, and the 
anticipation of escalating or future pain. 
1.35 When having mild pain, many SCD patients refrain from taking opioids because 
the pain is tolerable without, they are more able to focus in their working 
environment and less likely to make mistakes, they have family responsibilities, or 
they dislike the side effects. 
1.36 When having no pain, some SCD patients refrained from taking opioids 
altogether. 
1.37 On average, most SCD patients reported taking more opioids during the day in 
order to maintain comfort, to work during the day and finish tasks, and to maintain 
activity throughout the day. 
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1.38 Many SCD patients agreed that less medication was necessary at night due to the 
relaxation of sleep. 
1.39 For some SCD patients, taking more opioid medicine occurred at night to control 
the pain prior to bed, to deal with an accumulation of pain from activity throughout 
the day, and because colder temperatures at night increased pain. 
1.40 Some SCD patients took less medication during the daytime because of a need to 
be more productive, avoid side effects, fulfill familial responsibilities, and because 
more favorable weather was less associated with severe pain. 
1.41 SCD patients reported taking more rest when experiencing an unusual day with 
stronger pain and taking more medication to avoid escalation of pain. For others, an 
unusual day was one without pain, in which less or no medication would be taken. 
However, most participants reported that they would take their long-term medicine 
without fail. 
1.42 A typical day of pain, as described, was with limited activity with mild to no pain 
that increased in severity as the day passed. Pain would be judged upon waking and a 
typical medication-behavior route would be taken. Home remedies, such as using 
heat, were reported as commonly used and preferred over medicine if possible. 
1.43 SCD participants agreed that some things would make an unusual day with 
stronger pain more bearable. They suggested resting in bed, taking medication, 
sleeping/resting, drinking fluids, and taking slightly more medicine than from a 
typical day. 
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1.44 The surveyed patients shared their methods of relieving a crisis on an unusual day 
of pain. These ways involved taking more medicine, and going to the ER. 
1.45 SCD patients had a variety of ways of taking medicine specifically before going 
to the ER, sometime based on the time of day. For many, they would stop taking their 
medication after a certain number of doses and go straight to the ER if they realized 
they had crisis pain.  Others would either take more or less medication than   they 
would normally take. 
1.46 During a day with crisis, most patients would prefer to stay at home and self-treat 
than go to a hospital to go to the hospital. Additionally, some SCD patients also felt 
that they could better treat themselves at home, sometimes taking up to two days self-
treating before going to the hospital. Typically more short-acting medication would 
also probably be taken. 
1.47 Most patients would take their prescribed short-acting opioids when in severe 
pain or when trying to avoid a visit to the ER. However, some would also take it 
when running out of long-acting medication or when realizing they are out of long-
acting medication. Additionally, some patients would take short-acting medication for 
emotional symptoms (stress, anxiety, etc.), when in colder or unstable environments, 
or when feeling pain that is perceived as not bettered with long-acting medication.  
1.48 Patients with long-acting medication would take additional doses for long-term 
pain prevention over the day, to avoid extreme pain that would be otherwise 
unmanageable later in the day, or to get “back on track” to a self-scheduled dosage. 
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1.49 Patients were mindful of their medication in order to avoid dependency, to 
prevent overdose, to fulfill different tasks, and to prevent damage to their livers and 
kidneys. 
1.50 Some patients felt that during some crises, they were not receiving full care, not 
being admitted to, or being discharged early from the ER and sent home. 
1.51 Some patients did not take proper care of their medication duties by not going to 
the clinic or by not keeping up with appointments. 
1.52 On a typical day without pain, patient would take their long-acting medication, 
rarely take their short-acting medication, or take their short-acting and long-acting 
medication together. 
1.53 Patients reported taking more short- and long-acting medications in both 
frequency and amount of pills per dose when experiencing a day with pain. 
Additionally, one patient reported crushing their tablets and mixing it with tea, 
although most patients did not report any special medication behaviors for days they 
experienced pain. 
1.54 Factors encouraging medication use (as prescribed and take more than prescribed) 
were the severity of pain, a need for comfort, social encouragement by family and 
peers, perceived lack of pain relief, the location of pain, having access to medication, 
anticipation of pain (feeling an “aura” or otherwise), and fear for biological safety and 
preventing complications. 
1.55 Factors that make it difficult to take pain medicine included forgetting the exact 
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physician instructions, lack of understanding of when to take their medications, lack 
of availability, needing to carry the medication with them, fear of addiction, the 
severity of pain itself, the side effects, forgetfulness, difficulties in social situations, 
the stigma of SCD patients taking advantage of the medication, psychological factors, 
fear of death, need to fulfill activities of daily living, partial or complete 
ineffectiveness, and a difficult patient-physician relationship. 
1.56 Differences medication-taking behaviors were dependent on age, experience with 
medication, pain, responsibilities to others (e.g., children), side effects, time of day, 
weather, and any social events. 
1.57 The momentary environment also affected medication-taking behavior. 
Depending on how much need the patient requires “to function”, in order to sit 
through church, or to go to social gatherings. Additionally, they would often take 
medication before or after settings, to prevent later difficulties taking medication 
during the event. 
1.58 Some patients felt that they had to take medication in the company of family for 
the duration of the effects in order to avoid dangerous behaviors such as leaving the 
stovetop on. 
1.59 Some patients felt they could sufficiently bear the pain without medication, and 
would often stop taking or take less medication when feeling sufficiently well. 
1.60 SCD patients were divided on whether society affected the way they took 
medication. Some felt that the medication allowed them some power over their pain, 
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while others felt that the opioid medication could be used for impressing some friends 
and garnering popularity. Some felt isolated from society, sternly saying that society 
made absolutely no difference in their medication-taking behavior. For those that 
were neutral, SCD patients were still wary of what others might think of their 
medication taking medication and did not often take medication in front of strangers. 
1.61 The patient-physician/provider relationship impacted how patients took 
medication; some felt negative reactions were common from pharmacists who felt the 
patients were addicts. Others felt some dissonance between their pharmacists and 
doctors’ opinions. 
1.62 Some SCD patients were wary of being in the presence of others when using 
medication. One study participant recalled children taking advantage of the drowsy 
state during the duration of the medicine. Others hid their medication-taking behavior 
to avoid the negative stigma of taking strong pain medicine. Several patients did not 
care what others thought and simply took their medication as usual. 
1.63 Most participants felt that they had to be responsible to themselves and to others 
due to work and to avoid mistakes (such as when driving) or being a burden to others. 
1.64 Most patients reported taking pain medicine during moderate pain instead of only 
severe pain, but many felt stronger pain when experiencing cold weather or 
environments. Some would take increased medication in anticipation of a cold 
environment (e.g., a fan or the cool water in a pool). 
1.65 SCD patients would take their medicine after 4 to 24 hours of pain. 
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1.66 Most patients reported never missing medication when in moderate or severe 
pain, while many missed doses while experiencing mild pain. 
1.67 SCD patients missed doses frequently or occasionally, depending on a variety of 
factors. 
1.68 When missing doses, patients would wait to take their next dose (no change), take 
the medication whenever available and effectively shifting the medication “schedule”, 
taking the medication more frequently, or might even miss medication on purpose in 
order to avoid dependency. 
1.69 SCD patients had different perceptions about missed doses. Some felt missed 
doses would cause pain, that it would have no effect, or that missing few (1-2 doses) 
would have no effect on the pain level. 
1.70 The impact of an environment impacted how patients felt about their SCD. Many 
SCD patients felt that hospital staff viewed them negatively as drug-abusers based on 
the medication or based on their home location. Indoor vs. outdoor, weather, and 
events altered their medication schedules. Familial environment often led to 
encouragement and increased medication taking. 
1.71 SCD patients reported a wide variety of reasons for missing their medications. 
Among the most common reasons were travel, forgetfulness, and location. 
1.72 Many SCD patients felt that short-acting medication was impossible to miss, and 
pain was a major reminder. Context of the environment made some patients likely to 
remember to take their medication, while some would purposely miss their 
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medication when not in pain. 
1.73 SCD patients largely varied in opinions on taking medicine as prescribed. 
Opinions thought that medication was either not important at all or very important, 
but paid less importance to how they needed to take their medication. Others felt it 
was important, but felt equal or greater importance on “properly’ taking their 
medication. 
1.74 SCD patients felt that it was important to take the medications as prescribed in 
order to keep function as a “normal” individual, in order to relieve pain, in order to 
avoid addiction and dependence, in order to relieve health problems, and in belief that 
sickness can come from not taking the medication as prescribed. 
1.75 SCD patients find it important to take medication as prescribed when having any 
level of pain. 
1.76 SCD patients felt that the important of taking opioid medication was more, less, 
or rivaled the important of taking other medication for other conditions. 
1.77 When experiencing worse pain than usual would go immediately to the hospital, 
taking less than prescribed medication, using home remedies (such as heat, how 
baths), and trying massages. Some patients felt that the pain was not bettered by 
medication when in severe pain. 
1.78 In order to get rid of pain before going to a hospital, patients would increase the 
dose in frequency, amount, and/or shortened interval. This was often done in 
conjunction with home remedies. However, some patients would not change their 
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medication-taking behavior. 
1.79 After feeling some amount of pain relief after using pain medication, patients 
would often revert to their “regular schedule,” some would take more medication for 
some while, while others would decrease medication use in order to avoid addiction 
or dependency. 
1.80 After feeling better when not having pain, SCD patients would often use only 
long-acting medication, and some younger SCD patients would use opioid in 
anticipation of pain. 
1.81 Factors influencing how patients took their medication included effectiveness, 
information about medication-taking behavior (doctor, online, on the bottle), severity 
of pain, emotional state, social events, forgetfulness, social factors, other pains, and 
events. 
1.82 Experience with medication changed how patients took their medication. 
1.83 Some SCD patients took immediate release medication for only breakthrough 
pain, while using long-acting medication for pain prevention instead for active pain 
alleviation. 
1.84 When running out of medication, some SCD patients would use OTC 
medications; call their prescriber, take medication as needed, or going to the ER. 
1.85 Some patients would crush their medication for a faster effect. 
1.86 When having no pain but choosing to take pain medicine, SCD patients were 
often experiencing fear of pain coming back or recovering from the end of a crisis. 
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1.87 Some patients would save medication in anticipation of future need for pain 
medication. Other patients would take medication on a regular schedule in fear of 
recurring pain. 
1.88 When dealing with activities, patients would take medication as usual, take more 
after an event, or take some before an event. 
1.89 Most patients would take medication before social or religious events in order to 
“get through” the event, as a precaution to avoid pain, and to avoid possible resulting 
stigma from others seeing them take medication. 
1.90 SCD patients were fairly divergent regarding taking medication in front of others. 
Most did not mind taking medication in front of others or family, especially if they 
were secure about their role and the role of prescribed opioids in their lives. Some 
patients simply preferred being alone while under the effects of medication, while 
others did not like the presence of others in case of attracting a negative stigma. 
1.91 For family, social, and religious events or rituals, many SCD patients would take 
the minimum amount of pain medicine, forget to take medicine, take the medicine 
before the event, or postpone the event if possible 
1.92 Some SCD patients altered their medicine-taking behavior based on the location 
of pain. Some would take less, by changing the quantity, time interval, or changing 
the frequency of doses. Some patients would also not change their medicine-taking 
behavior. 
1.93 When not at home, patients varied in the extent they could take their medication 
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(very much to hardly ever) depending on when they felt they were in an appropriate 
situation. Those comfortable with their medicine were more likely to feel that they 
were frequently able to take their medication away from home. 
1.94 During events, SCD patients felt that outdoor activities affected their medication 
more than indoor events. Physical activities were likely to increase the need of pain 
medicine; so many patients also avoided physically-heavy events. 
1.95 When having pain during an event, many SCD patients either change the quantity, 
time interval, frequency, take inappropriate OTC medications, take medication in 
anticipation, postpone medication, leave the event, or use medication as typical. 
1.96 When medication is not accessible, some patients try to get to their medication to 
avoid further pain or miss their medicaiton. 
1.97 When having pain before a social event, SCD patients either made no adjustments 
or stayed home during the event. 
1.98 Most patients would not take medication for stress, but they would take 
medication if experiencing both pain and stress. Patients found that alternative 
therapies such as breathing, praying, or listening to calming music. 
1.99 SCD patients found a great deal of stressors, including: financial stress, possible 
loss of employment, familial strain, sickle cell pain, mental stress, social stress, and 
physical stress. 
1.100 When having pain and stress, patients would self-adjust their medication by 
changing the quantity, time interval, and frequency of their medication. Other patients 
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would make no change to their dosage. 
1.101 Many patients felt strongly that they should not take advantage of their 
medication due to the side effects. 
1.102 Most patients felt that taking more pain medicine in terms of time intervals would 
have a negative effect on their hearts, kidneys, and organs. 
1.103 Most of the older SCD participants felt that they took more pain medicine when 
they were younger and more carefree about their pain medicine. 
1.104 Most of the older SCD participants also felt that, when younger, they did not wait 
until they experienced severe pain to take their opioid medication. 
1.105 SCD patients who took more medication at younger age possibly took more 
medication due to more freedom and less responsibilities. 
1.106 A few patients also experienced their instructions changing over the years, often 
to a shorter time interval. 
1.107 When experiencing pain, many SCD patients felt that they should “catch” their 
pain before it worsened, and might take more medication in terms of frequency, time 
interval, and quantity. 
1.108 Participants varied in their opinion of an abnormal waiting time: 1-4 hours was 
typically see as too little of a waiting time under typical pain. 
1.109 A few patients felt that when having pain, then should keep their short-acting 
medication on a schedule to keep pain at a minimum throughout the day. 
1.110 Most SCD patients experienced preference for waiting, taking medicine ahead of 
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time, or as pain escalated. Others would have no preference for how to take pain 
medication as long as the medication worked. 
1.111 Several patients denied self-adjustment of medication timing, dosage, or type of 
medication. 
1.112 After missing a dose, the general reaction among SCD patients included more 
obvious pain, increased focus, having no or a lot of energy, feeling sick, or feeling a 
generally unwell feeling. 
1.113 Emotionally, patients missing a dose felt the same, felt “bad”, or were apathetic 
about missing a dose. 
1.114 Most patients strictly took their medication with water, while a few patients took 
medication with alcohol, another juice, dissolved their medicine, or crushed the 
medicine. 
1.115 Many patients felt that their ER stays were crowded, uncomfortable, cold, or 
caused more aching than self-treatment of crisis at home. 
1.116 The prescribed amount of medication varied greatly among patients based on the 
short- or long-acting medicine. 
1.117 Most participants felt that their medication was sufficiently effective, while 
several patients felt that their medication was either too strong or too weak to deal 
with their medicine. 
1.118 Many patients did not like their behavior under the influence of medication. Many 
did not like taking the medication due to possible long-term consequences of long-
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term medication use, lack of effectiveness, lack of control while under the influence 
of the medication, possibility of misuse, and the disadvantages of having to take 
medication. 
1.119 When pain is not relieved, many SCD patients resorted to bedrest, fluids, 
increasing medicine quantity/interval/dosage, or calling an ambulance. 
1.120 Medication was not always available for patients, although several patients cited 
the unpredictable nature of sickle cell disease and inability to prepare for it when 
traveling, out of the house or with different people. 
1.121 A majority of patients would not combine medications. 
1.122 Several patients would need/want medication but would not take it due to need for 
driving or fine motor skills or coordination  
1.123 When deviating from taking medicaiton when pain arose was typically intentional 
among patients. 
1.124 SCD patients would, at least some of the time, decreased the interval between two 
doses of long-acting intervals. However, several patients also forgot to take their 
medication. 
1.125 Most participants who missed doses did so at night. 
1.126 When taking short-acting, SCD patients increased the quantity, increased the 
frequency, taking medication regularly regardless of pain intensity, taking other 
prescribed or OTc medications concomitantly, or increasing the duration of therapy. 
1.127 Most SCD patients felt that they took their medication differently or less than 
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other SCD patients, although several noted that they probably deviated from the 
“right” methods of taking their medication. 
1.128 Methods of aberrancy included stopping medication use, missing doses, taking 
less than prescribed, taking ER medication instead of typical prescribed medicine, or 
not taking long-acting medication even when feeling well. 
1.129 Reasons for aberrancy is to take the prescribed medicine for reasons other than 
pain: stress, improve sleep or appetite, headaches, anxiety, nervousness, depression, 
and boredom. Many patients also took their medication out of habit. 
1.130 Some patients shared stories of overuse/addiction/aberrant behavior.  
1.131 A few SCD patients denied harm that could stem from opioids, and would ask for 
or take more opioids despite recognition of harmful effects. 
1.132 A few patients also did not adhere to physician advice by insisting, accepting, or 
asking for more opioids, despite going against medical advice or despite recognition 
of fatal effects. 
1.133 Some participants express inability to adhere to prescribed pain medication 
regiment because insurance refuse to approve the type and amount of medication 
necessary for treatment. 
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